

PATENT COOPERATION TREATY

PCT

NOTIFICATION OF THE RECORDING
OF A CHANGE(PCT Rule 92bis.1 and
Administrative Instructions, Section 422)

From the INTERNATIONAL BUREAU

To:

PLOUGMANN, VINGTOFT & PARTNERS A/S
Sankt Annæ Plads 11
Post Office Box 3007
DK-1021 Copenhagen K
DANEMARK

| | |
|--|---|
| Date of mailing (day/month/year) 19 October 2001 (19.10.01) | IMPORTANT NOTIFICATION |
| Applicant's or agent's file reference 23450 PC 1 | |
| International application No. PCT/DK00/00413 | International filing date (day/month/year) 20 July 2000 (20.07.00) |

| | | |
|---|---|--------------------------------------|
| 1. The following indications appeared on record concerning: | | |
| <input checked="" type="checkbox"/> the applicant | <input type="checkbox"/> the inventor | <input type="checkbox"/> the agent |
| <input type="checkbox"/> the common representative | | |
| Name and Address M & E BIOTECH A/S Kogle Allé 6 DK-2970 Hørsholm Denmark | State of Nationality DK | State of Residence DK |
| | Telephone No. | |
| | Facsimile No. | |
| | Teleprinter No. | |
| 2. The International Bureau hereby notifies the applicant that the following change has been recorded concerning: | | |
| <input type="checkbox"/> the person | <input checked="" type="checkbox"/> the name | <input type="checkbox"/> the address |
| <input type="checkbox"/> the nationality | | |
| <input type="checkbox"/> the residence | | |
| Name and Address PHARMEXA A/S Kogle Allé 6 DK-2970 Hørsholm Denmark | State of Nationality DK | State of Residence DK |
| | Telephone No. | |
| | Facsimile No. | |
| | Teleprinter No. | |
| 3. Further observations, if necessary: | | |
| 4. A copy of this notification has been sent to: | | |
| <input checked="" type="checkbox"/> the receiving Office | <input type="checkbox"/> the designated Offices concerned | |
| <input type="checkbox"/> the International Searching Authority | <input checked="" type="checkbox"/> the elected Offices concerned | |
| <input checked="" type="checkbox"/> the International Preliminary Examining Authority | <input type="checkbox"/> other: | |

| | |
|---|---|
| The International Bureau of WIPO 34, chemin des Colombettes 1211 Geneva 20, Switzerland | Authorized officer François BAECHLER |
| Facsimile No.: (41-22) 740.14.35 | Telephone No.: (41-22) 338.83.38 |

PATENT COOPERATION TREATY

PCT

NOTIFICATION OF THE RECORDING
OF A CHANGE(PCT Rule 92bis.1 and
Administrative Instructions, Section 422)

From the INTERNATIONAL BUREAU

To:

PLOUGMANN & VINGTOFT A/S
Sankt Annæ Plads 11
P.O. Box 3007
DK-1021 Copenhagen K
DANEMARK

Date of mailing (day/month/year)
28 January 2002 (28.01.02)

Applicant's or agent's file reference
23450 PC 1

International application No.
PCT/DK00/00413

IMPORTANT NOTIFICATION

International filing date (day/month/year)
20 July 2000 (20.07.00)

1. The following indications appeared on record concerning:

☐ the applicant ☐ the inventor ☒ the agent ☐ the common representative

Name and Address

PLOUGMANN, VINGTOFT & PARTNERS A/S
Sankt Annæ Plads 11
P.O. Box 3007
DK-1021 Copenhagen K
Denmark

State of Nationality

State of Residence

Telephone No.

+45 33 63 93 00

Facsimile No.

+45 33 63 96 00

Teleprinter No.

2. The International Bureau hereby notifies the applicant that the following change has been recorded concerning:

☐ the person ☒ the name ☐ the address ☐ the nationality ☐ the residence

Name and Address

PLOUGMANN & VINGTOFT A/S
Sankt Annæ Plads 11
P.O. Box 3007
DK-1021 Copenhagen K
Denmark

State of Nationality

State of Residence

Telephone No.

+45 33 63 93 00

Facsimile No.

+45 33 63 96 00

Teleprinter No.

3. Further observations, if necessary:

4. A copy of this notification has been sent to:

☒ the receiving Office ☐ the designated Offices concerned
☐ the International Searching Authority ☒ the elected Offices concerned
☐ the International Preliminary Examining Authority ☐ other:

The International Bureau of WIPO
34, chemin des Colombettes
1211 Geneva 20, Switzerland

Facsimile No.: (41-22) 740.14.35

Authorized officer

Jaime LEITAO

Telephone No.: (41-22) 338.83.38

PATENT COOPERATION TREATY

PCT

NOTIFICATION OF ELECTION

(PCT Rule 61.2)

From the INTERNATIONAL BUREAU

To:

Commissioner
US Department of Commerce
United States Patent and Trademark
Office, PCT
2011 South Clark Place Room
CP2/5C24
Arlington, VA 22202
ETATS-UNIS D'AMERIQUE
in its capacity as elected Office

| | |
|---|---|
| Date of mailing (day/month/year) 09 April 2001 (09.04.01) | |
| International application No. PCT/DK00/00413 | Applicant's or agent's file reference 23450 PC 1 |
| International filing date (day/month/year) 20 July 2000 (20.07.00) | Priority date (day/month/year) 20 July 1999 (20.07.99) |
| Applicant HALKIER, Torben et al | |

1. The designated Office is hereby notified of its election made:


☒ in the demand filed with the International Preliminary Examining Authority on:
19 February 2001 (19.02.01)

☐ in a notice effecting later election filed with the International Bureau on:

2. The election ☒ was
☐ was not

made before the expiration of 19 months from the priority date or, where Rule 32 applies, within the time limit under Rule 32.2(b).

| | |
|---|---|
| The International Bureau of WIPO 34, chemin des Colombettes 1211 Geneva 20, Switzerland Facsimile No.: (41-22) 740.14.35 | Authorized officer A. Karkachi Telephone No.: (41-22) 338.83.38 |
|---|---|



From the
INTERNATIONAL PRELIMINARY EXAMINING AUTHORITY

PCT

NOTIFICATION OF TRANSMITTAL OF
THE INTERNATIONAL PRELIMINARY
EXAMINATION REPORT

(PCT Rule 71.1)

To:

PLOUGMANN, VINGTOFF & PARTNERS A/S
Sankt Annæ Plads 11
P.O. Box 3007
DK-1051 COPENHAGEN K
DANEMARK

Date of mailing
(day/month/year)

08.11.2001

Applicant's or agent's file reference
23450 PC 1

IMPORTANT NOTIFICATION

International application No.
PCT/DK00/00413

International filing date (day/month/year)
20/07/2000

Priority date (day/month/year)
20/07/1999

Applicant

M&E BIOTECH A/S et al.

1. The applicant is hereby notified that this International Preliminary Examining Authority transmits herewith the international preliminary examination report and its annexes, if any, established on the international application.
2. A copy of the report and its annexes, if any, is being transmitted to the International Bureau for communication to all the elected Offices.
3. Where required by any of the elected Offices, the International Bureau will prepare an English translation of the report (but not of any annexes) and will transmit such translation to those Offices.

4. REMINDER


The applicant must enter the national phase before each elected Office by performing certain acts (filing translations and paying national fees) within 30 months from the priority date (or later in some Offices) (Article 39(1)) (see also the reminder sent by the International Bureau with Form PCT/IB/301).

Where a translation of the international application must be furnished to an elected Office, that translation must contain a translation of any annexes to the international preliminary examination report. It is the applicant's responsibility to prepare and furnish such translation directly to each elected Office concerned.

For further details on the applicable time limits and requirements of the elected Offices, see Volume II of the PCT Applicant's Guide.

Corrected IPER of 8.11.01

Name and mailing address of the IPEA

 European Patent Office
D-80298 Munich
Tel. +49 89 2399 - 0 Tx: 523656 epmu d
Fax: +49 89 2399 - 4465

Authorized officer

Guerin, A

Tel. +49 89 2399-8061



PATENT COOPERATION TREATY

PCT

INTERNATIONAL PRELIMINARY EXAMINATION REPORT

(PCT Article 36 and Rule 70)

| | | | |
|---|--|---|--|
| Applicant's or agent's file reference 23450 PC 1 | | FOR FURTHER ACTION See Notification of Transmittal of International Preliminary Examination Report (Form PCT/IPEA/416) | |
| International application No. PCT/DK00/00413 | International filing date (day/month/year) 20/07/2000 | Priority date (day/month/year) 20/07/1999 | |
| International Patent Classification (IPC) or national classification and IPC C07K14/00 | | | |
| Applicant M&E BIOTECH A/S et al. | | | |

1. This international preliminary examination report has been prepared by this International Preliminary Examining Authority and is transmitted to the applicant according to Article 36.



2. This REPORT consists of a total of 10 sheets, including this cover sheet.

☒ This report is also accompanied by ANNEXES, i.e. sheets of the description, claims and/or drawings which have been amended and are the basis for this report and/or sheets containing rectifications made before this Authority (see Rule 70.16 and Section 607 of the Administrative Instructions under the PCT).

These annexes consist of a total of 9 sheets.

3. This report contains indications relating to the following items:

- I ☒ Basis of the report
- II ☒ Priority
- III ☒ Non-establishment of opinion with regard to novelty, inventive step and industrial applicability
- IV ☒ Lack of unity of invention
- V ☒ Reasoned statement under Article 35(2) with regard to novelty, inventive step or industrial applicability; citations and explanations supporting such statement
- VI ☒ Certain documents cited
- VII ☒ Certain defects in the international application
- VIII ☐ Certain observations on the international application

| | |
|---|--|
| Date of submission of the demand 19/02/2001 | Date of completion of this report 08.11.2001 |
| Name and mailing address of the international preliminary examining authority:  European Patent Office D-80298 Munich Tel. +49 89 2399 - 0 Tx: 523656 epmu d Fax: +49 89 2399 - 4465 | Authorized officer Moonen, P Telephone No. +49 89 2399 8538  |

**INTERNATIONAL PRELIMINARY
EXAMINATION REPORT**

International application No. PCT/DK00/00413

I. Basis of the report

1. With regard to the **elements** of the international application (*Replacement sheets which have been furnished to the receiving Office in response to an invitation under Article 14 are referred to in this report as "originally filed" and are not annexed to this report since they do not contain amendments (Rules 70.16 and 70.17):*

Description, pages:

1-56 as originally filed

57 as received on 31/10/2000 with letter of 27/10/2000

Claims, No.:

1-47 as received on 27/07/2001 with letter of 24/07/2001

Drawings, sheets:

1/5-5/5 as originally filed

Sequence listing part of the description, pages:

1-35, as originally filed

2. With regard to the **language**, all the elements marked above were available or furnished to this Authority in the language in which the international application was filed, unless otherwise indicated under this item.

These elements were available or furnished to this Authority in the following language: , which is:

- ☐ the language of a translation furnished for the purposes of the international search (under Rule 23.1(b)).
- ☐ the language of publication of the international application (under Rule 48.3(b)).
- ☐ the language of a translation furnished for the purposes of international preliminary examination (under Rule 55.2 and/or 55.3).

3. With regard to any **nucleotide and/or amino acid sequence** disclosed in the international application, the international preliminary examination was carried out on the basis of the sequence listing:

- ☒ contained in the international application in written form.
- ☐ filed together with the international application in computer readable form.
- ☐ furnished subsequently to this Authority in written form.
- ☐ furnished subsequently to this Authority in computer readable form.
- ☐ The statement that the subsequently furnished written sequence listing does not go beyond the disclosure in the international application as filed has been furnished.
- ☐ The statement that the information recorded in computer readable form is identical to the written sequence

**INTERNATIONAL PRELIMINARY
EXAMINATION REPORT**

International application No. PCT/DK00/00413

listing has been furnished.

4. The amendments have resulted in the cancellation of:

- ☐ the description, pages:
- ☐ the claims, Nos.:
- ☐ the drawings, sheets:

5. ☐ This report has been established as if (some of) the amendments had not been made, since they have been considered to go beyond the disclosure as filed (Rule 70.2(c)):

(Any replacement sheet containing such amendments must be referred to under item 1 and annexed to this report.)

6. Additional observations, if necessary:**II. Priority****1. ☐ This report has been established as if no priority had been claimed due to the failure to furnish within the prescribed time limit the requested:**

- ☐ copy of the earlier application whose priority has been claimed.
- ☐ translation of the earlier application whose priority has been claimed.

2. ☒ This report has been established as if no priority had been claimed due to the fact that the priority claim has been found invalid.

Thus for the purposes of this report, the international filing date indicated above is considered to be the relevant date.

**3. Additional observations, if necessary:
see separate sheet****III. Non-establishment of opinion with regard to novelty, inventive step and industrial applicability****1. The questions whether the claimed invention appears to be novel, to involve an inventive step (to be non-obvious), or to be industrially applicable have not been examined in respect of:**

- ☐ the entire international application.
- ☒ claims Nos. 1-28 and 41-43.

because:

- ☒ the said international application, or the said claims Nos. 1-28 and 41-43 relate to the following subject matter which does not require an international preliminary examination (*specify*):
see separate sheet

**INTERNATIONAL PRELIMINARY
EXAMINATION REPORT**International application No. **PCT/DK00/00413**

- ☐ the description, claims or drawings (*indicate particular elements below*) or said claims Nos. are so unclear that no meaningful opinion could be formed (*specify*):
 - ☐ the claims, or said claims Nos. are so inadequately supported by the description that no meaningful opinion could be formed.
 - ☐ no international search report has been established for the said claims Nos. .
2. A meaningful international preliminary examination cannot be carried out due to the failure of the nucleotide and/or amino acid sequence listing to comply with the standard provided for in Annex C of the Administrative Instructions:
- ☐ the written form has not been furnished or does not comply with the standard.
 - ☐ the computer readable form has not been furnished or does not comply with the standard.

IV. Lack of unity of invention

1. In response to the invitation to restrict or pay additional fees the applicant has:
- ☒ restricted the claims.
 - ☐ paid additional fees.
 - ☐ paid additional fees under protest.
 - ☒ neither restricted nor paid additional fees.
2. ☐ This Authority found that the requirement of unity of invention is not complied and chose, according to Rule 68.1, not to invite the applicant to restrict or pay additional fees.
3. This Authority considers that the requirement of unity of invention in accordance with Rules 13.1, 13.2 and 13.3 is
- ☐ complied with.
 - ☒ not complied with for the following reasons:
see separate sheet
4. Consequently, the following parts of the international application were the subject of international preliminary examination in establishing this report:
- ☐ all parts.
 - ☒ the parts relating to claims Nos. 1-28 and 41-43.

V. Reasoned statement under Article 35(2) with regard to novelty, inventive step or industrial applicability; citations and explanations supporting such statement

1. Statement

**INTERNATIONAL PRELIMINARY
EXAMINATION REPORT**International application No. **PCT/DK00/00413**

| | | |
|-------------------------------|------|-----------------------|
| Novelty (N) | Yes: | Claims 1-28 and 41-43 |
| | No: | Claims |
| Inventive step (IS) | Yes: | Claims |
| | No: | Claims 1-28 and 41-43 |
| Industrial applicability (IA) | Yes: | Claims |
| | No: | Claims 1 (no opinion) |

2. Citations and explanations
see separate sheet

VI. Certain documents cited

1. Certain published documents (Rule 70.10)

and / or

2. Non-written disclosures (Rule 70.9)

see separate sheet

VII. Certain defects in the international application

The following defects in the form or contents of the international application have been noted:
see separate sheet

INTERNATIONAL PRELIMINARY

International application No. PCT/DK00/00413

EXAMINATION REPORT - SEPARATE SHEET

Reference is made to the following documents:

- D1: WO 99 02667 A1 (UNIVERSITY OF LIEGE) 21 January 1999
D2: WO 99 42573 A1 (BIOSTAR INC.) 26 August 1999; interfering document
D3: GB 2 333 706 A (MERCK & CO INC) 4 August 1999; interfering document
D4: PNAS 94 (1997) 12457-61

The document D4 was not cited in the international search report. A copy of the document has already been supplied to the applicant.

Re Item II**Priority**

1. The present application claims the priority dates of 2 priority applications, designated P1-P2. The subject-matter of P1 with filing date 20.07.99 as well as P2 with filing date 26.07.99 is more limited in scope than the internationally filed application.

In particular it is noted that in the specifying of "a foreign T_H epitope is inserted or substituted into any one of the loop areas or the flexible termini in the GDF-8 polypeptide" is missing in P1-P2.

D2-D3 are therefore fully citable as prior art with respect to subject-matter lacking the right of priority to P1/P2.

Re Item III**Non-establishment of opinion with regard to novelty, inventive step and industrial applicability**

2. For the assessment of the present **claims 1-28 and 41-43** on the question whether they are industrially applicable, no unified criteria exist in the PCT Contracting States. The patentability can also be dependent upon the formulation of the claims. The EPO, for example, does not recognize as industrially applicable the subject-matter of claims to the use of a compound in medical treatment, but

INTERNATIONAL PRELIMINARY

International application No. PCT/DK00/00413

EXAMINATION REPORT - SEPARATE SHEET

may allow, however, claims to a known compound for first use in medical treatment and the use of such a compound for the manufacture of a medicament for a new medical treatment.

Claims 1-28 and 41-43 include subject-matter considered by this Authority to be covered by the provisions of Rule 67.1(iv) PCT. Consequently, no opinion will be formulated with respect to the industrial applicability of the subject-matter of these claims (Article 34(4)(a)(i) PCT).

Re Item IV**Lack of unity of invention**

3. **Introduction:** GDF-8, also known as myostatin, is well known from the prior art, as well as mutations in myostatin genes leading to phenotypes of hypermuscularity in e.g. bovine and mouse (see D4, concerning an 11-nucleotide deletion in the third exon which causes a frameshift that eliminates virtually all of the mature, active region of the molecule, found in two breeds of double-muscled cattle).

D1 is a patent application and refers also to double-muscled cattle in relation to myostatin; D1 discloses the sequences and the method of use in order to increase muscle mass in a mammal by the production of antibodies against the GDF-8 polypeptide (claims 61-62) or by an effective amount of an antisense nucleic acid or oligonucleotide (claim 63).

4. This Authority considers that the requirement of unity of invention in accordance with Rules 13.1, 13.2 and 13.3 is not complied with for the following reasons:

PCT Rule 13 recites the basic principle of unity of invention that an application should relate to only invention or, if there is more than one invention, that applicant would have a right to include in a single application only those inventions which are so linked as to form a single inventive concept. According to Rule 13, a group of inventions is linked to form a single inventive concept where there is a technical relationship among the inventions that involves at least one common or corresponding special technical feature that defines the contribution which each

INTERNATIONAL PRELIMINARY

International application No. PCT/DK00/00413

EXAMINATION REPORT - SEPARATE SHEET

claimed invention, considered as a whole, makes over the prior art.

5. The inventions identified within the originally filed application were:
 - i. A method for in vivo down-regulation of GDF-8 activity in an animal e.g. to increase the muscle mass of an animal (claims 1-29 and 43-45); **present claims 1-28 and 41-43.**
 - ii. GDF-8 analogues and encoding sequences, immunogenic compositions (claims 30-42, 46-49); **present claims 29-40 and 44-47.**
 - iii. Methods for the identification of a modified GDF-8 polypeptide and their use (claims 50-52); **presently deleted.**

6. With respect to the reasons for the observation of non-unity the following is noted:

Given the above mentioned disclosures D1 and D4 referring to GDF-8 sequences and mutants in relation to the increase of muscle mass, a single general inventive concept (referred to in Rule 13 PCT and the PCT Preliminary Examination Guidelines Ch.III, 7) is not recognisable in the absence of a common, special technical feature: the identified groups therefore lack unity of invention.

7. An invitation to pay additional fees and/or to restrict the claims to one invention only was issued before the issue of the written opinion: the applicant amended the claims by filing of a new set of claims. This new set however did not overcome all unity objections (i.e. the examination and the present report concern only the in vivo methods and not e.g. the still included GDF-8 analogues). Moreover, it appears that the subject-matter of new claim 1 is also not unitarily linked with respect to subject-matter entitled or not-entitled to the priority date.

Page 54 (example 1) of the description mentions that "the rationale behind the present invention is to substitute stretches of amino acid residues in the target protein with foreign or artificial T-cell epitopes (e.g. the promiscuous tetanus toxin T-cell epitopes P2 and P30)"; it is concluded that the three specified stretches in claim 1 do not appear to share a common special technical feature.

INTERNATIONAL PRELIMINARY

International application No. PCT/DK00/00413

EXAMINATION REPORT - SEPARATE SHEET

Re Item V

Reasoned statement under Rule 66.2(a)(ii) with regard to novelty, inventive step or industrial applicability; citations and explanations supporting such statement

8. Present claim 1 specifies that immunization of an animal (including a human being) is carried with a GDF-8 analogue in which a substantial fraction of GDF-8 B-cell epitopes are preserved, and a foreign T_H epitope is introduced into any one of three specified positions of GDF-8 or into any one of the loop areas or the flexible termini in the GDF-8 polypeptide. It appears that the claimed subject-matter is novel over the available prior art documents.

It is however noted that the application seriously lacks support/disclosure as no example demonstrates that the technical problem is solved, let alone that an effect of the introduction of the T_H epitope is demonstrated: it merely refers to the expectation that the introduction of T_H epitopes should produce an improved immunogen. It is decided in the present case to still formulate an opinion with respect to inventive step: however, in particular in view of D1 concerning the immunisation with GDF-8 (page 22 lines 25-30 and claims 61-63) and the further speculation in the present application concerning the use of possible analogues with introduced T_H epitopes (a method known per se) it is considered that the claimed subject-matter is obvious to the skilled person. Thus, contrary to the requirements of Article 33(3) of the PCT, **claim 1** does not involve an inventive step; the same reasoning applies to the other depending claims, all additionally introduced technical features being based on common knowledge.

Re Item VI**Certain documents cited**

Certain published documents (Rule 70.10)

| Application No Patent No | Publication date (day/month/year) | Filing date (day/month/year) | Priority date (valid claim) (day/month/year) |
|-----------------------------|--------------------------------------|---------------------------------|---|
| D2 | 26.08.99 | 19.02.99 | 19.02.98 |

**INTERNATIONAL PRELIMINARY
EXAMINATION REPORT - SEPARATE SHEET**

International application No. PCT/DK00/00413

9. D2 appears to be relevant as an interfering application with respect to the novelty of the claimed subject-matter in the regional european phase of this application (under Article 54(3)(4) EPC for the common designated contracting states).

No european patent family member for D3 has been found; however, this document could be of relevance for subject-matter not entitled to the priority dates in July 1999.

Re Item VII

Certain defects in the international application

10. Contrary to the requirements of Rule 5.1(a)(ii) PCT, the relevant background art disclosed in the documents D1/D4 is not mentioned in the description, nor are these documents identified therein.

PATENT COOPERATION TREATY

PCT

INTERNATIONAL SEARCH REPORT

(PCT Article 18 and Rules 43 and 44)

| | |
|--|---|
| Applicant's or agent's file reference 23450 PC 1 | <div style="display: flex; justify-content: space-between;"> <div style="text-align: center;">FOR FURTHER ACTION</div> <div style="font-size: small;">see Notification of Transmittal of International Search Report (Form PCT/ISA/220) as well as, where applicable, item 5 below.</div> </div> |
| International application No. PCT/DK 00/00413 | <div style="display: flex; justify-content: space-between;"> <div style="width: 60%;">International filing date (<i>day/month/year</i>) 20 July 2000</div> <div style="width: 40%;">(Earliest) Priority Date (<i>day/month/year</i>) 20 July 1999</div> </div> |
| Applicant M&E BIOTECH A/S et al | |

This international search report has been prepared by this International Searching Authority and is transmitted to the applicant according to Article 18. A copy is being transmitted to the International Bureau.

This international search report consists of a total of 4 sheets.

☒ It is also accompanied by a copy of each prior art document cited in this report.

1. Basis of the report

- a. With regard to the **language**, the international search was carried out on the basis of the international application in the language in which it was filed, unless otherwise indicated under this item.
- ☐ the international search was carried out on the basis of a translation of the international application furnished to this Authority (Rule 23.1(b)).
- b. With regard to any **nucleotide and/or amino acid sequence** disclosed in the international application, the international search was carried out on the basis of the sequence listing:
- ☐ contained in the international application in written form.
- ☒ filed together with the international application in computer readable form.
- ☐ furnished subsequently to this Authority in written form.
- ☐ furnished subsequently to this Authority in computer readable form.
- ☐ the statement that the subsequently furnished written sequence listing does not go beyond the disclosure in the international application as filed has been furnished.
- ☐ the statement that the information recorded in computer readable form is identical to the written sequence listing has been furnished.

2. ☒ **Certain claims were found unsearchable** (See Box I).

3. ☐ **Unity of invention is lacking** (See Box II).

4. With regard to the **title**,

- ☒ the text is approved as submitted by the applicant.
- ☐ the text has been established by this Authority to read as follows:

5. With regard to the **abstract**,

- ☒ the text is approved as submitted by the applicant.
- ☐ the text has been established, according to Rule 38.2(b), by this Authority as it appears in Box III. The applicant may, within one month from the date of mailing of this international search report, submit comments to this Authority.

6. The figure of the **drawings** to be published with the abstract is Figure No. _____

- ☐ as suggested by the applicant. ☒ None of the figures.
- ☐ because the applicant failed to suggest a figure.
- ☐ because this figure better characterizes the invention.

INTERNATIONAL SEARCH REPORT

International application No.
PCT/DK00/00413

Box I Observations where certain claims were found unsearchable (Continuation of item 1 of first sheet)

This international search report has not been established in respect of certain claims under Article 17(2)(a) for the following reasons:

1. ☒ Claims Nos.: **1-29, 43-45**
because they relate to subject matter not required to be searched by this Authority, namely:
see next sheet
2. ☐ Claims Nos.:
because they relate to parts of the international application that do not comply with the prescribed requirements to such an extent that no meaningful international search can be carried out, specifically:
3. ☐ Claims Nos.:
because they are dependent claims and are not drafted in accordance with the second and third sentences of Rule 6.4(a).

Box II Observations where unity of invention is lacking (Continuation of item 2 of first sheet)

This International Searching Authority found multiple inventions in this international application, as follows:

1. ☐ As all required additional search fees were timely paid by the applicant, this international search report covers all searchable claims.
2. ☐ As all searchable claims could be searched without effort justifying an additional fee, this Authority did not invite payment of any additional fee.
3. ☐ As only some of the required additional search fees were timely paid by the applicant, this international search report covers only those claims for which fees were paid, specifically claims Nos.:
4. ☐ No required additional search fees were timely paid by the applicant. Consequently, this international search report is restricted to the invention first mentioned in the claims; it is covered by claims Nos.:

Remark on Protest

- ☐ The additional search fees were accompanied by the applicant's protest.
☐ No protest accompanied the payment of additional search fees.

INTERNATIONAL SEARCH REPORT

International application No.
/DK00/00413

Claims 1-29, 43-45 relate to methods of treatment of the human or animal body by surgery or by therapy/ diagnostic methods practised on the human or animal body/Rule 39.1.(iv). Nevertheless, a search has been executed for these claims. The search has been based on the alleged effects of the compounds/compositions.

INTERNATIONAL SEARCH REPORT

International application No.

/DK 00/00413

A. CLASSIFICATION OF SUBJECT MATTER

IPC7: A61K 39/00, C07K 14/475, A61K 38/18, C12N 15/12, A61K 48/00
According to International Patent Classification (IPC) or to both national classification and IPC

B. FIELDS SEARCHED

Minimum documentation searched (classification system followed by classification symbols)

IPC7: A61K, C07K

Documentation searched other than minimum documentation to the extent that such documents are included in the fields searched

Electronic data base consulted during the international search (name of data base and, where practicable, search terms used)

C. DOCUMENTS CONSIDERED TO BE RELEVANT

| Category* | Citation of document, with indication, where appropriate, of the relevant passages | Relevant to claim No. |
|-----------|---|-----------------------|
| X | WO 9902667 A1 (UNIVERSITY OF LIEGE), 21 January 1999 (21.01.99), see abstract; page 8, lines 7-9; claim 61 -- | 1-52 |
| P,X | WO 9942573 A1 (BIOSTAR INC.), 26 August 1999 (26.08.99), see abstract; page 30, line 10 - page 33, line 21; page 36, lines 12-20; page 48, line 28 - page 54, line 7 -- | 1-52 |
| P,X | GB 2333706 A (MERCK & CO INC), 4 August 1999 (04.08.99), see entire document -- ----- | 1-52 |

☐ Further documents are listed in the continuation of Box C.

☒ See patent family annex.

* Special categories of cited documents:

"A" document defining the general state of the art which is not considered to be of particular relevance

"E" earlier application or patent but published on or after the international filing date

"L" document which may throw doubts on priority claim(s) or which is cited to establish the publication date of another citation or other special reason (as specified)

"O" document referring to an oral disclosure, use, exhibition or other means

"P" document published prior to the international filing date but later than the priority date claimed

"T" later document published after the international filing date or priority date and not in conflict with the application but cited to understand the principle or theory underlying the invention

"X" document of particular relevance: the claimed invention cannot be considered novel or cannot be considered to involve an inventive step when the document is taken alone

"Y" document of particular relevance: the claimed invention cannot be considered to involve an inventive step when the document is combined with one or more other such documents, such combination being obvious to a person skilled in the art

"&" document member of the same patent family

Date of the actual completion of the international search

24 November 2000

Name and mailing address of the International Searching Authority
European Patent Office P.B. 5818 Patentlaan 2
NL-2280 HV Rijswijk
Tel(+31-70)340-2040, Tx 31 651 epo nl,
Fax(+31-70)340-3016

Date of mailing of the international search report

26. 01. 01

Authorized officer

HENRIK NILSSON/EÖ
Telephone No.

INTERNATIONAL SEARCH REPORT
Information on patent family members

02/11/00

International application No.
PCT/DK 00/00413

| Patent document cited in search report | | | Publication date | Patent family member(s) | | Publication date |
|---|---------|----|---------------------|----------------------------|-----------|---------------------|
| WO | 9902667 | A1 | 21/01/99 | AU | 8457198 A | 08/02/99 |
| | | | | EP | 1002068 A | 24/05/00 |
| | | | | US | 6103466 A | 15/08/00 |
| ----- | | | | | | |
| WO | 9942573 | A1 | 26/08/99 | AU | 2507399 A | 06/09/99 |
| ----- | | | | | | |
| GB | 2333706 | A | 04/08/99 | GB | 9902041 D | 00/00/00 |
| ----- | | | | | | |

REC'D 12 DEC 2001



WIPO

PCT

INTERNATIONAL PRELIMINARY EXAMINATION REPORT

(PCT Article 36 and Rule 70)

12

| | | | |
|---|--|--|--|
| Applicant's or agent's file reference 23450 PC: 1 | | FOR FURTHER ACTION See Notification of Transmittal of International Preliminary Examination Report (Form PCT/IPEA/416) | |
| International application No. PCT/DK00/00413 | International filing date (day/month/year) 20/07/2000 | Priority date (day/month/year) 20/07/1999 | |
| International Patent Classification (IPC) or national classification and IPC C07K14/00 | | | |
| Applicant [M&E BIOTECH A/S et al.] PHARMEXA A/S | | | |
| <p>1. This international preliminary examination report has been prepared by this International Preliminary Examining Authority and is transmitted to the applicant according to Article 36.</p> <p>2. This REPORT consists of a total of 10 sheets, including this cover sheet.</p> <p><input checked="" type="checkbox"/> This report is also accompanied by ANNEXES, i.e. sheets of the description, claims and/or drawings which have been amended and are the basis for this report and/or sheets containing rectifications made before this Authority (see Rule 70.16 and Section 607 of the Administrative Instructions under the PCT).</p> <p>These annexes consist of a total of ⁹₁ sheets.</p> | | | |
| <p>3. This report contains indications relating to the following items:</p> <ul style="list-style-type: none"> I <input checked="" type="checkbox"/> Basis of the report II <input checked="" type="checkbox"/> Priority III <input checked="" type="checkbox"/> Non-establishment of opinion with regard to novelty, inventive step and industrial applicability IV <input checked="" type="checkbox"/> Lack of unity of invention V <input checked="" type="checkbox"/> Reasoned statement under Article 35(2) with regard to novelty, inventive step or industrial applicability; citations and explanations supporting such statement VI <input checked="" type="checkbox"/> Certain documents cited VII <input checked="" type="checkbox"/> Certain defects in the international application VIII <input type="checkbox"/> Certain observations on the international application | | | |
| Date of submission of the demand 19/02/2001 | | Date of completion of this report 08.11.2001 | |
| Name and mailing address of the International preliminary examining authority:  European Patent Office D-80298 Munich Tel. +49 89 2399 - 0 Tx: 523658 epmu d Fax: +49 89 2399 - 4465 | | Authorized officer Moonen, P Telephone No. +49 89 2399 8538  | |

Form PCT/IPEA/409 (cover sheet) (January 1994)

INTERNATIONAL PRELIMINARY
EXAMINATION REPORT

International application No. PCT/DK00/00413

I. Basis of the report

1. With regard to the **elements** of the international application (*Replacement sheets which have been furnished to the receiving Office in response to an invitation under Article 14 are referred to in this report as "originally filed" and are not annexed to this report since they do not contain amendments (Rules 70.16 and 70.17)*):

Description, pages:

| | | | |
|------|---------------------|------------|---------------------------|
| 1-56 | as originally filed | | |
| 57 | as received on | 31/10/2000 | with letter of 27/10/2000 |

Claims, No.:

| | | | |
|------|----------------|------------|---------------------------|
| 1-47 | as received on | 27/07/2001 | with letter of 24/07/2001 |
|------|----------------|------------|---------------------------|

Drawings, sheets:

| | |
|---------|---------------------|
| 1/5-5/5 | as originally filed |
|---------|---------------------|

Sequence listing part of the description, pages:

1-35, as originally filed

2. With regard to the **language**, all the elements marked above were available or furnished to this Authority in the language in which the international application was filed, unless otherwise indicated under this item.

These elements were available or furnished to this Authority in the following language: , which is:

- ☐ the language of a translation furnished for the purposes of the international search (under Rule 23.1(b)).
- ☐ the language of publication of the international application (under Rule 48.3(b)).
- ☐ the language of a translation furnished for the purposes of international preliminary examination (under Rule 55.2 and/or 55.3).

3. With regard to any **nucleotide and/or amino acid sequence** disclosed in the international application, the international preliminary examination was carried out on the basis of the sequence listing:

- ☒ contained in the international application in written form.
- ☐ filed together with the international application in computer readable form.
- ☐ furnished subsequently to this Authority in written form.
- ☐ furnished subsequently to this Authority in computer readable form.
- ☐ The statement that the subsequently furnished written sequence listing does not go beyond the disclosure in the international application as filed has been furnished.
- ☐ The statement that the information recorded in computer readable form is identical to the written sequence

**INTERNATIONAL PRELIMINARY
EXAMINATION REPORT**

International application No. PCT/DK00/00413

listing has been furnished.

4. The amendments have resulted in the cancellation of:

- ☐ the description, pages:
- ☐ the claims, Nos.:
- ☐ the drawings, sheets:

5. ☐ This report has been established as if (some of) the amendments had not been made, since they have been considered to go beyond the disclosure as filed (Rule 70.2(c)):

(Any replacement sheet containing such amendments must be referred to under item 1 and annexed to this report.)

6. Additional observations, if necessary:

II. Priority

1. ☐ This report has been established as if no priority had been claimed due to the failure to furnish within the prescribed time limit the requested:

- ☐ copy of the earlier application whose priority has been claimed.
- ☐ translation of the earlier application whose priority has been claimed.

2. ☒ This report has been established as if no priority had been claimed due to the fact that the priority claim has been found invalid.

Thus for the purposes of this report, the international filing date indicated above is considered to be the relevant date.

3. Additional observations, if necessary:
see separate sheet

III. Non-establishment of opinion with regard to novelty, inventive step and industrial applicability

1. The questions whether the claimed invention appears to be novel, to involve an inventive step (to be non-obvious), or to be industrially applicable have not been examined in respect of:

- ☐ the entire international application.
- ☒ claims Nos. 1-28 and 41-43.

because:

- ☒ the said international application, or the said claims Nos. 1-28 and 41-43 relate to the following subject matter which does not require an international preliminary examination (*specify*):
see separate sheet

**INTERNATIONAL PRELIMINARY
EXAMINATION REPORT**

International application No. PCT/DK00/00413

- ☐ the description, claims or drawings (*indicate particular elements below*) or said claims Nos. are so unclear that no meaningful opinion could be formed (*specify*):
- ☐ the claims, or said claims Nos. are so inadequately supported by the description that no meaningful opinion could be formed.
- ☐ no international search report has been established for the said claims Nos. .
- 2. A meaningful international preliminary examination cannot be carried out due to the failure of the nucleotide and/or amino acid sequence listing to comply with the standard provided for in Annex C of the Administrative Instructions:
 - ☐ the written form has not been furnished or does not comply with the standard.
 - ☐ the computer readable form has not been furnished or does not comply with the standard.

IV. Lack of unity of invention

1. In response to the invitation to restrict or pay additional fees the applicant has:
 - ☒ restricted the claims.
 - ☐ paid additional fees.
 - ☐ paid additional fees under protest.
 - ☒ neither restricted nor paid additional fees.
2. ☐ This Authority found that the requirement of unity of invention is not complied and chose, according to Rule 68.1, not to invite the applicant to restrict or pay additional fees.
3. This Authority considers that the requirement of unity of invention in accordance with Rules 13.1, 13.2 and 13.3 is
 - ☐ complied with.
 - ☒ not complied with for the following reasons:
see separate sheet
4. Consequently, the following parts of the international application were the subject of international preliminary examination in establishing this report:
 - ☐ all parts.
 - ☒ the parts relating to claims Nos. 1-28 and 41-43.

V. Reasoned statement under Article 35(2) with regard to novelty, inventive step or industrial applicability; citations and explanations supporting such statement

1. Statement

**INTERNATIONAL PRELIMINARY
EXAMINATION REPORT**

International application No. PCT/DK00/00413

| | |
|-------------------------------|----------------------------|
| Novelty (N) | Yes: Claims 1-28 and 41-43 |
| | No: Claims |
| Inventive step (IS) | Yes: Claims |
| | No: Claims 1-28 and 41-43 |
| Industrial applicability (IA) | Yes: Claims |
| | No: Claims 1 (no opinion) |

2. Citations and explanations
see separate sheet

VI. Certain documents cited

1. Certain published documents (Rule 70.10)

and / or

2. Non-written disclosures (Rule 70.9)

see separate sheet

VII. Certain defects in the international application

The following defects in the form or contents of the international application have been noted:
see separate sheet

**INTERNATIONAL PRELIMINARY
EXAMINATION REPORT - SEPARATE SHEET**

International application No. PCT/DK00/00413

Reference is made to the following documents:

- D1:** WO 99 02667 A1 (UNIVERSITY OF LIEGE) 21 January 1999
D2: WO 99 42573 A1 (BIOSTAR INC.) 26 August 1999; interfering document
D3: GB 2 333 706 A (MERCK & CO INC) 4 August 1999; interfering document
D4: PNAS 94 (1997) 12457-61

The document D4 was not cited in the international search report. A copy of the document has already been supplied to the applicant.

Re Item II

Priority

1. The present application claims the priority dates of 2 priority applications, designated P1-P2. The subject-matter of P1 with filing date 20.07.99 as well as P2 with filing date 26.07.99 is more limited in scope than the internationally filed application.

In particular it is noted that in the specifying of "a foreign T_H epitope is inserted or substituted into any one of the loop areas or the flexible termini in the GDF-8 polypeptide" is missing in P1-P2.

D2-D3 are therefore fully citable as prior art with respect to subject-matter lacking the right of priority to P1/P2.

Re Item III

Non-establishment of opinion with regard to novelty, inventive step and industrial applicability

2. For the assessment of the present **claims 1-28 and 41-43** on the question whether they are industrially applicable, no unified criteria exist in the PCT Contracting States. The patentability can also be dependent upon the formulation of the claims. The EPO, for example, does not recognize as industrially applicable the subject-matter of claims to the use of a compound in medical treatment, but

**INTERNATIONAL PRELIMINARY
EXAMINATION REPORT - SEPARATE SHEET**

International application No. PCT/DK00/00413

may allow, however, claims to a known compound for first use in medical treatment and the use of such a compound for the manufacture of a medicament for a new medical treatment.

Claims 1-28 and 41-43 include subject-matter considered by this Authority to be covered by the provisions of Rule 67.1(iv) PCT. Consequently, no opinion will be formulated with respect to the industrial applicability of the subject-matter of these claims (Article 34(4)(a)(i) PCT).

Re Item IV

Lack of unity of invention

3. **Introduction:** GDF-8, also known as myostatin, is well known from the prior art, as well as mutations in myostatin genes leading to phenotypes of hypermuscularity in e.g. bovine and mouse (see D4, concerning an 11-nucleotide deletion in the third exon which causes a frameshift that eliminates virtually all of the mature, active region of the molecule, found in two breeds of double-muscled cattle).

D1 is a patent application and refers also to double-muscled cattle in relation to myostatin; D1 discloses the sequences and the method of use in order to increase muscle mass in a mammal by the production of antibodies against the GDF-8 polypeptide (claims 61-62) or by an effective amount of an antisense nucleic acid or oligonucleotide (claim 63).

4. This Authority considers that the requirement of unity of invention in accordance with Rules 13.1, 13.2 and 13.3 is not complied with for the following reasons:

PCT Rule 13 recites the basic principle of unity of invention that an application should relate to only invention or, if there is more than one invention, that applicant would have a right to include in a single application only those inventions which are so linked as to form a single inventive concept. According to Rule 13, a group of inventions is linked to form a single inventive concept where there is a technical relationship among the inventions that involves at least one common or corresponding special technical feature that defines the contribution which each

claimed invention, considered as a whole, makes over the prior art.

5. The inventions identified within the originally filed application were:
 - i. A method for in vivo down-regulation of GDF-8 activity in an animal e.g. to increase the muscle mass of an animal (claims 1-29 and 43-45); **present claims 1-28 and 41-43.**
 - ii. GDF-8 analogues and encoding sequences, immunogenic compositions (claims 30-42, 46-49); **present claims 29-40 and 44-47.**
 - iii. Methods for the identification of a modified GDF-8 polypeptide and their use (claims 50-52); **presently deleted.**
6. With respect to the reasons for the observation of non-unity the following is noted:

Given the above mentioned disclosures D1 and D4 referring to GDF-8 sequences and mutants in relation to the increase of muscle mass, a single general inventive concept (referred to in Rule 13 PCT and the PCT Preliminary Examination Guidelines Ch.III, 7) is not recognisable in the absence of a common, special technical feature: the identified groups therefore lack unity of invention.

7. An invitation to pay additional fees and/or to restrict the claims to one invention only was issued before the issue of the written opinion: the applicant amended the claims by filing of a new set of claims. This new set however did not overcome all unity objections (i.e. the examination and the present report concern only the in vivo methods and not e.g. the still included GDF-8 analogues). Moreover, it appears that the subject-matter of new claim 1 is also not unitarily linked with respect to subject-matter entitled or not-entitled to the priority date.

Page 54 (example 1) of the description mentions that "the rationale behind the present invention is to substitute stretches of amino acid residues in the target protein with foreign or artificial T-cell epitopes (e.g. the promiscuous tetanus toxin T-cell epitopes P2 and P30)"; it is concluded that the three specified stretches in claim 1 do not appear to share a common special technical feature.

**INTERNATIONAL PRELIMINARY
EXAMINATION REPORT - SEPARATE SHEET**

International application No. PCT/DK00/00413

Re Item V

Reasoned statement under Rule 66.2(a)(ii) with regard to novelty, inventive step or industrial applicability; citations and explanations supporting such statement

8. Present claim 1 specifies that immunization of an animal (including a human being) is carried with a GDF-8 analogue in which a substantial fraction of GDF-8 B-cell epitopes are preserved, and a foreign T_H epitope is introduced into any one of three specified positions of GDF-8 or into any one of the loop areas or the flexible termini in the GDF-8 polypeptide. It appears that the claimed subject-matter is novel over the available prior art documents.

It is however noted that the application seriously lacks support/disclosure as no example demonstrates that the technical problem is solved, let alone that an effect of the introduction of the T_H epitope is demonstrated: it merely refers to the expectation that the introduction of T_H epitopes should produce an improved immunogen. It is decided in the present case to still formulate an opinion with respect to inventive step: however, in particular in view of D1 concerning the immunisation with GDF-8 (page 22 lines 25-30 and claims 61-63) and the further speculation in the present application concerning the use of possible analogues with introduced T_H epitopes (a method known per se) it is considered that the claimed subject-matter is obvious to the skilled person. Thus, contrary to the requirements of Article 33(3) of the PCT, **claim 1** does not involve an inventive step; the same reasoning applies to the other depending claims, all additionally introduced technical features being based on common knowledge.

Re Item VI

Certain documents cited

Certain published documents (Rule 70.10)

| Application No Patent No | Publication date (day/month/year) | Filing date (day/month/year) | Priority date (valid claim) (day/month/year) |
|-----------------------------|--------------------------------------|---------------------------------|---|
| D2 | 26.08.99 | 19.02.99 | 19.02.98 |

9. D2 appears to be relevant as an interfering application with respect to the novelty of the claimed subject-matter in the regional european phase of this application (under Article 54(3)(4) EPC for the common designated contracting states).

No european patent family member for D3 has been found; however, this document could be of relevance for subject-matter not entitled to the priority dates in July 1999.

Re Item VII

Certain defects in the international application

10. Contrary to the requirements of Rule 5.1(a)(ii) PCT, the relevant background art disclosed in the documents D1/D4 is not mentioned in the description, nor are these documents identified therein.

mechanisms of such a response are most likely to be identical to those which have already been observed for TNF α , cf. WO 98/46642 and WO 95/05849.

EXAMPLE 3

In vivo models

Groups of mice will be immunised with the various constructs described in Example 1. The mice will be immunised at the age of about 4 weeks since they have to be immune competent in order to respond to the vaccine. Freund's Complete adjuvant will be used, but experiments will also be performed using an alum adjuvant such as Adjuphos™, which has previously been used successfully in admixture with TNF α autovaccine constructs. Adjuphos™ is accepted for both human and animal use. During the entire immunisation period the total body weight of GDF-8 immunised as well as control animals will be monitored regularly. When the mice are approximately 16 weeks of age, they will be sacrificed and the size of their muscle mass will be determined.

Due to the relatively narrow window in time where mice are immune competent but still not fully outgrown, it may be difficult to demonstrate an effect of anti-GDF-8 vaccination in these animals. If that proves to be the case, it is contemplated to alternatively immunise rats or larger animals such as pigs, cattle, etc.

The modified GDF-8 molecule, which superiorly increases the growth rate of the animals and/or superiorly increases the maximum muscle size, is selected for clinical development.

CLAIMS

1. A method for in vivo down-regulation of growth differentiation factor 8 (GDF-8) activity in an animal, including a human being, the method comprising effecting presentation to the
5 animal's immune system of an immunogenically effective amount of at least one GDF-8 analogue wherein is introduced at least one modification in the GDF-8 amino acid sequence which has as results that

- 10 - immunization of the animal with the analogue induces production of antibodies against the GDF-8 polypeptide, and
- a substantial fraction of GDF-8 B-cell epitopes are preserved, and
- 15 - a foreign T helper epitope (T_H epitope) is introduced corresponding to any one of residues 18-41, 49-69, or 79-104 in SEQ ID NO: 11 or 12 by means of addition, deletion, insertion or substitution, or introduced corresponding to an equivalent sequence from a GDF-8 polypeptide of different origin than human, bovine, porcine, chicken or turkey, or a foreign T_H epitope is
20 inserted or substituted into any one of the loop areas or the flexible termini in the GDF-8 polypeptide.

2. The method according to claim 1, which further comprises that

- 25 - at least one first moiety is introduced which effects targeting of the modified molecule to an antigen presenting cell (APC) or a B-lymphocyte, and/or

AMENDED SHEET

- at least one second moiety is introduced which stimulates the immune system, and/or
- at least one third moiety is introduced which optimises presentation of the modified GDF-8 polypeptide to the immune system.

3. The method according to claim 2, wherein the modification includes introduction as side groups, by covalent or non-covalent binding to suitable chemical groups in GDF-8 or a subsequence thereof, of the foreign T_H epitope and/or of the first and/or of the second and/or of the third moiety.

4. The method according to claim 4 or 5, wherein the modification includes amino acid substitution and/or deletion and/or insertion and/or addition.

5. The method according to claim 4, wherein the modification results in the provision of a fusion polypeptide.

6. The method according to claim 4 or 5, wherein introduction of the amino acid substitution and/or deletion and/or insertion and/or addition results in a substantial preservation of the overall tertiary structure of GDF-8.

7. The method according to any one of claims 1-6, wherein the modification includes duplication of at least one GDF-8 B-cell epitope and/or introduction of a hapten.

8. The method according to any one of claims 2-7, wherein the foreign T_H epitope is immunodominant in the animal.

9. The method according to any one of claims 2-8, wherein the foreign T_H epitope is promiscuous, such as a natural pro-

AMENDED SHEET

miscuous T_H epitope and an artificial MHC-II binding peptide sequence.

10. The method according to claim 9, wherein the natural T_H epitope is selected from a Tetanus toxoid epitope such as P2
5 or P30, a diphtheria toxoid epitope, an influenza virus hemagglutinin epitope, and a *P. falciparum* CS epitope.

11. The method according to any one of claims 2-10, wherein the first moiety is a substantially specific binding partner for a B-lymphocyte specific surface antigen or for an APC spe-
10 cific surface antigen, such as a hapten or a carbohydrate for which there is a receptor on the B-lymphocyte or the APC, such as mannan or mannose.

12. The method according to any one of claims 2-11, wherein the second moiety is selected from a cytokine, a hormone, and
15 a heat-shock protein.

13. The method according to claim 12, wherein the cytokine is selected from, or is an effective part of, interferon γ (IFN- γ), Flt3L, interleukin 1 (IL-1), interleukin 2 (IL-2), interleukin 4 (IL-4), interleukin 6 (IL-6), interleukin 12 (IL-12),
20 interleukin 13 (IL-13), interleukin 15 (IL-15), and granulocyte-macrophage colony stimulating factor (GM-CSF), and wherein the heat-shock protein is selected from the group consisting of HSP70, HSP90, HSC70, GRP94, and calreticulin (CRT), or an effective part thereof.

25 14. The method according to any one of claims 2-13, wherein the third moiety is of lipid nature, such as a palmitoyl group, a myristyl group, a farnesyl group, a geranyl-geranyl group, a GPI-anchor, and an N-acyl diglyceride group.

AMENDED SHEET

15. The method according to any one of the preceding claims, wherein the GDF-8 subsequence or the GDF-8 analogue is derived from the C-terminal, active form of GDF-8, such as subsequence or analogue derived from a bovine, porcine, human, chicken,
5 sheep, or turkey GDF-8 polypeptide.

16. The method according to claim 15, wherein the GDF-8 polypeptide has been modified by substituting at least one amino acid sequence in SEQ ID NO: 11 or 12 with at least one amino acid sequence of equal or different length which contains a
10 foreign T_H epitope, wherein substituted amino acid sequences are comprised in residues 1-12, 18-41, 43-48, 49-69, or 79-104 in SEQ ID NO: 11 or 12, or wherein the GDF-8 polypeptide has been modified by inserting at least one amino acid sequence which contains a foreign T_H epitope, wherein insertion is
15 performed anywhere in positions 1-12, 18-30, 42-51, 82-86, and 105-109 in SEQ ID NO: 11 or 12.

17. The method according to any one of the preceding claims, wherein presentation to the immune system is effected by having at least two copies of the GDF-8 polypeptide, the subse-
20 quence thereof or the modified GDF-8 polypeptide covalently or non-covalently linked to a carrier molecule capable of effecting presentation of multiple copies of antigenic determinants.

18. The method according to any one of the preceding claims, wherein an effective amount of the GDF-8 polypeptide or the
25 GDF-8 analogue is administered to the animal via a route selected from the parenteral route such as the intradermal, the subdermal, the intracutaneous, the subcutaneous, and the intramuscular routes; the peritoneal route; the oral route; the buccal route; the sublingual route; the epidural route; the
30 spinal route; the anal route; and the intracranial route.

AMENDED SHEET

19. The method according to claim 18, wherein the effective amount is between 0.5 μ g and 2,000 μ g of the GDF-8 polypeptide, the subsequence thereof or the analogue thereof.

20. The method according to claim 18 or 19, which includes at least one administration of the GDF-8 polypeptide or analogue per year, such as at least 2, at least 3, at least 4, at least 6, and at least 12 administrations per year.

21. The method according to any one of claims 18-20, wherein the GDF-8 polypeptide, the subsequence thereof, or the modified GDF-8 polypeptide optionally has been formulated with a pharmaceutically and immunologically acceptable carrier and/or vehicle and has been formulated with an adjuvant which facilitates breaking of autotolerance to autoantigens, such as an adjuvant selected from the group consisting of an immune targeting adjuvant; an immune modulating adjuvant such as a toxin, a cytokine and a mycobacterial derivative; an oil formulation; a polymer; a micelle forming adjuvant; a saponin; an immunostimulating complex matrix (an ISCOM matrix); a particle; DDA; aluminium adjuvants; DNA adjuvants; γ -inulin; and an encapsulating adjuvant.

22. The method according to any one of claims 19-21, wherein the GDF-8 polypeptide or analogue is contained in a virtual lymph node (VLN) device.

23. The method according to any one of claims 1-17, wherein presentation of modified GDF-8 to the immune system is effected by introducing nucleic acid(s) encoding the modified GDF-8 into the animal's cells and thereby obtaining *in vivo* expression by the cells of the nucleic acid(s) introduced.

AMENDED SHEET

24. The method according to claim 23, wherein the nucleic acid(s) introduced is/are selected from naked DNA, DNA formulated with charged or uncharged lipids, DNA formulated in liposomes, DNA included in a viral vector, DNA formulated with a transfection-facilitating protein or polypeptide, DNA formulated with a targeting protein or polypeptide, DNA formulated with Calcium precipitating agents, DNA coupled to an inert carrier molecule, DNA formulated with chitin or chitosan, and DNA formulated with an adjuvant.
25. The method according to claim 23 or 24, wherein the nucleic acids are administered intraarterially, intravenously, or by the routes defined in claim 18.
26. The method according to claim 24 or 25, wherein the nucleic acid(s) is/are contained in a VLN device and/or are formulated as defined in claim 21.
27. The method according to any one of claims 24-26, which includes at least one administration of the nucleic acids per year, such as at least 2, at least 3, at least 4, at least 6, and at least 12 administrations per year
28. A method for increasing the muscle mass of an animal, the method comprising down-regulating GDF-8 activity according to the method of any one of claims 1-27 to such an extent such that the muscle mass is increased at least 5% when compared to animals which exhibit normal GDF-8 activity, such as at least 10, 15, 20, 25, 30, 35, 40, and 45%.
29. A GDF-8 analogue which is derived from an animal GDF-8 polypeptide wherein is introduced a modification as defined in any one of claims 1-17.

AMENDED SHEET

30. An immunogenic composition comprising an immunogenically effective amount of an GDF-8 analogue according to claim 29, the composition further comprising a pharmaceutically and immunologically acceptable carrier and/or vehicle and optionally
5 an adjuvant.

31. An immunogenic composition according to claim 30, wherein the adjuvant is selected from the group consisting of the adjuvants of claim 21.

32. A nucleic acid fragment which encodes a GDF-8 analogue
10 according to claim 29.

33. A vector carrying the nucleic acid fragment according to claim 32, such as a vector capable of autonomous replication.

34. The vector according to claim 33 which is selected from the group consisting of a plasmid, a phage, a cosmid, a mini-
15 chromosome, and a virus.

35. The vector according to claim 33 or 34, comprising, in the 5'→3' direction and in operable linkage, a promoter for driving expression of the nucleic acid fragment according to claim 32, optionally a nucleic acid sequence encoding a leader
20 peptide enabling secretion of or integration into the membrane of the polypeptide fragment, the nucleic acid fragment according to claim 32, and optionally a terminator.

36. The vector according to any one of claims 33-35 which, when introduced into a host cell, is either capable of being
25 integrated in the host cell genome or which is not capable of being integrated in the host cell genome.

AMENDED SHEET

37. The vector according to claim 35 or 36 when dependent on claim 35, wherein the promoter drives expression in a eukaryotic cell or drives expression in a prokaryotic cell.

38. A transformed cell carrying the vector of any one of 5 claims 33-37, such as a transformed cell which is capable of replicating the nucleic acid fragment according to claim 32.

39. The transformed cell according to claim 38, which is a micro-organism selected from a bacterium, such as a bacterium of the genus *Escherichia* (preferably *E. coli*), *Bacillus*, *Salmonella*, or *Mycobacterium* (preferably a non-pathogenic *Mycobacterium* cell such as *M. bovis* BCG), a yeast, a protozoan, or a 10 cell derived from a multicellular organism selected from a fungus, an insect cell such as an S₂ or an SF cell, a plant cell, and a mammalian cell.

15 40. The transformed cell according to claim 38 or 39, which expresses the nucleic acid fragment according to claim 32, such as a transformed cell which secretes or carries on its surface, the GDF-8 analogue according to claim 29.

41. The method according to any one of claims 1-17, wherein 20 presentation to the immune system is effected by administering a non-pathogenic micro-organism or virus which is carrying a nucleic acid fragment which encodes and expresses the GDF-8 polypeptide or analogue.

42. The method according to claim 41, wherein the virus is a 25 non-virulent pox virus such as a vaccinia virus or wherein the micro-organism is a bacterium such as the bacterium defined in claim 39.

AMENDED SHEET

43. The method according to any claim 41 or 42, wherein the non-pathogenic micro-organism or virus is administered one single time to the animal.

44. A composition for inducing production of antibodies
5 against GDF-8, the composition comprising

- a nucleic acid fragment according to claim 32 or a vector according to any one of claims 33-37, and
- a pharmaceutically and immunologically acceptable carrier and/or vehicle and/or adjuvant.

10 45. The composition according to claim 44, wherein the nucleic acid fragment is formulated according to claim 24 or 26.

46. A stable cell line which carries the vector according to any one of claims 33-37 and which expresses the nucleic acid fragment according to claim 32, and which optionally secretes
15 or carries the GDF-8 analogue according to claim 29 on its surface.

47. A method for the preparation of the cell according to any one of claims 38-40, the method comprising transforming a host cell with the nucleic acid fragment according to claim 32 or
20 with the vector according to any one of claims 33-37.

AMENDED SHEET

PATENT COOPERATION TREATY

From the INTERNATIONAL SEARCHING AUTHORITY

PCT

NOTIFICATION OF TRANSMITTAL OF
THE INTERNATIONAL SEARCH REPORT
OR THE DECLARATION

(PCT Rule 44.1)

To:
c/o M&E Biotech A/S
Attn. KOEFOED, Peter
Kogle Alle 6
DK-2970 Horsholm
DENMARK

| | |
|-------------------------------------|------------|
| Date of mailing (day/month/year) | 26/01/2001 |
|-------------------------------------|------------|

| | |
|--|--|
| Applicant's or agent's file reference 23450 PC 1 | FOR FURTHER ACTION See paragraphs 1 and 4 below |
|--|--|

| | |
|---|---|
| International application No. PCT/DK 00/00413 | International filing date (day/month/year) 20/07/2000 |
|---|---|

| |
|--|
| Applicant M&E BIOTECH A/S et al. |
|--|

1. ☒ The applicant is hereby notified that the International Search Report has been established and is transmitted herewith.
Filing of amendments and statement under Article 19:
 The applicant is entitled, if he so wishes, to amend the claims of the International Application (see Rule 46):

When? The time limit for filing such amendments is normally 2 months from the date of transmittal of the International Search Report; however, for more details, see the notes on the accompanying sheet.

Where? Directly to the International Bureau of WIPO
 34, chemin des Colombettes
 1211 Geneva 20, Switzerland
 Facsimile No.: (41-22) 740.14.35

For more detailed instructions, see the notes on the accompanying sheet.
2. ☐ The applicant is hereby notified that no International Search Report will be established and that the declaration under Article 17(2)(a) to that effect is transmitted herewith.
3. ☐ **With regard to the protest** against payment of (an) additional fee(s) under Rule 40.2, the applicant is notified that:


☐ the protest together with the decision thereon has been transmitted to the International Bureau together with the applicant's request to forward the texts of both the protest and the decision thereon to the designated Offices.

☐ no decision has been made yet on the protest; the applicant will be notified as soon as a decision is made.
4. **Further action(s):** The applicant is reminded of the following:

Shortly after **18 months** from the priority date, the international application will be published by the International Bureau. If the applicant wishes to avoid or postpone publication, a notice of withdrawal of the international application, or of the priority claim, must reach the International Bureau as provided in Rules 90bis.1 and 90bis.3, respectively, before the completion of the technical preparations for international publication.

Within **19 months** from the priority date, a demand for international preliminary examination must be filed if the applicant wishes to postpone the entry into the national phase until 30 months from the priority date (in some Offices even later).

Within **20 months** from the priority date, the applicant must perform the prescribed acts for entry into the national phase before all designated Offices which have not been elected in the demand or in a later election within 19 months from the priority date or could not be elected because they are not bound by Chapter II.

| | |
|--|--|
| Name and mailing address of the International Searching Authority  European Patent Office, P.B. 5818 Patentlaan 2 NL-2280 HV Rijswijk Tel. (+31-70) 340-2040, Tx. 31 651 epo nl, Fax: (+31-70) 340-3016 | Authorized officer Mireille Claudepierre |
|--|--|

NOTES TO FORM PCT/ISA/220

These Notes are intended to give the basic instructions concerning the filing of amendments under article 19. The Notes are based on the requirements of the Patent Cooperation Treaty, the Regulations and the Administrative Instructions under that Treaty. In case of discrepancy between these Notes and those requirements, the latter are applicable. For more detailed information, see also the PCT Applicant's Guide, a publication of WIPO.

In these Notes, "Article", "Rule", and "Section" refer to the provisions of the PCT, the PCT Regulations and the PCT Administrative Instructions, respectively.

INSTRUCTIONS CONCERNING AMENDMENTS UNDER ARTICLE 19

The applicant has, after having received the international search report, one opportunity to amend the claims of the international application. It should however be emphasized that, since all parts of the international application (claims, description and drawings) may be amended during the international preliminary examination procedure, there is usually no need to file amendments of the claims under Article 19 except where, e.g. the applicant wants the latter to be published for the purposes of provisional protection or has another reason for amending the claims before international publication. Furthermore, it should be emphasized that provisional protection is available in some States only.

What parts of the International application may be amended?

Under Article 19, only the claims may be amended.

During the international phase, the claims may also be amended (or further amended) under Article 34 before the International Preliminary Examining Authority. The description and drawings may only be amended under Article 34 before the International Examining Authority.

Upon entry into the national phase, all parts of the international application may be amended under Article 28 or, where applicable, Article 41.

When?

Within 2 months from the date of transmittal of the international search report or 16 months from the priority date, whichever time limit expires later. It should be noted, however, that the amendments will be considered as having been received on time if they are received by the International Bureau after the expiration of the applicable time limit but before the completion of the technical preparations for international publication (Rule 46.1).

Where not to file the amendments?

The amendments may only be filed with the International Bureau and not with the receiving Office or the International Searching Authority (Rule 46.2).

Where a demand for international preliminary examination has been/is filed, see below.

How?

Either by cancelling one or more entire claims, by adding one or more new claims or by amending the text of one or more of the claims as filed.

A replacement sheet must be submitted for each sheet of the claims which, on account of an amendment or amendments, differs from the sheet originally filed.

All the claims appearing on a replacement sheet must be numbered in Arabic numerals. Where a claim is cancelled, no renumbering of the other claims is required. In all cases where claims are renumbered, they must be renumbered consecutively (Administrative Instructions, Section 205(b)).

The amendments must be made in the language in which the international application is to be published.

What documents must/may accompany the amendments?

Letter (Section 205(b)):

The amendments must be submitted with a letter.

The letter will not be published with the international application and the amended claims. It should not be confused with the "Statement under Article 19(1)" (see below, under "Statement under Article 19(1)").

The letter must be in English or French, at the choice of the applicant. However, if the language of the international application is English, the letter must be in English; if the language of the international application is French, the letter must be in French.

The letter must indicate the differences between the claims as filed and the claims as amended. It must, in particular, indicate, in connection with each claim appearing in the international application (it being understood that identical indications concerning several claims may be grouped), whether

- (i) the claim is unchanged;
- (ii) the claim is cancelled;
- (iii) the claim is new;
- (iv) the claim replaces one or more claims as filed;
- (v) the claim is the result of the division of a claim as filed.

The following examples illustrate the manner in which amendments must be explained in the accompanying letter:

1. [Where originally there were 48 claims and after amendment of some claims there are 51]:
"Claims 1 to 29, 31, 32, 34, 35, 37 to 48 replaced by amended claims bearing the same numbers; claims 30, 33 and 36 unchanged; new claims 49 to 51 added."
2. [Where originally there were 15 claims and after amendment of all claims there are 11]:
"Claims 1 to 15 replaced by amended claims 1 to 11."
3. [Where originally there were 14 claims and the amendments consist in cancelling some claims and in adding new claims]:
"Claims 1 to 6 and 14 unchanged; claims 7 to 13 cancelled; new claims 15, 16 and 17 added." or
"Claims 7 to 13 cancelled; new claims 15, 16 and 17 added; all other claims unchanged."
4. [Where various kinds of amendments are made]:
"Claims 1-10 unchanged; claims 11 to 13, 18 and 19 cancelled; claims 14, 15 and 16 replaced by amended claim 14; claim 17 subdivided into amended claims 15, 16 and 17; new claims 20 and 21 added."

"Statement under article 19(1)" (Rule 46.4)

The amendments may be accompanied by a statement explaining the amendments and indicating any impact that such amendments might have on the description and the drawings (which cannot be amended under Article 19(1)).

The statement will be published with the international application and the amended claims.

It must be in the language in which the international application is to be published.

It must be brief, not exceeding 500 words if in English or if translated into English.

It should not be confused with and does not replace the letter indicating the differences between the claims as filed and as amended. It must be filed on a separate sheet and must be identified as such by a heading, preferably by using the words "Statement under Article 19(1)."

It may not contain any disparaging comments on the international search report or the relevance of citations contained in that report. Reference to citations, relevant to a given claim, contained in the international search report may be made only in connection with an amendment of that claim.

Consequence if a demand for international preliminary examination has already been filed

If, at the time of filing any amendments and any accompanying statement, under Article 19, a demand for international preliminary examination has already been submitted, the applicant must preferably, at the time of filing the amendments (and any statement) with the International Bureau, also file with the International Preliminary Examining Authority a copy of such amendments (and of any statement) and, where required, a translation of such amendments for the procedure before that Authority (see Rules 55.3(a) and 62.2, first sentence). For further information, see the Notes to the demand form (PCT/IPEA/401).

Consequence with regard to translation of the international application for entry into the national phase

The applicant's attention is drawn to the fact that, upon entry into the national phase, a translation of the claims as amended under Article 19 may have to be furnished to the designated/elected Offices, instead of, or in addition to, the translation of the claims as filed.

For further details on the requirements of each designated/elected Office, see Volume II of the PCT Applicant's Guide.

PATENT COOPERATION TREATY

PCT

INTERNATIONAL SEARCH REPORT

(PCT Article 18 and Rules 43 and 44)

| | | |
|--|---|--|
| Applicant's or agent's file reference 23450 PC 1 | FOR FURTHER ACTION | see Notification of Transmittal of International Search Report (Form PCT/ISA/220) as well as, where applicable, item 5 below. |
| International application No. PCT/DK 00/00413 | International filing date (day/month/year) 20 July 2000 | (Earliest) Priority Date (day/month/year) 20 July 1999 |
| Applicant M&E BIOTECH A/S et al | | |

This international search report has been prepared by this International Searching Authority and is transmitted to the applicant according to Article 18. A copy is being transmitted to the International Bureau.

This international search report consists of a total of 4 sheets.

☒ It is also accompanied by a copy of each prior art document cited in this report.

1. Basis of the report

a. With regard to the language, the international search was carried out on the basis of the international application in the language in which it was filed, unless otherwise indicated under this item.

☐ the international search was carried out on the basis of a translation of the international application furnished to this Authority (Rule 23.1(b)).

b. With regard to any nucleotide and/or amino acid sequence disclosed in the international application, the international search was carried out on the basis of the sequence listing:

☐ contained in the international application in written form.

☒ filed together with the international application in computer readable form.

☐ furnished subsequently to this Authority in written form.

☐ furnished subsequently to this Authority in computer readable form.

☐ the statement that the subsequently furnished written sequence listing does not go beyond the disclosure in the international application as filed has been furnished.

☐ the statement that the information recorded in computer readable form is identical to the written sequence listing has been furnished.

2. ☒ Certain claims were found unsearchable (See Box I).

3. ☐ Unity of invention is lacking (See Box II).

4. With regard to the title,

☒ the text is approved as submitted by the applicant.

☐ the text has been established by this Authority to read as follows:

5. With regard to the abstract,

☒ the text is approved as submitted by the applicant.

☐ the text has been established, according to Rule 38.2(b), by this Authority as it appears in Box III. The applicant may, within one month from the date of mailing of this international search report, submit comments to this Authority.

6. The figure of the drawings to be published with the abstract is Figure No. _____

☐ as suggested by the applicant.

☐ because the applicant failed to suggest a figure.

☐ because this figure better characterizes the invention.

☒ None of the figures.

Box I Observations where certain claims were found unsearchable (Continuation of item 1 of first sheet)

This international search report has not been established in respect of certain claims under Article 17(2)(a) for the following reasons:

1. ☒ Claims Nos.: 1-29, 43-45
because they relate to subject matter not required to be searched by this Authority, namely:
see next sheet
2. ☐ Claims Nos.:
because they relate to parts of the international application that do not comply with the prescribed requirements to such an extent that no meaningful international search can be carried out, specifically:
3. ☐ Claims Nos.:
because they are dependent claims and are not drafted in accordance with the second and third sentences of Rule 6.4(a).

Box II Observations where unity of invention is lacking (Continuation of item 2 of first sheet)

This International Searching Authority found multiple inventions in this international application, as follows:

1. ☐ As all required additional search fees were timely paid by the applicant, this international search report covers all searchable claims.
2. ☐ As all searchable claims could be searched without effort justifying an additional fee, this Authority did not invite payment of any additional fee.
3. ☐ As only some of the required additional search fees were timely paid by the applicant, this international search report covers only those claims for which fees were paid, specifically claims Nos.:
4. ☐ No required additional search fees were timely paid by the applicant. Consequently, this international search report is restricted to the invention first mentioned in the claims; it is covered by claims Nos.:

Remark on Protest

- ☐ The additional search fees were accompanied by the applicant's protest.
☐ No protest accompanied the payment of additional search fees.

Claims 1-29, 43-45 relate to methods of treatment of the human or animal body by surgery or by therapy/ diagnostic methods practised on the human or animal body/Rule 39.1.(iv). Nevertheless, a search has been executed for these claims. The search has been based on the alleged effects of the compounds/compositions.

INTERNATIONAL SEARCH REPORT

International application No.

PCT/DK 00/00413

A. CLASSIFICATION OF SUBJECT MATTER

IPC7: A61K 39/00, C07K 14/475, A61K 38/18, C12N 15/12, A61K 48/00
According to International Patent Classification (IPC) or to both national classification and IPC

B. FIELDS SEARCHED

Minimum documentation searched (classification system followed by classification symbols)

IPC7: A61K, C07K

Documentation searched other than minimum documentation to the extent that such documents are included in the fields searched

Electronic data base consulted during the international search (name of data base and, where practicable, search terms used)

C. DOCUMENTS CONSIDERED TO BE RELEVANT

| Category* | Citation of document, with indication, where appropriate, of the relevant passages | Relevant to claim No. |
|-----------|---|-----------------------|
| X | WO 9902667 A1 (UNIVERSITY OF LIEGE), 21 January 1999 (21.01.99), see abstract; page 8, lines 7-9; claim 61 -- | 1-52 |
| P,X | WO 9942573 A1 (BIOSTAR INC.), 26 August 1999 (26.08.99), see abstract; page 30, line 10 - page 33, line 21; page 36, lines 12-20; page 48, line 28 - page 54, line 7 -- | 1-52 |
| P,X | GB 2333706 A (MERCK & CO INC), 4 August 1999 (04.08.99), see entire document -- ----- | 1-52 |

☐ Further documents are listed in the continuation of Box C.

☒ See patent family annex.

* Special categories of cited documents:

"A" document defining the general state of the art which is not considered to be of particular relevance

"E" earlier application or patent but published on or after the international filing date

"L" document which may throw doubts on priority claim(s) or which is cited to establish the publication date of another citation or other special reason (as specified)

"O" document referring to an oral disclosure, use, exhibition or other means

"P" document published prior to the international filing date but later than the priority date claimed

"T" later document published after the international filing date or priority date and not in conflict with the application but cited to understand the principle or theory underlying the invention

"X" document of particular relevance: the claimed invention cannot be considered novel or cannot be considered to involve an inventive step when the document is taken alone

"Y" document of particular relevance: the claimed invention cannot be considered to involve an inventive step when the document is combined with one or more other such documents, such combination being obvious to a person skilled in the art

"&" document member of the same patent family

Date of the actual completion of the international search

24 November 2000

Date of mailing of the international search report

26.01.01

Name and mailing address of the International Searching Authority
European Patent Office P.B. 5818 Patentlaan 2
NL-2280 HV Rijswijk
Tel: (+31-70) 340-2040, Tx 31 651 epo nl,
Fax: (+31-70) 340-3018

Authorized officer

HENRIK NILSSON/EÖ
Telephone No.

INTERNATIONAL SEARCH REPORT
Information on patent family members

292978

02/11/00

International application No.

PCT/DK 00/00413

| Patent document cited in search report | | | Publication date | | Patent family member(s) | | Publication date | |
|---|---------|----|---------------------|----|----------------------------|---|---------------------|--|
| WO | 9902667 | A1 | 21/01/99 | AU | 8457198 | A | 08/02/99 | |
| | | | | EP | 1002068 | A | 24/05/00 | |
| | | | | US | 6103466 | A | 15/08/00 | |
| ----- | | | | | | | | |
| WO | 9942573 | A1 | 26/08/99 | AU | 2507399 | A | 06/09/99 | |
| ----- | | | | | | | | |
| GB | 2333706 | A | 04/08/99 | GB | 9902041 | D | 00/00/00 | |
| ----- | | | | | | | | |

(19) World Intellectual Property Organization
International Bureau



(43) International Publication Date
25 January 2001 (25.01.2001)

PCT

(10) International Publication Number
WO 01/05820 A3

(51) International Patent Classification⁷: A61K 39/00,
C07K 14/475, A61K 38/18, C12N 15/12, A61K 48/00

(21) International Application Number: PCT/DK00/00413

(22) International Filing Date: 20 July 2000 (20.07.2000)

(25) Filing Language: English

(26) Publication Language: English

(30) Priority Data:
PA 1999 01014 20 July 1999 (20.07.1999) DK
60/145,275 26 July 1999 (26.07.1999) US

(71) Applicant (for all designated States except US): M & E
BIOTECH A/S [DK/DK]; Kogle Allé 6, DK-2970 Hør-
sholm (DK).

(72) Inventors; and

(75) Inventors/Applicants (for US only): HALKIER, Tor-
ben [DK/DK]; Lyngvej 5, DK-2680 Solrød Strand (DK).
MOURITSEN, Søren [DK/DK]; Høveltevej 78, DK-3460
Birkerød (DK). KLYSNER, Steen [DK/DK]; Sandvig-
gårdsvej 10, DK-3400 Hillerød (DK).

(74) Agent: KOEFOED, Peter; M & E Biotech A/S, Kogle
Allé 6, DK-2970 Hørsholm (DK).

(81) Designated States (*national*): AE, AG, AL, AM, AT, AT
(utility model), AU, AZ, BA, BB, BG, BR, BY, BZ, CA,
CH, CN, CR, CU, CZ, CZ (utility model), DE, DE (utility
model), DK, DK (utility model), DM, DZ, EE, EE (utility
model), ES, FI, FI (utility model), GB, GD, GE, GH, GM,
HR, HU, ID, IL, IN, IS, JP, KE, KG, KP, KR, KZ, LC, LK,
LR, LS, LT, LU, LV, MA, MD, MG, MK, MN, MW, MX,
MZ, NO, NZ, PL, PT, RO, RU, SD, SE, SG, SI, SK, SK
(utility model), SL, TJ, TM, TR, TT, TZ, UA, UG, US, UZ,
VN, YU, ZA, ZW.

(84) Designated States (*regional*): ARIPO patent (GH, GM,
KE, LS, MW, MZ, SD, SL, SZ, TZ, UG, ZW), Eurasian
patent (AM, AZ, BY, KG, KZ, MD, RU, TJ, TM), European
patent (AT, BE, CH, CY, DE, DK, ES, FI, FR, GB, GR, IE,
IT, LU, MC, NL, PT, SE), OAPI patent (BF, BJ, CF, CG,
CI, CM, GA, GN, GW, ML, MR, NE, SN, TD, TG).

Published:

— with international search report

(88) Date of publication of the international search report:
19 July 2001

For two-letter codes and other abbreviations, refer to the "Guid-
ance Notes on Codes and Abbreviations" appearing at the begin-
ning of each regular issue of the PCT Gazette.

(54) Title: METHOD FOR DOWN-REGULATING GDF-8 ACTIVITY

(57) Abstract: Disclosed are novel methods for increasing muscle mass by means of immunization against Growth Differentiation Factor 8 (GDF-8, myostatin). Immunization is preferably effected by administration of analogues of GDF-8 which are capable of inducing antibody production against homologous GDF-8. Especially preferred as an immunogen is homologous GDF-8 which has been modified by introduction of one single or a few foreign, immunodominant and promiscuous T-cell epitopes while substantially preserving the tertiary structure of the homologous GDF-8. Also disclosed are nucleic acid vaccination against GDF-8 and vaccination using live vaccines as well as methods and means useful for the vaccination. Such methods and means include methods for identification of useful immunogenic GDF-8 analogues, methods for the preparation of analogues and pharmaceutical formulations, as well as nucleic acid fragments, vectors, transformed cells, polypeptides and pharmaceutical formulations.



WO 01/05820 A3

INTERNATIONAL SEARCH REPORT

International application No.

PCT/DK 00/00413

A. CLASSIFICATION OF SUBJECT MATTER

IPC7: A61K 39/00, C07K 14/475, A61K 38/18, C12N 15/12, A61K 48/00
According to International Patent Classification (IPC) or to both national classification and IPC

B. FIELDS SEARCHED

Minimum documentation searched (classification system followed by classification symbols)

IPC7: A61K, C07K

Documentation searched other than minimum documentation to the extent that such documents are included in the fields searched

Electronic data base consulted during the international search (name of data base and, where practicable, search terms used)

C. DOCUMENTS CONSIDERED TO BE RELEVANT

| Category* | Citation of document, with indication, where appropriate, of the relevant passages | Relevant to claim No. |
|-----------|---|-----------------------|
| X | WO 9902667 A1 (UNIVERSITY OF LIEGE), 21 January 1999 (21.01.99), see abstract; page 8, lines 7-9; claim 61 -- | 1-52 |
| P,X | WO 9942573 A1 (BIOSTAR INC.), 26 August 1999 (26.08.99), see abstract; page 30, line 10 - page 33, line 21; page 36, lines 12-20; page 48, line 28 - page 54, line 7 -- | 1-52 |
| P,X | GB 2333706 A (MERCK & CO INC), 4 August 1999 (04.08.99), see entire document -- ----- | 1-52 |

☐ Further documents are listed in the continuation of Box C.

☒ See patent family annex.

* Special categories of cited documents:

"A" document defining the general state of the art which is not considered to be of particular relevance

"E" earlier application or patent but published on or after the international filing date

"I" document which may throw doubts on priority claim(s) or which is cited to establish the publication date of another citation or other special reason (as specified)

"O" document referring to an oral disclosure, use, exhibition or other means

"P" document published prior to the international filing date but later than the priority date claimed

"T" later document published after the international filing date or priority date and not in conflict with the application but cited to understand the principle or theory underlying the invention

"X" document of particular relevance: the claimed invention cannot be considered novel or cannot be considered to involve an inventive step when the document is taken alone

"Y" document of particular relevance: the claimed invention cannot be considered to involve an inventive step when the document is combined with one or more other such documents, such combination being obvious to a person skilled in the art

"&" document member of the same patent family

Date of the actual completion of the international search

24 November 2000

Date of mailing of the international search report

26.01.01

Name and mailing address of the International Searching Authority
European Patent Office P.B. 5818 Patentlaan 2
NL-2280 HV Rijswijk
Tel: (+31-70) 340-2040, Tx 31 651 epo nl,
Fax: (+31-70) 340-3016

Authorized officer

HENRIK NILSSON/EÖ

Telephone No.

INTERNATIONAL SEARCH REPORT

International application No.
PC/DK00/00413

Box I Observations where certain claims were found unsearchable (Continuation of item 1 of first sheet)

This international search report has not been established in respect of certain claims under Article 17(2)(a) for the following reasons:

1. ☒ Claims Nos.: **1-29, 43-45**
because they relate to subject matter not required to be searched by this Authority, namely:
see next sheet
2. ☐ Claims Nos.:
because they relate to parts of the international application that do not comply with the prescribed requirements to such an extent that no meaningful international search can be carried out, specifically:
3. ☐ Claims Nos.:
because they are dependent claims and are not drafted in accordance with the second and third sentences of Rule 6.4(a).

Box II Observations where unity of invention is lacking (Continuation of item 2 of first sheet)

This International Searching Authority found multiple inventions in this international application, as follows:

1. ☐ As all required additional search fees were timely paid by the applicant, this international search report covers all searchable claims.
2. ☐ As all searchable claims could be searched without effort justifying an additional fee, this Authority did not invite payment of any additional fee.
3. ☐ As only some of the required additional search fees were timely paid by the applicant, this international search report covers only those claims for which fees were paid, specifically claims Nos.:
4. ☐ No required additional search fees were timely paid by the applicant. Consequently, this international search report is restricted to the invention first mentioned in the claims; it is covered by claims Nos.:

Remark on Protest

- ☐ The additional search fees were accompanied by the applicant's protest.
☐ No protest accompanied the payment of additional search fees.

Claims 1-29, 43-45 relate to methods of treatment of the human or animal body by surgery or by therapy/ diagnostic methods practised on the human or animal body/Rule 39.1.(iv). Nevertheless, a search has been executed for these claims. The search has been based on the alleged effects of the compounds/compositions.

INTERNATIONAL SEARCH REPORT

Information on family members

02/11/00

International application No.

PCT/DK 00/00413

| Patent document cited in search report | | | Publication date | Patent family member(s) | | | Publication date |
|---|---------|----|---------------------|----------------------------|-----------|----------|---------------------|
| WO | 9902667 | A1 | 21/01/99 | AU | 8457198 A | 08/02/99 | |
| | | | | EP | 1002068 A | 24/05/00 | |
| | | | | US | 6103466 A | 15/08/00 | |
| ----- | | | | | | | |
| WO | 9942573 | A1 | 26/08/99 | AU | 2507399 A | 06/09/99 | |
| ----- | | | | | | | |
| GB | 2333706 | A | 04/08/99 | GB | 9902041 D | 00/00/00 | |
| ----- | | | | | | | |



(utility model), SL, TJ, TM, TR, TT, TZ, UA, UG, US, UZ, VN, YU, ZA, ZW.

(84) Designated States (regional): ARIPO patent (GH, GM, KE, LS, MW, MZ, SD, SL, SZ, TZ, UG, ZW), Eurasian patent (AM, AZ, BY, KG, KZ, MD, RU, TJ, TM), European patent (AT, BE, CH, CY, DE, DK, ES, FI, FR, GB, GR, IE, IT, LU, MC, NL, PT, SE), OAPI patent (BF, BJ, CF, CG, CI, CM, GA, GN, GW, ML, MR, NE, SN, TD, TG).

Published:

— Without international search report and to be republished upon receipt of that report.

For two-letter codes and other abbreviations, refer to the "Guidance Notes on Codes and Abbreviations" appearing at the beginning of each regular issue of the PCT Gazette.

METHOD FOR DOWN-REGULATING GDF-8 ACTIVITY

FIELD OF THE INVENTION

5 The present invention generally relates to the fields of animal and poultry husbandry as well as to human medicine. More specifically, the present invention pertains to improvements in controlling and increasing muscle growth, especially in farm animals for slaughter. Thus, provided are novel methods
10 and means for increasing muscle growth in animals for slaughter.

BACKGROUND OF THE INVENTION

15

Currently, two different medical approaches are used in order to increase the growth rate of farm animals: On the one hand the administration to farm animals of antibiotics or antibiotic-like compounds, and on the other the administration of
20 growth hormones.

The administration of antibiotics and antibiotic-like compounds in farm animals (notably pigs) in order to promote the growth rate of these animals has in later years been proven to
25 cause several problems. Some of these compounds are chemically closely related to antibiotics used for treatment of human disease, and evidence is building up that extensive use of such compounds in farm animals induces cross-resistance towards human antibiotics in micro-organisms pathogenic in man.
30 Further, relatively low increases in growth rates of 1-3% are obtained with these compounds.

The use of growth hormones in farm animals is expensive, and the treatment has to be repeated at rather short intervals due

to the relatively short half-life of growth hormone. Furthermore, the presence of potential residual growth hormone in meat produced from treated animals has created some concerns in European consumers particularly.

5

GDF-8

GDF-8 or myostatin was discovered in May 1997 as a growth regulating factor selectively down-regulating skeletal muscle growth (McPherron *et al.*, Nature, 387, 83-90, 1997). GDF-8 expression is restricted to the myotome compartment of developing embryonic somites, but it is also expressed in various muscle tissues throughout the body in the adult animal.

15 GDF-8 knock-out mice exhibit a strongly increased skeletal muscle mass. The increase in skeletal muscle mass appear to be widespread throughout the body, and isolated muscles from GDF-8 negative mice weigh about 2-3 times more than wild type muscles. The total body weights of the knock-out mice are
20 about 35% higher than wild type mice and mice lacking the GDF-8 gene has more than 80% more muscle fibres compared to normal mice. The massive skeletal muscle enlargement observed in the knock-out mice is, however, not merely due to an increase in muscle fibre numbers but also to a significant muscle fibre hypertrophy. The cross-sectional muscle area of the
25 GDF-8 knock-out mice is increased by about 14 to 49% depending on muscle type.

Interestingly, there is also observed an enhanced rate of muscle mass increase in adult transgenic mice compared to adult
30 non-transgenic mice. Further, all GDF-8 negative mice has been shown to be viable and fertile.

In November 1997 the authors who originally discovered GDF-8 published that two breeds of cattle that are characterized by strongly increased muscle mass, Belgian Blue and Piedmontese, have mutations in the GDF-8 coding sequence and that this accounts for their large muscles (McPherron and Se-Jin Lee, 1997, PNAS 94, 12457-12461). This phenomenon of "double muscling" has been observed in many breeds of cattle for the past 190 years, and the animals have an average increase in muscle mass of 20-25%. They also show an increased feed efficiency, but they still produce high-quality meat.

Unlike the GDF-8 knock-out mice, however, the Belgian Blue cattle also exhibit a reduction in mass of most other organs. These "natural knock-out cows" also suffer from reduced female fertility, reduced viability of offspring, and a delayed sexual maturation.

The relative increase in muscle mass in "knock-out cows" is not nearly as pronounced as is observed in the knock-out mice - in fact, it corresponds to the extent of muscle hypertrophy observed in the mice. McPherron *et al.* speculate that one reason could be that normal cattle may be nearer than mice to a maximum limit of muscle size (and hence to the maximum obtainable number of muscle fibres) after generations of selective breeding. No data regarding the number of muscle fibre hyperplasia versus hypertrophy in cattle was published by the authors, but based on this assumption and the muscle hypertrophy observed in the knock-out mice, it could be possible that the increase in muscle mass and growth rate observed in e.g. the Belgian Blue cattle is largely due to muscle hypertrophy and to a lesser extent muscle hyperplasia.

Physiological role of GDF-8

Expression of GDF-8 is highly restricted to skeletal muscle. There is a low level of expression in adipose tissue, but notably there is no expression in heart muscle. The physiological role of GDF-8 in the adult individual is not known, although it seems that GDF-8 may function as a specific negative regulator of skeletal muscle growth. Speculations about the physiological role centres upon important functions in exercise induced muscle hypertrophy or regeneration after muscle injury. GDF-8 may, however, also suppress adipose tissue growth. It is not known whether GDF-8 works locally or systemically during the growth of the animal.

Structure of GDF-8

GDF-8 belongs to the transforming growth factor β (TGF- β) super family which encompasses a group of structurally-related proteins involved in embryonic development. Human and bovine GDF-8 are produced as 375 amino acids long precursor proteins. As other TGF- β super family proteins GDF-8 is probably processed proteolytically into a much shorter C-terminal fragment of about 109 amino acids which form disulphide linked homodimers. The homodimer is probably the biologically active form of GDF-8.

The amino acid sequences of murine, rat, human, baboon, bovine, porcine, sheep, chicken and turkey GDF-8 are known and the GDF-8 molecule is highly conserved (McPherron and Se-Jin Lee, PNAS, **94**, 12457-12461, 1997). The sequences of murine, rat, human, porcine, chicken and turkey GDF-8 are 100% identical in the C-terminal region, which probably contains the biologically active part of GDF-8. Both bovine and sheep GDF-8 only differ by two amino acid residues from human GDF-8 in the

C-terminal region. Bovine GDF-8 has the sequence -Glu-Gly- instead of -Lys-Glu- in positions 356-357, and sheep GDF-8 has two conservative substitutions (a Val in position 316 and an Arg in position 333 instead of Leu and Lys, respectively).

- 5 None of the known GDF-8 proteins include potential N-glycosylation sites in their active C-terminal region.

OBJECT OF THE INVENTION

10

It is an object of the present invention to provide a recombinant therapeutic vaccine capable of effecting down-regulation of growth differentiation factor 8 (GDF-8) (also known as myostatin) in order to increase the muscle growth rate of farm
15 animals. It is a further object to provide a method of vaccinating animals in order to increase the muscle growth rate. It is also an object to provide variants of GDF-8 which are capable of breaking autotolerance against autologous GDF-8. Yet a further object is to provide nucleic acid fragments, vectors
20 and transformed cells which are all useful in the preparation of the vaccines and GDF-8 variants.

SUMMARY OF THE INVENTION

25

Based on the above-referenced findings in transgenic GDF-8 knock-out animals and in Belgian Blue and Piedmontese, the present inventors have developed the theory that it will be possible to down-regulate GDF-8 in animals by inducing an effective and fine-tuned immune response against GDF-8. Hence,
30 what is basically provided by the present invention is a method and means to immunologically down-regulate GDF-8 in order to effect an increase the muscle mass in animals.

The advantages of this approach over known growth-enhancing measures in farm animals are several. First of all, problems relating to cross-resistance in pathological micro-organisms will not arise when using the present approach. Further, there
5 will be no potential residual exogenously administered growth hormone in meat from animals which have been subjected to the present treatment. Finally, the ethical problems involved in the breeding and production of cattle like the Belgian Blue and the Piedmontese (where many calves are born by means of
10 Caesarean section and where other organs are of reduced size) can be completely avoided by postponing the down-regulation of GDF-8 in the animals until after birth (e.g. in adult life only) - in fact, animals having an increased muscle mass need not give birth at all, and the treatment can therefore be re-
15 served to those animals which are predestined to become slaughtered.

Since the number and type of muscle fibres is determined during embryonic life, it is not very likely that an anti-GDF-8
20 vaccine would increase the *number* of muscle fibres in adult farm animals. It is therefore neither certain nor likely that an anti-GDF-8 vaccine would be able to suppress GDF-8 to the same level as seen in GDF-8 knock-out animals. This would probably not be desirably either, since this perhaps could
25 negatively affect meat quality, breeding capability, and fat ratio. Nevertheless, an increase in growth rate and/or maximum body weight of 5-25 % obtained in vaccinated animals due to post partum muscle hypertrophy (a figure range which does not seem unrealistic) would still be interesting in the production
30 of meat from cows, pigs and poultry.

The sequence identity of GDF-8 relative to other members of the TGF- β family is only 30-40 percent at the amino acid level. This low sequence identity will in all likelihood not create

problems with cross-reactivity of antibodies induced towards GDF-8.

Thus, in its broadest and most general scope, the present invention relates to a method for *in vivo* down-regulation of growth differentiation factor 8 (GDF-8) activity in an animal, including a human being, the method comprising effecting presentation to the animal's immune system of an immunologically effective amount of

- 10 - at least one GDF-8 polypeptide or subsequence thereof which has been formulated so that immunization of the animal with the GDF-8 polypeptide or subsequence thereof induces production of antibodies against the GDF-8 polypeptide, and/or
- 15 - at least one GDF-8 analogue wherein is introduced at least one modification in the GDF-8 amino acid sequence which has as a result that immunization of the animal with the analogue induces production of antibodies against the GDF-8 polypeptide.

20

It is expected that 1-4 annual injections with an immunogenic composition according to the invention will be sufficient to obtain the desired effect, whereas administration of both growth hormones and antibiotics require much more frequent administrations to the animal in question.

The invention also relates to GDF-8 analogues as well as to nucleic acid fragments encoding a subset of these. Also immunogenic compositions comprising the analogues or the nucleic acid fragments are part of the invention.

The invention also relates to a method of identifying immunogenically effective analogues of GDF-8 as well as a method for preparing composition comprising the GDF-8 analogues.

LEGENDS TO THE FIGURES

5 Fig. 1: Models of GDF-8 derived autovaccine constructs.

Stretches indicated in dark grey are the stretches in which substitutions with P2 and P30, respectively, are proposed to take place.

A: Monomer construct with P2 epitope inserts. "1" indicates a
10 P2 substitution of amino acid residues 18-32 of the 109 aa C-terminal GDF-8 fragment, "2" indicates a P2 substitution of amino acid residues 52-66 of the 109 aa C-terminal GDF-8 fragment, and "3" indicates a P2 substitution of amino acid residues 83-97 of the 109 aa C-terminal GDF-8 fragment.

15 B: Monomer construct with P30 epitope inserts. "1" indicates a P30 substitution of amino acid residues 21-41 of the 109 aa C-terminal GDF-8 fragment, "2" indicates a P30 substitution of amino acid residues 49-69 of the 109 aa C-terminal GDF-8 fragment, and "3" indicates a P30 substitution of amino acid residues
20 79-99 or 84-104 of the 109 aa C-terminal GDF-8 fragment.

C: Extended monomer construct with P2 and P30 substituted into the 160 aa C-terminal GDF-8 fragment.

D: Dimer construct with the P2 and P30 epitopes serially
25 linked between two copies of the 109 C-terminal GDF-8 fragment.

Fig. 2: Expected 3D structure of the TGF- β protein.

The model is based on an analogous domain (TGJ-1) from the TGF- β protein. β -sheets are shown as arrows and helices as cylinders.
30

DETAILED DISCLOSURE OF THE INVENTION

Definitions

5 In the following, a number of terms used in the present specification and claims will be defined and explained in detail in order to clarify the metes and bounds of the invention.

The terms "T-lymphocyte" and "T-cell" will be used interchangeably for lymphocytes of thymic origin which are responsible for various cell mediated immune responses as well as for helper activity in the humoral immune response. Likewise, the terms "B-lymphocyte" and "B-cell" will be used interchangeably for antibody-producing lymphocytes.

15

A "GDF-8 polypeptide" is herein intended to denote polypeptides having the amino acid sequence of the above-discussed GDF-8 proteins derived from a number of animals (or truncates thereof sharing a substantial amount of B-cell epitopes with intact GDF-8), but also polypeptides having the amino acid sequence identical to xeno-analogues of these two proteins isolated from other species are embraced by the term. When using the term is normally meant the biologically active form, *i.e.* the C-terminal peptide which in humans is of 109 amino acids in length. Also unglycosylated forms of GDF-8 which are prepared in prokaryotic system are included within the boundaries of the term as are forms having varying O-glycosylation patterns due to the use of *e.g.* yeasts or other non-mammalian eukaryotic expression systems. It should, however, be noted that when using the term "a GDF-8 polypeptide" it is intended that the polypeptide in question is normally non-immunogenic when presented to the animal to be treated. In other words, the GDF-8 polypeptide is a self-protein or is a xeno-analogue of

such a self-protein which will not normally give rise to an immune response against GDF-8 of the animal in question.

A "GDF-8 analogue" is a GDF-8 polypeptide which has been subjected to changes in its primary structure. Such a change can e.g. be in the form of fusion of a GDF-8 polypeptide to a suitable fusion partner (*i.e.* a change in primary structure exclusively involving C- and/or N-terminal additions of amino acid residues) and/or it can be in the form of insertions and/or deletions and/or substitutions in the GDF-8 polypeptide's amino acid sequence. Also derivatized GDF-8 molecules are encompassed by the term a "GDF-8 analogue", cf. the discussion below which deals with modifications of GDF-8.

It should be noted that the use as a vaccine in a human of e.g. a canine analogue of human GDF-8 can be imagined to produce the desired immunity against GDF-8. Such use of an xeno-analogue for immunization is also considered to be an "GDF-8 analogue" as defined above.

20

The term "polypeptide" is in the present context intended to mean both short peptides of from 2 to 10 amino acid residues, oligopeptides of from 11 to 100 amino acid residues, and polypeptides of more than 100 amino acid residues. Furthermore, the term is also intended to include proteins, *i.e.* functional biomolecules comprising at least one polypeptide; when comprising at least two polypeptides, these may form complexes, be covalently linked, or may be non-covalently linked. The polypeptide(s) in a protein can be glycosylated and/or lipidated and/or comprise prosthetic groups.

The term "subsequence" means any consecutive stretch of at least 3 amino acids or, when relevant, of at least 3 nucleo-

tides, derived directly from a naturally occurring GDF-8 amino acid sequence or nucleic acid sequence, respectively.

The term "animal" is in the present context in general intended to denote an animal species (preferably mammalian), such as *Homo sapiens*, *Canis domesticus*, etc. and not just one single animal. However, the term also denotes a population of such an animal species, since it is important that the individuals immunized according to the method of the invention all harbour substantially the same GDF-8 allowing for immunization of the animals with the same immunogen(s). If, for instance, genetic variants of GDF-8 exist in a different population it may be necessary to use different immunogens in these different populations in order to be able to break the autotolerance towards GDF-8 in each population. It will be clear to the skilled person that an animal in the present context is a living being which has an immune system. It is preferred that the animal is a vertebrate, such as a mammal.

By the term "in vivo down-regulation of GDF-8 activity" is herein meant reduction in the living organism of the number of interactions between GDF-8 and its receptors (or between GDF-8 and other possible biologically important binding partners for this molecule). The down-regulation can be obtained by means of several mechanisms: Of these, simple interference with the active site in GDF-8 by antibody binding is the most simple. However, it is also within the scope of the present invention that the antibody binding results in removal of GDF-8 by scavenger cells (such as macrophages and other phagocytic cells).

30

The expression "effecting presentation ... to the immune system" is intended to denote that the animal's immune system is subjected to an immunogenic challenge in a controlled manner. As will appear from the disclosure below, such challenge of

the immune system can be effected in a number of ways of which the most important are vaccination with polypeptide containing "pharmaccines" (*i.e.* a vaccine which is administered to treat or ameliorate ongoing disease) or nucleic acid "pharmaccine" vaccination. The important result to achieve is that immune competent cells in the animal are confronted with the antigen in an immunologically effective manner, whereas the precise mode of achieving this result is of less importance to the inventive idea underlying the present invention.

10

The term "immunogenically effective amount" has its usual meaning in the art, *i.e.* an amount of an immunogen which is capable of inducing an immune response which significantly engages pathogenic agents which share immunological features with the immunogen.

15

When using the expression that the GDF-8 has been "modified" is herein meant a chemical modification of the polypeptide which constitutes the backbone of GDF-8. Such a modification can e.g. be derivatization (e.g. alkylation, acylation, esterification etc.) of certain amino acid residues in the GDF-8 sequence, but as will be appreciated from the disclosure below, the preferred modifications comprise changes of (or additions to) the primary structure of the GDF-8 amino acid sequence, *i.e.* modifications which results in the provision of a GDF-8 analogue where the primary amino acid sequence has been modified.

20

25

When discussing "autotolerance towards GDF-8" is understood that since GDF-8 is a self-protein in the population to be vaccinated, normal individuals in the population do not mount an immune response against GDF-8; it cannot be excluded, though, that occasional individuals in an animal population might be able to produce antibodies against native GDF-8, e.g.

30

as part of an autoimmune disorder. At any rate, an animal will normally only be autotolerant towards its own GDF-8, but it cannot be excluded that GDF-8 analogues derived from other animal species or from a population having a different GDF-8 phenotype would also be tolerated by said animal.

A "foreign T-cell epitope" (or: "foreign T-lymphocyte epitope") is a peptide which is able to bind to an MHC molecule and which stimulates T-cells in an animal species. Preferred foreign T-cell epitopes in the invention are "promiscuous" epitopes, i.e. epitopes which bind to a substantial fraction of a particular class of MHC molecules in an animal species or population. Only a very limited number of such promiscuous T-cell epitopes are known, and they will be discussed in detail below. It should be noted that in order for the immunogens which are used according to the present invention to be effective in as large a fraction of an animal population as possible, it may be necessary to 1) insert several foreign T-cell epitopes in the same GDF-8 analogue or 2) prepare several GDF-8 analogues wherein each analogue has a different promiscuous epitope inserted. It should be noted also that the concept of foreign T-cell epitopes also encompasses use of cryptic T-cell epitopes, i.e. epitopes which are derived from a self-protein and which only exerts immunogenic behaviour when existing in isolated form without being part of the self-protein in question.

A "foreign T helper lymphocyte epitope" (a foreign T_H epitope) is a foreign T cell epitope which binds an MHC Class II molecule and can be presented on the surface of an antigen presenting cell (APC) bound to the MHC Class II molecule.

A "functional part" of a (bio)molecule is in the present context intended to mean the part of the molecule which is re-

sponsible for at least one of the biochemical or physiological effects exerted by the molecule. It is well-known in the art that many enzymes and other effector molecules have an active site which is responsible for the effects exerted by the molecule in question. Other parts of the molecule may serve a stabilizing or solubility enhancing purpose and can therefore be left out if these purposes are not of relevance in the context of a certain embodiment of the present invention. For instance it is possible to use certain other cytokines as a modifying moiety in GDF-8 (cf. the detailed discussion below), and in such a case, the issue of stability may be irrelevant since the coupling to GDF-8 provides the stability necessary.

The term "adjuvant" has its usual meaning in the art of vaccine technology, i.e. a substance or a composition of matter which is 1) not in itself capable of mounting an immune response against the immunogen of the vaccine, but which is 2) nevertheless capable of enhancing the immune response against the immunogen. Or, in other words, vaccination with the adjuvant alone does not provide an immune response against the immunogen, vaccination with the immunogen may or may not give rise to an immune response against the immunogen, but the combined vaccination with immunogen and adjuvant induces an immune response against the immunogen which is furthermore stronger than that induced by the immunogen alone.

"Targeting" of a molecule is in the present context intended to denote the situation where a molecule upon introduction in the animal will appear preferentially in certain tissue(s) or will be preferentially associated with certain cells or cell types. The effect can be accomplished in a number of ways including formulation of the molecule in composition facilitating targeting or by introduction in the molecule of groups

which facilitates targeting. These issues will be discussed in detail below.

"Stimulation of the immune system" means that a substance or composition of matter exhibits a general, non-specific immunostimulatory effect. A number of adjuvants and putative adjuvants (such as certain cytokines) share the ability to stimulate the immune system. The result of using an immunostimulating agent is an increased "alertness" of the immune system meaning that simultaneous or subsequent immunization with an immunogen induces a significantly more effective immune response compared to isolated use of the immunogen.

Preferred embodiments of GDF-8 activity down-regulation

15

It is preferred that the GDF-8 polypeptide used as an immunogen in the method of the invention is a modified molecule wherein at least one change is present in the GDF-8 amino acid sequence, since the chances of obtaining the all-important breaking of autotolerance towards GDF-8 is greatly facilitated that way. It should be noted that this does not exclude the possibility of using such a modified GDF-8 in formulations which further facilitate the breaking of autotolerance against GDF-8, e.g. formulations containing certain adjuvants discussed in detail below.

It has been shown (in Dalum I et al., 1996, J. Immunol. 157: 4796-4804) that potentially self-reactive B-lymphocytes recognizing self-proteins are physiologically present in normal individuals. However, in order for these B-lymphocytes to be induced to actually produce antibodies reactive with the relevant self-proteins, assistance is needed from cytokine producing T-helper lymphocytes (T_H -cells or T_H -lymphocytes). Normally this help is not provided because T-lymphocytes in gene-

ral do not recognize T-cell epitopes derived from self-proteins when presented by antigen presenting cells (APCs). However, by providing an element of "foreignness" in a self-protein (i.e. by introducing an immunologically significant modification), T-cells recognizing the foreign element are activated upon recognizing the foreign epitope on an APC (such as, initially, a mononuclear cell). Polyclonal B-lymphocytes (which are also specialised APCs) capable of recognising self-epitopes on the modified self-protein also internalise the antigen and subsequently presents the foreign T-cell epitope(s) thereof, and the activated T-lymphocytes subsequently provide cytokine help to these self-reactive polyclonal B-lymphocytes. Since the antibodies produced by these polyclonal B-lymphocytes are reactive with different epitopes on the modified polypeptide, including those which are also present in the native polypeptide, an antibody cross-reactive with the non-modified self-protein is induced. In conclusion, the T-lymphocytes can be led to act as if the population of polyclonal B-lymphocytes have recognised an entirely foreign antigen, whereas in fact only the inserted epitope(s) is/are foreign to the host. In this way, antibodies capable of cross-reacting with non-modified self-antigens are induced.

Several ways of modifying a peptide self-antigen in order to obtain breaking of autotolerance are known in the art. Hence, according to the invention, the modification can include that

- at least one foreign T-cell epitope is introduced, and/or
- at least one first moiety is introduced which effects targeting of the modified molecule to an antigen presenting cell (APC), and/or
- at least one second moiety is introduced which stimulates the immune system, and/or

- at least one third moiety is introduced which optimises presentation of the modified GDF-8 polypeptide to the immune system.

- 5 However, all these modifications should be carried out while maintaining a substantial fraction of the original B-lymphocyte epitopes in active GDF-8, since the B-lymphocyte recognition of the native molecule is thereby enhanced.
- 10 In one preferred embodiment, side groups (in the form of foreign T-cell epitopes or the above-mentioned first, second and third moieties) are covalently or non-covalently introduced. This is intended to mean that stretches of amino acid residues derived from GDF-8 are derivatized without altering the pri-
- 15 mary amino acid sequence, or at least without introducing changes in the peptide bonds between the individual amino acids in the chain.

- An alternative, and preferred, embodiment utilises amino acid
- 20 substitution and/or deletion and/or insertion and/or addition (which may be effected by recombinant means or by means of peptide synthesis; modifications which involves longer stretches of amino acids can give rise to fusion polypeptides). One especially preferred version of this embodiment is
- 25 the technique described in WO 95/05849, which discloses a method for down-regulating self-proteins by immunising with analogues of the self-proteins wherein a number of amino acid sequence(s) has been substituted with a corresponding number of amino acid sequence(s) which each comprise a foreign immu-
- 30 nodominant T-cell epitope, while at the same time maintaining the overall tertiary structure of the self-protein in the analogue. For the purposes of the present invention, it is however sufficient if the modification (be it an amino acid insertion, addition, deletion or substitution) gives rise to a

foreign T-cell epitope and at the same time preserves a substantial number of the B-cell epitopes in GDF-8. However, in order to obtain maximum efficacy of the immune response induced, it is preferred that the overall tertiary structure of GDF-8 is maintained in the modified molecule.

The following formula describes the GDF-8 constructs generally covered by the invention:

$$(MOD_1)_{s1} (GDF-8_{e1})_{n1} (MOD_2)_{s2} (GDF-8_{e2})_{n2} \dots (MOD_x)_{sx} (GDF-8_{ex})_{nx} \quad (I)$$

-where GDF-8_{e1}-GDF-8_{ex} are x B-cell epitope containing subsequences of GDF-8 which independently are identical or non-identical and which may contain or not contain foreign side groups, x is an integer ≥ 3 , n₁-n_x are x integers ≥ 0 (at least one is ≥ 1), MOD₁-MOD_x are x modifications introduced between the preserved B-cell epitopes, and s₁-s_x are x integers ≥ 0 (at least one is ≥ 1 if no side groups are introduced in the GDF-8_e sequences). Thus, given the general functional restraints on the immunogenicity of the constructs, the invention allows for all kinds of permutations of the original GDF-8 sequence, and all kinds of modifications therein. Thus, included in the invention are modified GDF-8 obtained by omission of parts of the GDF-8 sequence which e.g. exhibit adverse effects *in vivo* or omission of parts which could give rise to undesired immunological reactions.

Maintenance of a substantial fraction of B-cell epitopes or even the overall tertiary structure of a protein which is subjected to modification as described herein can be achieved in several ways. One is simply to prepare a polyclonal antiserum directed against GDF-8 (e.g. an antiserum prepared in a rabbit) and thereafter use this antiserum as a test reagent (e.g.

in a competitive ELISA) against the modified proteins which are produced. Modified versions (analogues) which react to the same extent with the antiserum as does GDF-8 must be regarded as having the same overall tertiary structure as GDF-8 whereas analogues exhibiting a limited (but still significant and specific) reactivity with such an antiserum are regarded as having maintained a substantial fraction of the original B-cell epitopes.

10 Alternatively, a selection of monoclonal antibodies reactive with distinct epitopes on GDF-8 can be prepared and used as a test panel. This approach has the advantage of allowing 1) an epitope mapping of GDF-8 and 2) a mapping of the epitopes which are maintained in the analogues prepared.

15 Of course, a third approach would be to resolve the 3-dimensional structure of GDF-8 or of a biologically active truncate thereof (cf. above) and compare this to the resolved three-dimensional structure of the analogues prepared. Three-dimensional structure can be resolved by the aid of X-ray diffraction studies and NMR-spectroscopy. Further information relating to the tertiary structure can to some extent be obtained from circular dichroism studies which have the advantage of merely requiring the polypeptide in pure form (whereas X-ray diffraction requires the provision of crystallized polypeptide

20 and NMR requires the provision of isotopic variants of the polypeptide) in order to provide useful information about the tertiary structure of a given molecule. However, ultimately X-ray diffraction and/or NMR are necessary to obtain conclusive data since circular dichroism can only provide indirect evidence of correct 3-dimensional structure via information of secondary structure elements.

25
30

One preferred embodiment of the invention utilises multiple presentations of B-lymphocyte epitopes of GDF-8 (i.e. formula

I wherein at least one B-cell epitope is present in two positions). This effect can be achieved in various ways, e.g. by simply preparing fusion polypeptides comprising the structure $(\text{GDF-8})_m$, where m is an integer ≥ 2 and then introduce the
5 modifications discussed herein in at least one of the GDF-8 sequences, or alternatively, inserted between at least two of the GDF-8 amino acid sequences. It is preferred that the modifications introduced includes at least one duplication of a B-lymphocyte epitope and/or the introduction of a hapten.

10

As mentioned above, the introduction of a foreign T-cell epitope can be accomplished by introduction of at least one amino acid insertion, addition, deletion, or substitution. Of course, the normal situation will be the introduction of more
15 than one change in the amino acid sequence (e.g. insertion of or substitution by a complete T-cell epitope) but the important goal to reach is that the GDF-8 analogue, when processed by an antigen presenting cell (APC), will give rise to such a foreign immunodominant T-cell epitope being presented in con-
20 text of an MCH Class II molecule on the surface of the APC. Thus, if the GDF-8 amino acid sequence in appropriate positions comprises a number of amino acid residues which can also be found in a foreign T_H epitope then the introduction of a foreign T_H epitope can be accomplished by providing the remain-
25 ing amino acids of the foreign epitope by means of amino acid insertion, addition, deletion and substitution. In other words, it is not necessary to introduce a complete T_H epitope by insertion or substitution.

30 It is preferred that the number of amino acid insertions, deletions, substitutions or additions is at least 2, such as 3, 4, 5, 6, 7, 8, 9, 10, 11, 12, 13, 14, 15, 16, 17, 18, 19, 20, and 25 insertions, substitutions, additions or deletions. It is furthermore preferred that the number of amino acid inser-

tions, substitutions, additions or deletions is not in excess of 150, such as at most 100, at most 90, at most 80, and at most 70. It is especially preferred that the number of substitutions, insertions, deletions, or additions does not exceed 5 60, and in particular the number should not exceed 50 or even 40. Most preferred is a number of not more than 30. With respect to amino acid additions, it should be noted that these, when the resulting construct is in the form of a fusion polypeptide, is often considerably higher than 150.

10

Preferred embodiments of the invention include modification by introducing at least one foreign immunodominant T_H epitope. It will be understood that the question of immune dominance of a T_H epitope depends on the animal species in question. As used 15 herein, the term "immunodominance" simply refers to epitopes which in the vaccinated individual gives rise to a significant immune response, but it is a well-known fact that a T_H epitope which is immunodominant in one individual is not necessarily immunodominant in another individual of the same species, even 20 though it may be capable of binding MHC-II molecules in the latter individual.

Another important point is the issue of MHC restriction of T_H epitopes. In general, naturally occurring T_H epitopes are MHC 25 restricted, i.e. a certain peptide constituting a T_H epitope will only bind effectively to a subset of MHC Class II molecules. This in turn has the effect that in most cases the use of one specific T_H epitope will result in a vaccine component which is effective in a fraction of the population only, and 30 depending on the size of that fraction, it can be necessary to include more T_H epitopes in the same molecule, or alternatively prepare a multi-component vaccine wherein the components are GDF-8 variants which are distinguished from each other by the nature of the T_H epitope introduced.

If the MHC restriction of the T-cells used is completely unknown (for instance in a situation where the vaccinated animal has a poorly defined MHC composition), the fraction of the animal population covered by a specific vaccine composition can be determined by means of the following formula:

$$f_{\text{population}} = 1 - \prod_{i=1}^n (1 - p_i) \quad (\text{II})$$

-where p_i is the frequency in the population of responders to the i^{th} foreign T-cell epitope present in the vaccine composition, and n is the total number of foreign T-cell epitopes in the vaccine composition. Thus, a vaccine composition containing 3 foreign T-cell epitopes having response frequencies in the population of 0.8, 0.7, and 0.6, respectively, would give

$$1 - 0.2 \times 0.3 \times 0.4 = 0.976$$

-i.e. 97.6 percent of the population will statistically mount an MHC-II mediated response to the vaccine.

The above formula does not apply in situations where a more or less precise MHC restriction pattern of the peptides used is known. If, for instance a certain peptide only binds the human MHC-II molecules encoded by HLA-DR alleles DR1, DR3, DR5, and DR7, then the use of this peptide together with another peptide which binds the remaining MHC-II molecules encoded by HLA-DR alleles will accomplish 100% coverage in the population in question. Likewise, if the second peptide only binds DR3 and DR5, the addition of this peptide will not increase the coverage at all. If one bases the calculation of population response purely on MHC restriction of T-cell epitopes in the vaccine, the fraction of the population covered by a specific vaccine composition can be determined by means of the follow-

ing formula:

$$f_{population} = 1 - \prod_{j=1}^3 (1 - \phi_j)^2 \quad (III)$$

5 -wherein ϕ_j is the sum of frequencies in the population of allelic haplotypes encoding MHC molecules which bind any one of the T-cell epitopes in the vaccine and which belong to the j^{th} of the 3 known HLA loci (DP, DR and DQ); in practice, it is first determined which MHC molecules will recognize each T-
 10 cell epitope in the vaccine and thereafter these MHC molecules are listed by type (DP, DR and DQ) - then, the individual frequencies of the different listed allelic haplotypes are summed for each type, thereby yielding ϕ_1 , ϕ_2 , and ϕ_3 .

15 It may occur that the value p_i in formula II exceeds the corresponding theoretical value π_i :

$$\pi_i = 1 - \prod_{j=1}^3 (1 - v_j)^2 \quad (IV)$$

20 -wherein v_j is the sum of frequencies in the population of allelic haplotypes encoding MHC molecules which bind the i^{th} T-cell epitope in the vaccine and which belong to the j^{th} of the 3 known HLA loci (DP, DR and DQ). This means that in $1 - \pi_i$ of the population there is a frequency of responders of

25 $f_{residual_i} = (p_i - \pi_i) / (1 - \pi_i)$. Therefore, formula III can be adjusted so as to yield formula V:

$$f_{population} = 1 - \prod_{j=1}^3 (1 - \phi_j)^2 + \left(1 - \prod_{i=1}^n (1 - f_{residual_i}) \right) \quad (V)$$

30 -where the term $1 - f_{residual_i}$ is set to zero if negative. It should be noted that formula V requires that all epitopes have been haplotype mapped against identical sets of haplotypes.

Therefore, when selecting T-cell epitopes to be introduced in the IL5 analogue, it is important to include all knowledge of the epitopes which is available: 1) The frequency of responders in the population to each epitope, 2) MHC restriction data, and 3) frequency in the population of the relevant haplotypes.

There exists a number of naturally occurring "promiscuous" T-cell epitopes which are active in a large proportion of individuals of an animal species or an animal population and these are preferably introduced in the vaccine thereby reducing the need for a very large number of different GDF-8 analogues in the same vaccine.

The promiscuous epitope can according to the invention be a naturally occurring human T-cell epitope such as epitopes from tetanus toxoid (e.g. the P2 and P30 epitopes), diphtheria toxoid, Influenza virus hemagglutinin (HA), and *P. falciparum* CS antigen. Of course, when vaccinating other animals than humans care should be taken to utilise naturally occurring T-cell epitopes which are promiscuous in the animal in question.

Over the years a number of other promiscuous T-cell epitopes have been identified. Especially peptides capable of binding a large proportion of HLA-DR molecules encoded by the different HLA-DR alleles have been identified and these are all possible T-cell epitopes to be introduced in the GDF-8 analogues used according to the present invention. Cf. also the epitopes discussed in the following references which are hereby all incorporated by reference herein: WO 98/23635 (Frazer IH et al., assigned to The University of Queensland); Southwood S et al., 1998, J. Immunol. **160**: 3363-3373; Sinigaglia F et al., 1988, Nature **336**: 778-780; Chiczy RM et al., 1993, J. Exp. Med **178**: 27-47; Hammer J et al., 1993, Cell **74**: 197-203; and Falk K et

al., 1994, Immunogenetics 39: 230-242. The latter reference also deals with HLA-DQ and -DP ligands. All epitopes listed in these 5 references are relevant as candidate natural epitopes to be used in the present invention, as are epitopes which
5 share common motifs with these.

Alternatively, the epitope can be any artificial T-cell epitope which is capable of binding a large proportion of MHC Class II molecules. In this context the pan DR epitope peptides ("PADRE") described in WO 95/07707 and in the corresponding paper Alexander J et al., 1994, Immunity 1: 751-761 (both disclosures are incorporated by reference herein) are interesting candidates for epitopes to be used according to the present invention. It should be noted that the most effective
15 PADRE peptides disclosed in these papers carry D-amino acids in the C- and N-termini in order to improve stability when administered. However, the present invention primarily aims at incorporating the relevant epitopes as part of the modified GDF-8 which should then subsequently be broken down
20 enzymatically inside the lysosomal compartment of APCs to allow subsequent presentation in the context of an MHC-II molecule and therefore it is not expedient to incorporate D-amino acids in the epitopes used in the present invention.

25 One especially preferred PADRE peptide is the one having the amino acid sequence AKFVAAWTLKAAA or an immunologically effective subsequence thereof. This, and other epitopes having the same lack of MHC restriction are preferred T-cell epitopes which should be present in the GDF-8 analogues used in the inventive method. Such super-promiscuous epitopes will allow for
30 the most simple embodiments of the invention wherein only one single modified GDF-8 is presented to the vaccinated animal's immune system.

As mentioned above, the modification of GDF-8 can also include the introduction of a first moiety which targets the modified GDF-8 to an APC or a B-lymphocyte. For instance, the first moiety can be a specific binding partner for a B-lymphocyte specific surface antigen or for an APC specific surface antigen. Many such specific surface antigens are known in the art. For instance, the moiety can be a carbohydrate for which there is a receptor on the B-lymphocyte or on the APC (e.g. mannan or mannose). Alternatively, the second moiety can be a hapten. Also an antibody fragment which specifically recognizes a surface molecule on APCs or lymphocytes can be used as a first moiety (the surface molecule can e.g. be an FC γ receptor of macrophages and monocytes, such as FC γ RI or, alternatively any other specific surface marker such as CD40 or CTLA-4). It should be noted that all these exemplary targeting molecules can be used as part of an adjuvant also, cf. below.

As an alternative or supplement to targeting the modified GDF-8 polypeptide to a certain cell type in order to achieve an enhanced immune response, it is possible to increase the level of responsiveness of the immune system by including the above-mentioned second moiety which stimulates the immune system. Typical examples of such second moieties are cytokines, and heat-shock proteins, as well as effective parts thereof.

25

Suitable cytokines to be used according to the invention are those which will normally also function as adjuvants in a vaccine composition, i.e. for instance interferon γ (IFN- γ), Flt3L, interleukin 1 (IL-1), interleukin 2 (IL-2), interleukin 4 (IL-4), interleukin 6 (IL-6), interleukin 12 (IL-12), interleukin 13 (IL-13), interleukin 15 (IL-15), and granulocyte-macrophage colony stimulating factor (GM-CSF); alternatively, the functional part of the cytokine molecule may suffice as

the second moiety. With respect to the use of such cytokines as adjuvant substances, cf. the discussion below.

According to the invention, suitable heat shock proteins used
5 as the second moiety can be HSP70, HSP90, HSC70, GRP94 (also known as gp96, cf. Wearsch PA et al. 1998, Biochemistry 37: 5709-19), and CRT (calreticulin).

Alternatively, the second moiety can be a toxin, such as listeriolysin (LLO), lipid A and heat-labile enterotoxin. Also, a
10 number of mycobacterial derivatives such as MDP (muramyl dipeptide) and the trehalose diesters TDM and TDE are interesting possibilities.

15 Also the possibility of introducing a third moiety which enhances the presentation of the modified GDF-8 to the immune system is an important embodiment of the invention. The art has shown several examples of this principle. For instance, it is known that the palmitoyl lipidation anchor in the *Borrelia*
20 *burgdorferi* protein OspA can be utilised so as to provide self-adjuvating polypeptides (cf. e.g. WO 96/40718). It seems that the lipidated proteins form up micelle-like structures with a core consisting of the lipidation anchor parts of the polypeptides and the remaining parts of the molecule protruding therefrom, resulting in multiple presentations of the an-
25 tigenic determinants. Hence, the use of this and related approaches using different lipidation anchors (e.g. a myristyl group, a myristyl group, a farnesyl group, a geranyl-geranyl group, a GPI-anchor, and an N-acyl diglyceride group) are preferred
30 embodiments of the invention, especially since the provision of such a lipidation anchor in a recombinantly produced protein is fairly straightforward and merely requires use of e.g. a naturally occurring signal sequence as a fusion partner for the modified GDF-8 polypeptide. Another possibility is use

of the C3d fragment of complement factor C3 or C3 itself (cf. Dempsey et al., 1996, Science 271, 348-350 and Lou & Kohler, 1998, Nature Biotechnology 16, 458-462).

- 5 An alternative embodiment of the invention which also results in the preferred presentation of multiple (e.g. at least 2) copies of the important epitopic regions of GDF-8 to the immune system is the covalent or non-covalent coupling of GDF-8, subsequence or variants thereof to certain carrier molecules.
- 10 For instance, polymers can be used, e.g. carbohydrates such as dextran, cf. e.g. Lees A et al., 1994, Vaccine 12: 1160-1166; Lees A et al., 1990, J Immunol. 145: 3594-3600, but also mannose and mannan are useful alternatives. Integral membrane proteins from e.g. *E. coli* and other bacteria are also useful
- 15 conjugation partners. The traditional carrier molecules such as keyhole limpet hemocyanin (KLH), tetanus toxoid, diphtheria toxoid, and bovine serum albumin (BSA) are also preferred and useful conjugation partners.
- 20 Certain areas of native GDF-8 are believed to be superiorly suited for performing modifications. It is predicted that modifications in at least one of the following subsequences of C-terminal GDF-8 will result in suitable immunogenic molecules: Residues 18-41, 49-69, or 79-104 in SEQ ID NO: 11 or
- 25 12, or corresponding subsequences from GDF-8 polypeptides of different origin than human, bovine, porcine, chicken or turkey. Considerations underlying these chosen areas are a) preservation of B-cell epitopes, b) preservation of secondary, tertiary and quaternary structures etc. At any rate, as discussed herein, it is fairly easy to screen a set of modified
- 30 GDF-8 molecules (which have all been subjected to introduction of a T-cell epitope in different locations) for immune reactivity with antibodies raised against a native GDF-8. It is especially preferred that the modification is performed by

substituting an amino acid sequence with at least one amino acid sequence of equal or different length which contains a foreign T_H epitope. The rationale behind such constructs is discussed in detail in the examples. Also insertion (or
5 substitution) into any one of the loop areas or the flexible termini (residues 1-12, 18-30, 42-51, 82-86, and 105-109) of the C-terminal GDF-8 fragment is preferred.

Formulation of GDF-8 and modified GDF-8 polypeptides

10

When effecting presentation of the GDF-8 polypeptide or the modified GDF-8 polypeptide to an animal's immune system by means of administration thereof to the animal, the formulation of the polypeptide follows the principles generally acknow-
15 ledged in the art.

Preparation of vaccines which contain peptide sequences as active ingredients is generally well understood in the art, as exemplified by U.S. Patents 4,608,251; 4,601,903; 4,599,231;
20 4,599,230; 4,596,792; and 4,578,770, all incorporated herein by reference. Typically, such vaccines are prepared as injectables either as liquid solutions or suspensions; solid forms suitable for solution in, or suspension in, liquid prior to injection may also be prepared. The preparation may also be
25 emulsified. The active immunogenic ingredient is often mixed with excipients which are pharmaceutically acceptable and compatible with the active ingredient. Suitable excipients are, for example, water, saline, dextrose, glycerol, ethanol, or the like, and combinations thereof. In addition, if desired,
30 the vaccine may contain minor amounts of auxiliary substances such as wetting or emulsifying agents, pH buffering agents, or adjuvants which enhance the effectiveness of the vaccines; cf. the detailed discussion of adjuvants below.

The vaccines are conventionally administered parenterally, by injection, for example, either subcutaneously, intracutaneously, intradermally, subdermally or intramuscularly. Additional formulations which are suitable for other modes of administration include suppositories and, in some cases, oral, buccal, sublingual, intraperitoneal, intravaginal, anal, epidural, spinal, and intracranial formulations. For suppositories, traditional binders and carriers may include, for example, polyalkylene glycols or triglycerides; such suppositories may be formed from mixtures containing the active ingredient in the range of 0.5% to 10%, preferably 1-2%. Oral formulations include such normally employed excipients as, for example, pharmaceutical grades of mannitol, lactose, starch, magnesium stearate, sodium saccharine, cellulose, magnesium carbonate, and the like. These compositions take the form of solutions, suspensions, tablets, pills, capsules, sustained release formulations or powders and contain 10-95% of active ingredient, preferably 25-70%. For oral formulations, cholera toxin is an interesting formulation partner (and also a possible conjugation partner).

The polypeptides may be formulated into the vaccine as neutral or salt forms. Pharmaceutically acceptable salts include acid addition salts (formed with the free amino groups of the peptide) and which are formed with inorganic acids such as, for example, hydrochloric or phosphoric acids, or such organic acids as acetic, oxalic, tartaric, mandelic, and the like. Salts formed with the free carboxyl groups may also be derived from inorganic bases such as, for example, sodium, potassium, ammonium, calcium, or ferric hydroxides, and such organic bases as isopropylamine, trimethylamine, 2-ethylamino ethanol, histidine, procaine, and the like.

The vaccines are administered in a manner compatible with the dosage formulation, and in such amount as will be therapeutically effective and immunogenic. The quantity to be administered depends on the subject to be treated, including, e.g.,
5 the capacity of the individual's immune system to mount an immune response, and the degree of protection desired. Suitable dosage ranges are of the order of several hundred micrograms active ingredient per vaccination with a preferred range from about 0.1 µg to 2000 µg (even though higher amounts in the 1-
10 10 mg range are contemplated), such as in the range from about 0.5 µg to 1000 µg, preferably in the range from 1 µg to 500 µg and especially in the range from about 10 µg to 100 µg. Suitable regimens for initial administration and booster shots are also variable but are typified by an initial administration
15 followed by subsequent inoculations or other administrations.

The manner of application may be varied widely. Any of the conventional methods for administration of a vaccine are applicable. These include oral application on a solid physiologically
20 gically acceptable base or in a physiologically acceptable dispersion, parenterally, by injection or the like. The dosage of the vaccine will depend on the route of administration and will vary according to the age of the person to be vaccinated and the formulation of the antigen.

25

Some of the polypeptides of the vaccine are sufficiently immunogenic in a vaccine, but for some of the others the immune response will be enhanced if the vaccine further comprises an adjuvant substance.

30

Various methods of achieving adjuvant effect for the vaccine are known. General principles and methods are detailed in "The Theory and Practical Application of Adjuvants", 1995, Duncan E.S. Stewart-Tull (ed.), John Wiley & Sons Ltd, ISBN 0-471-

95170-6, and also in "Vaccines: New Generation Immunological Adjuvants", 1995, Gregoriadis G et al. (eds.), Plenum Press, New York, ISBN 0-306-45283-9, both of which are hereby incorporated by reference herein.

5

It is especially preferred to use an adjuvant which can be demonstrated to facilitate breaking of the autotolerance to autoantigens; in fact, this is essential in cases where unmodified GDF-8 is used as the active ingredient in the auto-
10 vaccine. Non-limiting examples of suitable adjuvants are selected from the group consisting of an immune targeting adjuvant; an immune modulating adjuvant such as a toxin, a cytokine, and a mycobacterial derivative; an oil formulation; a polymer; a micelle forming adjuvant; a saponin; an immunosti-
15 mulating complex matrix (ISCOM matrix); a particle; DDA; aluminium adjuvants; DNA adjuvants; γ -inulin; and an encapsulating adjuvant. In general it should be noted that the disclosures above which relate to compounds and agents useful as first, second and third moieties in the analogues also refer *mutatis*
20 *mutandis* to their use in the adjuvant of a vaccine of the invention.

The application of adjuvants include use of agents such as aluminium hydroxide or phosphate (alum), commonly used as 0.05
25 to 0.1 percent solution in buffered saline, admixture with synthetic polymers of sugars (e.g. Carbopol®) used as 0.25 percent solution, aggregation of the protein in the vaccine by heat treatment with temperatures ranging between 70 to 101°C for 30 second to 2 minute periods respectively and also aggregation by means of cross-linking agents are possible. Aggregation by reactivation with pepsin treated antibodies (Fab fragments) to albumin, mixture with bacterial cells such as *C. parvum* or endotoxins or lipopolysaccharide components of gram-negative bacteria, emulsion in physiologically acceptable oil

vehicles such as mannide mono-oleate (Aracel A) or emulsion with 20 percent solution of a perfluorocarbon (Fluosol-DA) used as a block substitute may also be employed. Admixture with oils such as squalene and IFA is also preferred.

5

According to the invention DDA (dimethyldioctadecylammonium bromide) is an interesting candidate for an adjuvant as is DNA and γ -inulin, but also Freund's complete and incomplete adjuvants as well as *quillaja* saponins such as QuilA and QS21 are
10 interesting as is RIBI. Further possibilities are monophosphoryl lipid A (MPL), the above mentioned C3 and C3d, and muramyl dipeptide (MDP).

Liposome formulations are also known to confer adjuvant effects,
15 and therefore liposome adjuvants are preferred according to the invention.

Also immunostimulating complex matrix type (ISCOM® matrix) adjuvants are preferred choices according to the invention, especially since it has been shown that this type of adjuvants
20 are capable of up-regulating MHC Class II expression by APCs. An ISCOM® matrix consists of (optionally fractionated) saponins (triterpenoids) from *Quillaja saponaria*, cholesterol, and phospholipid. When admixed with the immunogenic protein, the
25 resulting particulate formulation is what is known as an ISCOM particle where the saponin constitutes 60-70% w/w, the cholesterol and phospholipid 10-15% w/w, and the protein 10-15% w/w. Details relating to composition and use of immunostimulating complexes can e.g. be found in the above-mentioned text-books
30 dealing with adjuvants, but also Morein B et al., 1995, Clin. Immunother. 3: 461-475 as well as Barr IG and Mitchell GF, 1996, Immunol. and Cell Biol. 74: 8-25 (both incorporated by reference herein) provide useful instructions for the preparation of complete immunostimulating complexes.

Another highly interesting (and thus, preferred) possibility of achieving adjuvant effect is to employ the technique described in Gosselin et al., 1992 (which is hereby incorporated by reference herein). In brief, the presentation of a relevant antigen such as an antigen of the present invention can be enhanced by conjugating the antigen to antibodies (or antigen binding antibody fragments) against the Fcγ receptors on monocytes/macrophages. Especially conjugates between antigen and anti-FcγRI have been demonstrated to enhance immunogenicity for the purposes of vaccination.

Other possibilities involve the use of the targeting and immune modulating substances (i.a. cytokines) mentioned above as candidates for the first and second moieties in the modified versions of GDF-8. In this connection, also synthetic inducers of cytokines like poly I:C are possibilities.

Suitable mycobacterial derivatives are selected from the group consisting of muramyl dipeptide, complete Freund's adjuvant, RIBI, and a diester of trehalose such as TDM and TDE.

Suitable immune targeting adjuvants are selected from the group consisting of CD40 ligand and CD40 antibodies or specifically binding fragments thereof (cf. the discussion above), mannose, a Fab fragment, and CTLA-4.

Suitable polymer adjuvants are selected from the group consisting of a carbohydrate such as dextran, PEG, starch, mannan, and mannose; a plastic polymer such as; and latex such as latex beads.

Yet another interesting way of modulating an immune response is to include the GDF-8 immunogen (optionally together with

adjuvants and pharmaceutically acceptable carriers and vehicles) in a "virtual lymph node" (VLN) (a proprietary medical device developed by ImmunoTherapy, Inc., 360 Lexington Avenue, New York, NY 10017-6501). The VLN (a thin tubular device) mimics the structure and function of a lymph node. Insertion of a VLN under the skin creates a site of sterile inflammation with an upsurge of cytokines and chemokines. T- and B-cells as well as APCs rapidly respond to the danger signals, home to the inflamed site and accumulate inside the porous matrix of the VLN. It has been shown that the necessary antigen dose required to mount an immune response to an antigen is reduced when using the VLN and that immune protection conferred by vaccination using a VLN surpassed conventional immunization using Ribi as an adjuvant. The technology is *i.a.* described briefly in Gelber C et al., 1998, "Elicitation of Robust Cellular and Humoral Immune Responses to Small Amounts of Immunogens Using a Novel Medical Device Designated the Virtual Lymph Node", in: "From the Laboratory to the Clinic, Book of Abstracts, October 12th - 15th 1998, Seascape Resort, Aptos, California".

It is expected that the vaccine should be administered at least once a year, such as at least 1, 2, 3, 4, 5, 6, and 12 times a year. More specifically, 1-12 times per year is expected, such as 1, 2, 3, 4, 5, 6, 7, 8, 9, 10, 11, or 12 times a year to an individual in need thereof. It has previously been shown that the memory immunity induced by the use of the preferred autovaccines according to the invention is not permanent, and therefore the immune system needs to be periodically challenged with the analogues.

Due to genetic variation, different individuals may react with immune responses of varying strength to the same polypeptide. Therefore, the vaccine according to the invention may comprise

several different polypeptides in order to increase the immune response, cf. also the discussion above concerning the choice of foreign T-cell epitope introductions. The vaccine may comprise two or more polypeptides, where all of the polypeptides
5 are as defined above.

The vaccine may consequently comprise 3-20 different modified or unmodified polypeptides, such as 3-10 different polypeptides. However, normally the number of polypeptides will be
10 sought kept to a minimum such as 1 or 2 polypeptides.

Nucleic acid vaccination

As an alternative to classic administration of a peptide-based
15 vaccine, the technology of nucleic acid vaccination (also known as "nucleic acid immunisation", "genetic immunisation", and "gene immunisation") offers a number of attractive features.

20 First, in contrast to the traditional vaccine approach, nucleic acid vaccination does not require resource consuming large-scale production of the immunogenic agent (e.g. in the form of industrial scale fermentation of micro-organisms producing modified GDF-8). Furthermore, there is no need to devise purification and refolding schemes for the immunogen. And finally,
25 since nucleic acid vaccination relies on the biochemical apparatus of the vaccinated individual in order to produce the expression product of the nucleic acid introduced, the optimum posttranslational processing of the expression product is expected to occur; this is especially important in the case of
30 autovaccination, since, as mentioned above, a significant fraction of the original GDF-8 B-cell epitopes should be preserved in the modified molecule, and since B-cell epitopes in principle can be constituted by parts of any (bio)molecule

(e.g. carbohydrate, lipid, protein etc.). Therefore, native glycosylation and lipidation patterns of the immunogen may very well be of importance for the overall immunogenicity and this is expected to be ensured by having the host producing
5 the immunogen.

Hence, a preferred embodiment of the invention comprises effecting presentation of modified GDF-8 to the immune system by introducing nucleic acid(s) encoding the modified GDF-8 into
10 the animal's cells and thereby obtaining *in vivo* expression by the cells of the nucleic acid(s) introduced.

In this embodiment, the introduced nucleic acid is preferably DNA which can be in the form of naked DNA, DNA formulated with
15 charged or uncharged lipids, DNA formulated in liposomes, DNA included in a viral vector, DNA formulated with a transfection-facilitating protein or polypeptide, DNA formulated with a targeting protein or polypeptide, DNA formulated with Calcium precipitating agents, DNA coupled to an inert carrier
20 molecule, and DNA formulated with an adjuvant. In this context it is noted that practically all considerations pertaining to the use of adjuvants in traditional vaccine formulation apply for the formulation of DNA vaccines. Hence, all disclosures herein which relate to use of adjuvants in the context of
25 polypeptide based vaccines apply *mutatis mutandis* to their use in nucleic acid vaccination technology.

As for routes of administration and administration schemes of polypeptide based vaccines which have been detailed above,
30 these are also applicable for the nucleic acid vaccines of the invention and all discussions above pertaining to routes of administration and administration schemes for polypeptides apply *mutatis mutandis* to nucleic acids. To this should be added that nucleic acid vaccines can suitably be administered intra-

venously and intraarterially. Furthermore, it is well-known in the art that nucleic acid vaccines can be administered by use of a so-called gene gun, and hence also this and equivalent modes of administration are regarded as part of the present invention. Finally, also the use of a VLN in the administration of nucleic acids has been reported to yield good results, and therefore this particular mode of administration is particularly preferred.

Furthermore, the nucleic acid(s) used as an immunization agent can contain regions encoding the 1st, 2nd and/or 3rd moieties, e.g. in the form of the immunomodulating substances described above such as the cytokines discussed as useful adjuvants. A preferred version of this embodiment encompasses having the coding region for the analogue and the coding region for the immunomodulator in different reading frames or at least under the control of different promoters. Thereby it is avoided that the analogue or epitope is produced as a fusion partner to the immunomodulator. Alternatively, two distinct nucleotide fragments can be used, but this is less preferred because of the advantage of ensured co-expression when having both coding regions included in the same molecule.

Accordingly, the invention also relates to a composition for inducing production of antibodies against GDF-8, the composition comprising

- a nucleic acid fragment or a vector of the invention (cf. the discussion of vectors below), and
- a pharmaceutically and immunologically acceptable vehicle and/or carrier and/or adjuvant as discussed above.

Under normal circumstances, the GDF-8 variant-encoding nucleic acid is introduced in the form of a vector wherein expression is under control of a viral promoter. For more detailed dis-

cussions of vectors and DNA fragments according to the invention, cf. the discussion below. Also, detailed disclosures relating to the formulation and use of nucleic acid vaccines are available, cf. Donnelly JJ et al., 1997, Annu. Rev. Immunol.

5 15: 617-648 and Donnelly JJ et al., 1997, Life Sciences 60: 163-172. Both of these references are incorporated by reference herein.

Live vaccines

10

A third alternative for effecting presentation of modified GDF-8 to the immune system is the use of live vaccine technology. In live vaccination, presentation to the immune system is effected by administering, to the animal, a non-pathogenic
15 micro-organism which has been transformed with a nucleic acid fragment encoding a modified GDF-8 or with a vector incorporating such a nucleic acid fragment. The non-pathogenic micro-organism can be any suitable attenuated bacterial strain (attenuated by means of passaging or by means of removal of
20 pathogenic expression products by recombinant DNA technology), e.g. *Mycobacterium bovis* BCG., non-pathogenic *Streptococcus* spp., *E. coli*, *Salmonella* spp., *Vibrio cholerae*, *Shigella*, etc. Reviews dealing with preparation of state-of-the-art live vaccines can e.g. be found in Saliou P, 1995, Rev. Prat. 45:
25 1492-1496 and Walker PD, 1992, Vaccine 10: 977-990, both incorporated by reference herein. For details about the nucleic acid fragments and vectors used in such live vaccines, cf. the discussion below.

30 As an alternative to bacterial live vaccines, the nucleic acid fragment of the invention discussed below can be incorporated in a non-virulent viral vaccine vector such as a vaccinia strain or any other suitable pox virus which will be infectious in the animal to be vaccinated.

Normally, the non-pathogenic micro-organism or virus is administered only once to the animal, but in certain cases it may be necessary to administer the micro-organism more than once
5 in a lifetime in order to maintain protective immunity. It is even contemplated that immunization schemes as those detailed above for polypeptide vaccination will be useful when using live or virus vaccines.

10 Alternatively, live or virus vaccination is combined with previous or subsequent polypeptide and/or nucleic acid vaccination. For instance, it is possible to effect primary immunization with a live or virus vaccine followed by subsequent booster immunizations using the polypeptide or nucleic acid
15 approach.

The micro-organism or virus can be transformed with nucleic acid(s) containing regions encoding the 1st, 2nd and/or 3rd moieties, e.g. in the form of the immunomodulating substances
20 described above such as the cytokines discussed as useful adjuvants. A preferred version of this embodiment encompasses having the coding region for the analogue and the coding region for the immunomodulator in different reading frames or at least under the control of different promoters. Thereby it is
25 avoided that the analogue or epitopes are produced as fusion partners to the immunomodulator. Alternatively, two distinct nucleotide fragments can be used as transforming agents. Of course, having the 1st and/or 2nd and/or 3rd moieties in the same reading frame can provide as an expression product, an
30 analogue of the invention, and such an embodiment is especially preferred according to the present invention.

Use of the method of the invention in meat production and in
disease treatment

As will be appreciated from the discussions above, the provi-
5 sion of the method of the invention for down-regulation of
GDF-8 activity allows for stimulation of the growth of skele-
tal muscle mass in animals. Hence, an important embodiment of
the method of the invention for down-regulating GDF-8 activity
comprises increasing the skeletal muscle mass of an animal,
10 the method comprising down-regulating GDF-8 activity according
to the method of the invention to such an extent that the mus-
cle mass is statistically significantly increased (at a confi-
dence level of 95%) and with at least 5%, when compared to
control animals exhibiting a normal GDF-8 activity.

15 The increase in muscle mass may preferably be higher, such as
at least 10, 15, 20, 25, 30, 35, 40, or even 45%, cf. the in-
creases in muscle mass which have been observed in transgenic
mice and naturally occurring GDF-8 deficient animals.

20 The muscle mass can be determined by any convenient method
known in the art for assessing total and/or relative muscle
mass.

25 An anti-GDF-8 vaccine could potentially also be useful for
treatment of certain human diseases such as cancer cachexia,
where muscular atrophy is a pronounced phenomenon, and it is
also a feasible means of treatment/amelioration in other atro-
phic muscular diseases. Recent reports also suggest that sup-
30 pression of GDF-8 would be beneficial in patients suffering
from acute and chronic heart failure.

Peptides, polypeptides, and compositions of the invention

As will be apparent from the above, the present invention is based on the concept of immunising individuals against the GDF-8 antigen in order to obtain an increase in muscle growth rate. The preferred way of obtaining such an immunization is to use modified versions of GDF-8, thereby providing molecules which have not previously been disclosed in the art.

10 It is believed that the modified GDF-8 molecules discussed herein are inventive in their own right, and therefore an important part of the invention pertains to a GDF-8 analogue which is derived from an animal GDF-8 wherein is introduced a modification which has as a result that immunization of the
15 animal with the analogue induces production of antibodies reacting specifically with the unmodified GDF-8 polypeptide. Preferably, the nature of the modification conforms with the types of modifications described above when discussing various embodiments of the method of the invention when using modified
20 GDF-8. Hence, any disclosure presented herein pertaining to modified GDF-8 molecules are relevant for the purpose of describing the GDF-8 analogues of the invention, and any such disclosures apply *mutatis mutandis* to the description of these analogues.

25

It should be noted that preferred modified GDF-8 molecules comprise modifications which results in a polypeptide having a sequence identity of at least 70% with GDF-8 or with a subsequence thereof of at least 10 amino acids in length. Higher
30 sequence identities are preferred, e.g. at least 75% or even at least 80% or 85%. The sequence identity for proteins and nucleic acids can be calculated as $(N_{ref} - N_{dif}) \cdot 100 / N_{ref}$, wherein N_{dif} is the total number of non-identical residues in the two sequences when aligned and wherein N_{ref} is the number

of residues in one of the sequences. Hence, the DNA sequence AGTCAGTC will have a sequence identity of 75% with the sequence AATCAATC ($N_{dif}=2$ and $N_{ref}=8$).

5 The invention also pertains to compositions useful in exercising the method of the invention. Hence, the invention also relates to an immunogenic composition comprising an immunogenically effective amount of a GDF-8 polypeptide which is a self-protein in an animal, said GDF-8 polypeptide being formulated together with an immunologically acceptable adjuvant so
10 as to break the animal's autotolerance towards the GDF-8 polypeptide, the composition further comprising a pharmaceutically and immunologically acceptable vehicle and/or carrier. In other words, this part of the invention pertains to the formulations of naturally occurring GDF-8 polypeptides which have
15 been described in connection with embodiments of the method of the invention.

The invention also relates to an immunogenic composition comprising an immunologically effective amount of a GDF-8 analogue defined above, said composition further comprising a pharmaceutically and immunologically acceptable diluent and/or vehicle and/or carrier and/or excipient and optionally an adjuvant. In other words, this part of the invention concerns formulations of modified GDF-8, essentially as described herein-
25 above. The choice of adjuvants, carriers, and vehicles is accordingly in line with what has been discussed above when referring to formulation of modified and unmodified GDF-8 for use in the inventive method for the down-regulation of GDF-8.

30

The polypeptides are prepared according to methods well-known in the art. Longer polypeptides are normally prepared by means of recombinant gene technology including introduction of a nucleic acid sequence encoding the GDF-8 analogue into a suit-

able vector, transformation of a suitable host cell with the vector, expression of the nucleic acid sequence, recovery of the expression product from the host cells or their culture supernatant, and subsequent purification and optional further
5 modification, e.g. refolding or derivatization.

Shorter peptides are preferably prepared by means of the well-known techniques of solid- or liquid-phase peptide synthesis. However, recent advances in this technology has rendered possible the production of full-length polypeptides and proteins
10 by these means, and therefore it is also within the scope of the present invention to prepare the long constructs by synthetic means.

15 Nucleic acid fragments and vectors of the invention

It will be appreciated from the above disclosure that modified GDF-8 polypeptides can be prepared by means of recombinant gene technology but also by means of chemical synthesis or
20 semisynthesis; the latter two options are especially relevant when the modification consists in coupling to protein carriers (such as KLH, diphtheria toxoid, tetanus toxoid, and BSA) and non-proteinaceous molecules such as carbohydrate polymers and of course also when the modification comprises addition of
25 side chains or side groups to a GDF-8 polypeptide-derived peptide chain.

For the purpose of recombinant gene technology, and of course also for the purpose of nucleic acid immunization, nucleic
30 acid fragments encoding modified GDF-8 are important chemical products. Hence, an important part of the invention pertains to a nucleic acid fragment which encodes a GDF-8 analogue, i.e. a GDF-8 derived polypeptide which either comprises the natural GDF-8 sequence to which has been added or inserted a

fusion partner or, preferably a GDF-8 derived polypeptide wherein has been introduced a foreign T-cell epitope by means of insertion and/or addition, preferably by means of substitution and/or deletion. The nucleic acid fragments of the invention are either DNA or RNA fragments.

The nucleic acid fragments of the invention will normally be inserted in suitable vectors to form cloning or expression vectors carrying the nucleic acid fragments of the invention; such novel vectors are also part of the invention. Details concerning the construction of these vectors of the invention will be discussed in context of transformed cells and microorganisms below. The vectors can, depending on purpose and type of application, be in the form of plasmids, phages, cosmids, mini-chromosomes, or virus, but also naked DNA which is only expressed transiently in certain cells is an important vector. Preferred cloning and expression vectors of the invention are capable of autonomous replication, thereby enabling high copy-numbers for the purposes of high-level expression or high-level replication for subsequent cloning.

The general outline of a vector of the invention comprises the following features in the 5'→3' direction and in operable linkage: a promoter for driving expression of the nucleic acid fragment of the invention, optionally a nucleic acid sequence encoding a leader peptide enabling secretion (to the extracellular phase or, where applicable, into the periplasma of a bacterium) of or integration into the membrane of the polypeptide fragment, the nucleic acid fragment of the invention, and optionally a nucleic acid sequence encoding a terminator. When operating with expression vectors in producer strains or cell-lines it is for the purposes of genetic stability of the transformed cell preferred that the vector when introduced into a host cell is integrated in the host cell genome. In

contrast, when working with vectors to be used for effecting
in vivo expression in an animal (i.e. when using the vector in
DNA vaccination) it is for security reasons preferred that the
vector is not incapable of being integrated in the host cell
5 genome; typically, naked DNA or non-integrating viral vectors
are used, the choices of which are well-known to the person
skilled in the art.

The vectors of the invention are used to transform host cells
10 to produce the modified GDF-8 polypeptide of the invention.
Such transformed cells, which are also part of the invention,
can be cultured cells or cell lines used for propagation of
the nucleic acid fragments and vectors of the invention, or
used for recombinant production of the modified GDF-8 polypep-
15 tides of the invention. Alternatively, the transformed cells
can be suitable live vaccine strains wherein the nucleic acid
fragment (one single or multiple copies) have been inserted so
as to effect secretion or integration into the bacterial mem-
brane or cell-wall of the modified GDF-8.

20

Preferred transformed cells of the invention are micro-organ-
isms such as bacteria (such as the species *Escherichia* [e.g.
E. coli], *Bacillus* [e.g. *Bacillus subtilis*], *Salmonella*, or
Mycobacterium [preferably non-pathogenic, e.g. *M. bovis* BCG]),
25 yeasts (such as *Saccharomyces cerevisiae*), and protozoans. Al-
ternatively, the transformed cells are derived from a multi-
cellular organism such as a fungus, an insect cell, a plant
cell, or a mammalian cell. Recent results have shown great
promise in the use of a commercially available *Drosophila*
30 *melanogaster* cell line (the Schneider 2 (S₂) cell line and vec-
tor system available from Invitrogen) for the recombinant pro-
duction of IL-5 analogues of the invention, and therefore this
expression system is particularly preferred, also for the pur-
poses of the present invention.

For the purposes of cloning and/or optimised expression it is preferred that the transformed cell is capable of replicating the nucleic acid fragment of the invention. Cells expressing
5 the nucleic acid fragment are preferred useful embodiments of the invention; they can be used for small-scale or large-scale preparation of the modified GDF-8 or, in the case of non-pathogenic bacteria, as vaccine constituents in a live vaccine.

10

When producing the modified GDF-8 of the invention by means of transformed cells, it is convenient, although far from essential, that the expression product is either exported out into the culture medium or carried on the surface of the trans-
15 formed cell.

When an effective producer cell has been identified it is preferred, on the basis thereof, to establish a stable cell line which carries the vector of the invention and which expresses
20 the nucleic acid fragment encoding the modified GDF-8. Preferably, this stable cell line secretes or carries the GDF-8 analogue of the invention, thereby facilitating purification thereof.

25 In general, plasmid vectors containing replicon and control sequences which are derived from species compatible with the host cell are used in connection with the hosts. The vector ordinarily carries a replication site, as well as marking sequences which are capable of providing phenotypic selection in
30 transformed cells. For example, *E. coli* is typically transformed using pBR322, a plasmid derived from an *E. coli* species (see, e.g., Bolivar et al., 1977). The pBR322 plasmid contains genes for ampicillin and tetracycline resistance and thus provides easy means for identifying transformed cells. The pBR

plasmid, or other microbial plasmid or phage must also contain, or be modified to contain, promoters which can be used by the prokaryotic micro-organism for expression.

5 Those promoters most commonly used in recombinant DNA construction include the B-lactamase (penicillinase) and lactose promoter systems (Chang et al., 1978; Itakura et al., 1977; Goeddel et al., 1979) and a tryptophan (trp) promoter system (Goeddel et al., 1979; EP-A-0 036 776). While these are the
10 most commonly used, other microbial promoters have been discovered and utilized, and details concerning their nucleotide sequences have been published, enabling a skilled worker to ligate them functionally with plasmid vectors (Siebwenlist et al., 1980). Certain genes from prokaryotes may be expressed
15 efficiently in *E. coli* from their own promoter sequences, precluding the need for addition of another promoter by artificial means.

In addition to prokaryotes, eukaryotic microbes, such as yeast
20 cultures may also be used, and here the promoter should be capable of driving expression. *Saccharomyces cerevisiae*, or common baker's yeast is the most commonly used among eukaryotic micro-organisms, although a number of other strains are commonly available. For expression in *Saccharomyces*, the plasmid
25 YRp7, for example, is commonly used (Stinchcomb et al., 1979; Kingsman et al., 1979; Tschemper et al., 1980). This plasmid already contains the *trp1* gene which provides a selection marker for a mutant strain of yeast lacking the ability to grow in tryptophan for example ATCC No. 44076 or PEP4-1
30 (Jones, 1977). The presence of the *trp1* lesion as a characteristic of the yeast host cell genome then provides an effective environment for detecting transformation by growth in the absence of tryptophan.

Suitable promoting sequences in yeast vectors include the promoters for 3-phosphoglycerate kinase (Hitzman *et al.*, 1980) or other glycolytic enzymes (Hess *et al.*, 1968; Holland *et al.*, 1978), such as enolase, glyceraldehyde-3-phosphate dehydrogenase, hexokinase, pyruvate decarboxylase, phosphofructokinase, glucose-6-phosphate isomerase, 3-phosphoglycerate mutase, pyruvate kinase, triosephosphate isomerase, phosphoglucose isomerase, and glucokinase. In constructing suitable expression plasmids, the termination sequences associated with these genes are also ligated into the expression vector 3' of the sequence desired to be expressed to provide polyadenylation of the mRNA and termination.

Other promoters, which have the additional advantage of transcription controlled by growth conditions are the promoter region for alcohol dehydrogenase 2, isocytochrome C, acid phosphatase, degradative enzymes associated with nitrogen metabolism, and the aforementioned glyceraldehyde-3-phosphate dehydrogenase, and enzymes responsible for maltose and galactose utilization. Any plasmid vector containing a yeast-compatible promoter, origin of replication and termination sequences is suitable.

In addition to micro-organisms, cultures of cells derived from multicellular organisms may also be used as hosts. In principle, any such cell culture is workable, whether from vertebrate or invertebrate culture. However, interest has been greatest in vertebrate cells, and propagation of vertebrate in culture (tissue culture) has become a routine procedure in recent years (Tissue Culture, 1973). Examples of such useful host cell lines are VERO and HeLa cells, Chinese hamster ovary (CHO) cell lines, and W138, BHK, COS-7 293, *Drosophila melanogaster* and *Spodoptera frugiperda* (SF) cells (commercially available as complete expression systems from *i.a.* Pro-

tein Sciences, 1000 Research Parkway, Meriden, CT 06450, U.S.A. and from Invitrogen), and MDCK cell lines. In the present invention, especially preferred cell lines are S₂ and SF₂₁ available from Invitrogen, PO Box 2312, 9704 CH Groningen, The Netherlands.

Expression vectors for such cells ordinarily include (if necessary) an origin of replication, a promoter located in front of the gene to be expressed, along with any necessary ribosome binding sites, RNA splice sites, polyadenylation site, and transcriptional terminator sequences.

For use in mammalian cells, the control functions on the expression vectors are often provided by viral material. For example, commonly used promoters are derived from polyoma, Adenovirus 2, and most frequently Simian Virus 40 (SV40). The early and late promoters of SV40 virus are particularly useful because both are obtained easily from the virus as a fragment which also contains the SV40 viral origin of replication (Fiers et al., 1978). Smaller or larger SV40 fragments may also be used, provided there is included the approximately 250 bp sequence extending from the *HindIII* site toward the *BglII* site located in the viral origin of replication. Further, it is also possible, and often desirable, to utilize promoter or control sequences normally associated with the desired gene sequence, provided such control sequences are compatible with the host cell systems.

An origin of replication may be provided either by construction of the vector to include an exogenous origin, such as may be derived from SV40 or other viral (e.g., Polyoma, Adeno, VSV, BPV) or may be provided by the host cell chromosomal replication mechanism. If the vector is integrated into the host cell chromosome, the latter is often sufficient.

Identification of useful GDF-8 analogues

It will be clear to the skilled person that not all variants
5 or modifications of native GDF-8 will have the ability to
elicit antibodies in an animal which are cross-reactive with
the native form. It is, however, not difficult to set up an
effective standard screen for modified GDF-8 molecules which
fulfil the minimum requirements for immunological reactivity
10 discussed herein. Hence, another part of the invention con-
cerns a method for the identification of a modified GDF-8
polypeptide which is capable of inducing antibodies against
unmodified GDF-8 in an animal species where the unmodified
GDF-8 polypeptide is a self-protein, the method comprising

15

- preparing, by means of peptide synthesis or by genetic
engineering methods, a set of mutually distinct modified
GDF-8 polypeptides wherein amino acids have been added
to, inserted in, deleted from, or substituted into the
20 amino acid sequence of a GDF-8 polypeptide of the animal
species thereby giving rise to amino acid sequences in
the set which comprise T-cell epitopes which are foreign
to the animal species,
- testing members of the set for their ability to induce
25 production of antibodies by the animal species against
the unmodified GDF-8, and
- isolating the member(s) of the set which significantly
induces antibody production against unmodified GDF-8 in
the animal species.

30

In this context, the "set of mutually distinct modified GDF-8
polypeptides" is a collection of non-identical modified GDF-8
polypeptides which have e.g. been selected on the basis of the
criteria discussed above (e.g. in combination with studies of

circular dichroism, NMR spectra, and/or X-ray diffraction patterns). The set may consist of only a few members but it is contemplated that the set may contain several hundred members.

- 5 The set may be "prepared" *in vivo* insofar that one applicable testing system is to prepare nucleic acid fragments encoding the members and then using these nucleic acid fragments in nucleic acid immunization as described herein so as to determine whether the expression products are immunogenic. Hence, the
- 10 test of members of the set can be performed *in vivo*, but a number of *in vitro* tests can be applied which narrow down the number of modified molecules which will serve the purpose of the invention.
- 15 Since the goal of introducing the foreign T-cell epitopes is to support the B-cell response by T-cell help, a prerequisite is that T-cell proliferation is induced by the modified GDF-8. T-cell proliferation can be tested by standardized proliferation assays *in vitro*. In short, a sample enriched for T-cells
- 20 is obtained from a subject and subsequently kept in culture. The cultured T-cells are contacted with APCs of the subject which have previously taken up the modified molecule and processed it to present its T-cell epitopes. The proliferation of T-cells is monitored and compared to a suitable control (e.g.
- 25 T-cells in culture contacted with APCs which have processed intact, native GDF-8). Alternatively, proliferation can be measured by determining the concentration of relevant cytokines released by the T-cells in response to their recognition of foreign T-cells.

30

Having rendered highly probable that at least one modified GDF-8 of the set is capable of inducing antibody production against GDF-8, it is possible to prepare an immunogenic composition comprising at least one modified GDF-8 polypeptide

which is capable of inducing antibodies against unmodified GDF-8 in an animal species where the unmodified GDF-8 polypeptide is a self-protein, the method comprising admixing the member(s) of the set which significantly induces production of antibodies in the animal species which are reactive with GDF-8 with a pharmaceutically and immunologically acceptable carrier and/or vehicle and/or diluent and/or excipient, optionally in combination with at least one pharmaceutically and immunologically acceptable adjuvant.

10

The above aspects of the invention are conveniently carried out by initially preparing a number of mutually distinct nucleic acid sequences or vectors of the invention, inserting these into appropriate expression vectors, transforming suitable host cells with the vectors, and expressing the nucleic acid sequences of the invention. These steps can be followed by isolation of the expression products. It is preferred that the nucleic acid sequences and/or vectors are prepared by methods comprising exercise of a molecular amplification technique such as PCR or by means of nucleic acid synthesis.

20

PREAMBLE TO EXAMPLES

25 Expression of the 109 amino acid residue C-terminal region of GDF-8 fused to an N-terminal His-tag has been obtained in *E. coli* and the purified fusion protein has been used for immunisation of rabbits. Full-length GDF-8 has been expressed in CHO cells and shown to be secreted as dimers of unprocessed and processed GDF-8, respectively (McPherron et al., Nature 387, 83-90, 1997). Thus, no problems are expected with expression of the below-discussed GDF-8 autovaccine constructs. The most likely expression systems to be used for production of the GDF-8 AutoVac constructs are *E. coli*, the yeast *P. pastoris*

30

and CHO cells and insect cells such as the above mentioned *Drosophila* cells.

5 EXAMPLE 1

Vaccine design

The rationale behind the present invention is to substitute
10 stretches of amino acid residues in the target protein with
foreign or artificial T-cell epitopes e.g. the promiscuous
tetanus toxin T-cell epitopes P2 and P30. Preferably these
substitutions should only minimally disturb the authentic
three dimensional structure of the target protein.

15

The target protein here is the 109 amino acid residue C-termi-
nal region of GDF-8, the homodimer of which is expected to be
the biologically active form of GDF-8. The three-dimensional
structure of this region of GDF-8 is not known but based on
20 the structure of the homologous TGF- β protein the model of
monomeric GDF-8 shown in Fig. 2 can be anticipated to be rea-
sonably close to reality. In this model of the wild type GDF-8
(wt) α -helices are shown as cylinders and β -sheets are shown as
arrows. The cysteine-residues and thus the disulfide-bonds are
25 very closely positioned in the structure.

It should be borne in mind that the presence of the relatively
high number cysteines (9) and thus disulfide-bonds in the 109
amino acid residue C-terminal region of GDF-8 limits the pos-
30 sible sites where the foreign T-cell epitopes can be posi-
tioned.

In addition to producing the 109 amino acid residue C-terminal
region of GDF-8 without substitutions (i.e. residues 267-375

of SEQ ID NOs: 1-10), the following GDF-8 AutoVac constructs are proposed.

GDF-8 P2-1 (SEQ ID NO: 15) is the 109 amino acid residue C-terminal region of GDF-8 with amino acid residues 18-32 substituted by P2.

GDF-8 P2-2 (SEQ ID NO: 16) is the 109 amino acid residue C-terminal region of GDF-8 with amino acid residues 52-66 substituted by P2.

GDF-8 P2-3 (SEQ ID NO: 17) is the 109 amino acid residue C-terminal region of GDF-8 with amino acid residues 83-97 substituted by P2.

15

GDF-8 P30-1 (SEQ ID NO: 18) is the 109 amino acid residue C-terminal region of GDF-8 with amino acid residues 21-41 substituted by P30.

20 GDF-8 P30-2 (SEQ ID NO: 19) is the 109 amino acid residue C-terminal region of GDF-8 with amino acid residues 49-69 substituted by P30.

GDF-8 P30-3A (SEQ ID NO: 20) is the 109 amino acid residue C-terminal region of GDF-8 with amino acid residues 79-99 substituted by P30.

GDF-8 P30-3B (SEQ ID NO: 21) is the 109 amino acid residue C-terminal region of GDF-8 with amino acid residues 84-104 substituted by P30.

GDF-8 dimer (SEQ ID NO: 22) is two copies of the 109 amino acid residue C-terminal region of GDF-8 covalently connected through the P2 and P30 epitopes. In other words the molecule

is comprised of two halves. The first half is the 109 amino acid residue C-terminal region of GDF-8 having P2 fused to its C-terminus while the second half is the 109 amino acid residue C-terminal region of GDF-8 having P30 fused to its N-terminus.

5

GDF-8 ext (SEQ ID NO: 23) consists of the C-terminal 160 amino acid residue of GDF-8 with residues 16-36 substituted by P30 and residues 37-51 substituted by P2. This construct is the 109 amino acid residue C-terminal region of GDF-8 with an N-terminal extension containing both the P2 and the P30 epitopes.

In all exemplary constructs except from the latter 2, it is contemplated to produce a variant where Cys73 is substituted with Ser to avoid dimerisation through disulfide-bond formation. In **GDF-8 ext** it is contemplated to perform a similar substitution in the corresponding position (i.e. Cys124 → Ser124).

20

EXAMPLE 2

In vitro models

25 It is contemplated to initially immunise mice with purified GDF-8 variants as described above. After e.g. three immunisations antibodies will be measured in ELISA using the non-modified GDF-8 molecule as the antigen. The primary reason for these initial experiments is to confirm that the AutoVac™
30 technology is applicable for creating anti-GDF-8 cross reactive autoantibodies and, importantly, to identify the optimal dosing and immunisation regimen. It would, however, be very surprising if antibodies against GDF-8 were not raised using the present technology, since the fundamental immunological

mechanisms of such a response are most likely to be identical to those which have already been observed for TNF α , cf. WO 98/46642 and WO 95/05849.

EXAMPLE 3

In vivo models

Groups of mice will be immunised with the various constructs described in Example 1. The mice will be immunised at the age of about 4 weeks since they have to be immune competent in order to respond to the vaccine. Freund's Complete adjuvant will be used, but experiments will also be performed using an alum adjuvant such as Adjuphos™, which has previously been used successfully in admixture with TNF α autovaccine constructs. Adjuphos™ is accepted for both human and animal use. During the entire immunisation period the total body weight of GDF-8 immunised as well as control animals will be monitored regularly. When the mice are approximately 16 weeks of age, they will be sacrificed and the size of their muscle mass will be determined.

Due to the relatively narrow window in time where mice are immune competent but still not fully outgrown, it may be difficult to demonstrate an effect of anti-GDF-8 vaccination in these animals. If that proves to be the case, it is contemplated to alternatively immunise rats or larger animals such as pigs, cattle, etc.

The modified GDF-8 molecule, which superiorly increases the growth rate of the animals and/or superiorly increases the maximum muscle size, is selected for clinical development.

CLAIMS

1. A method for *in vivo* down-regulation of growth differentiation factor 8 (GDF-8) activity in an animal, including a human
5 being, the method comprising effecting presentation to the animal's immune system of an immunogenically effective amount of
- at least one GDF-8 polypeptide or subsequence thereof which has been formulated so that immunization of the
10 animal with the GDF-8 polypeptide or subsequence thereof induces production of antibodies against the GDF-8 polypeptide, and/or
 - at least one GDF-8 analogue wherein is introduced at least one modification in the GDF-8 amino acid sequence
15 which has as a result that immunization of the animal with the analogue induces production of antibodies against the GDF-8 polypeptide.
2. The method according to claim 1, wherein is presented a
20 GDF-8 analogue with at least one modification of the GDF-8 amino acid sequence.
3. The method according to claim 2, wherein the modification has as a result that a substantial fraction of GDF-8 B-cell
25 epitopes are preserved and that
- at least one foreign T helper lymphocyte epitope (T_H epitope) is introduced, and/or
 - at least one first moiety is introduced which effects targeting of the modified molecule to an antigen presenting cell (APC) or a B-lymphocyte, and/or
30
 - at least one second moiety is introduced which stimulates the immune system, and/or

- at least one third moiety is introduced which optimises presentation of the modified GDF-8 polypeptide to the immune system.

5 4. The method according to claim 3, wherein the modification includes introduction as side groups, by covalent or non-covalent binding to suitable chemical groups in GDF-8 or a subsequence thereof, of the foreign T_H epitope and/or of the first and/or of the second and/or of the third moiety.

10

5. The method according to claim 3 or 4, wherein the modification includes amino acid substitution and/or deletion and/or insertion and/or addition.

15 6. The method according to claim 5, wherein the modification results in the provision of a fusion polypeptide.

7. The method according to claim 5 or 6, wherein introduction of the amino acid substitution and/or deletion and/or insertion and/or addition results in a substantial preservation of the overall tertiary structure of GDF-8.

8. The method according to any one of claims 2-7, wherein the modification includes duplication of at least one GDF-8 B-cell epitope and/or introduction of a hapten.

9. The method according to any one of claims 3-8, wherein the foreign T-cell epitope is immunodominant in the animal.

30 10. The method according to any one of claims 3-9, wherein the foreign T-cell epitope is promiscuous, such as a natural promiscuous T-cell epitope and an artificial MHC-II binding peptide sequence.

11. The method according to claim 10, wherein the natural T-cell epitope is selected from a Tetanus toxoid epitope such as P2 or P30, a diphtheria toxoid epitope, an influenza virus hemagglutinin epitope, and a *P. falciparum* CS epitope.

5

12. The method according to any one of claims 3-11, wherein the first moiety is a substantially specific binding partner for a B-lymphocyte specific surface antigen or for an APC specific surface antigen, such as a hapten or a carbohydrate for
10 which there is a receptor on the B-lymphocyte or the APC, such as mannan or mannose.

13. The method according to any one of claims 3-12, wherein the second moiety is selected from a cytokine, a hormone, and
15 a heat-shock protein.

14. The method according to claim 13, wherein the cytokine is selected from, or is an effective part of, interferon γ (IFN- γ), Flt3L, interleukin 1 (IL-1), interleukin 2 (IL-2), interleukin 4 (IL-4), interleukin 6 (IL-6), interleukin 12 (IL-12),
20 interleukin 13 (IL-13), interleukin 15 (IL-15), and granulocyte-macrophage colony stimulating factor (GM-CSF), and wherein the heat-shock protein is selected from the group consisting of HSP70, HSP90, HSC70, GRP94, and calreticulin (CRT),
25 or an effective part thereof.

15. The method according to any one of claims 3-14, wherein the third moiety is of lipid nature, such as a palmitoyl group, a myristyl group, a farnesyl group, a geranyl-geranyl
30 group, a GPI-anchor, and an N-acyl diglyceride group.

16. The method according to any one of the preceding claims, wherein the GDF-8 subsequence or the GDF-8 analogue is derived from the C-terminal, active form of GDF-8, such as subsequence

or analogue derived from a bovine, porcine, human, chicken, sheep, or turkey GDF-8 polypeptide.

17. The method according to claim 16, wherein the GDF-8 polypeptide has been modified by substituting at least one amino acid sequence in SEQ ID NO: 11 or 12 with at least one amino acid sequence of equal or different length which contains a foreign T_H epitope, wherein substituted amino acid sequences are comprised in residues 1-12, 18-41, 43-48, 49-69, or 79-104 in SEQ ID NO: 11 or 12, or wherein the GDF-8 polypeptide has been modified by inserting at least one amino acid sequence which contains a foreign T_H epitope, wherein insertion is performed anywhere in positions 1-12, 18-30, 42-51, 82-86, and 105-109 in SEQ ID NO: 11 or 12.

15

18. The method according to any one of the preceding claims, wherein presentation to the immune system is effected by having at least two copies of the GDF-8 polypeptide, the subsequence thereof or the modified GDF-8 polypeptide covalently or non-covalently linked to a carrier molecule capable of effecting presentation of multiple copies of antigenic determinants.

19. The method according to any one of the preceding claims, wherein an effective amount of the GDF-8 polypeptide or the GDF-8 analogue is administered to the animal via a route selected from the parenteral route such as the intradermal, the subdermal, the intracutaneous, the subcutaneous, and the intramuscular routes; the peritoneal route; the oral route; the buccal route; the sublingual route; the epidural route; the spinal route; the anal route; and the intracranial route.

20. The method according to claim 19, wherein the effective amount is between 0.5 µg and 2,000 µg of the GDF-8 polypeptide, the subsequence thereof or the analogue thereof.

21. The method according to claim 19 or 20, which includes at least one administration of the GDF-8 polypeptide or analogue per year, such as at least 2, at least 3, at least 4, at least 5 6, and at least 12 administrations per year.

22. The method according to any one of claims 19-21, wherein the GDF-8 polypeptide, the subsequence thereof, or the modified GDF-8 polypeptide optionally has been formulated with a 10 pharmaceutically and immunologically acceptable carrier and/or vehicle and has been formulated with an adjuvant which facilitates breaking of autotolerance to autoantigens, such as an adjuvant selected from the group consisting of an immune targeting adjuvant; an immune modulating adjuvant such as a 15 toxin, a cytokine and a mycobacterial derivative; an oil formulation; a polymer; a micelle forming adjuvant; a saponin; an immunostimulating complex matrix (an ISCOM matrix); a particle; DDA; aluminium adjuvants; DNA adjuvants; γ -inulin; and an encapsulating adjuvant.

20

23. The method according to any one of claims 20-22, wherein the GDF-8 polypeptide or analogue is contained in a virtual lymph node (VLN) device.

25 24. The method according to any one of claims 1-18, wherein presentation of modified GDF-8 to the immune system is effected by introducing nucleic acid(s) encoding the modified GDF-8 into the animal's cells and thereby obtaining *in vivo* expression by the cells of the nucleic acid(s) introduced.

30

25. The method according to claim 24, wherein the nucleic acid(s) introduced is/are selected from naked DNA, DNA formulated with charged or uncharged lipids, DNA formulated in liposomes, DNA included in a viral vector, DNA formulated with a

transfection-facilitating protein or polypeptide, DNA formulated with a targeting protein or polypeptide, DNA formulated with Calcium precipitating agents, DNA coupled to an inert carrier molecule, DNA formulated with chitin or chitosan, and
5 DNA formulated with an adjuvant.

26. The method according to claim 24 or 25, wherein the nucleic acids are administered intraarterially, intravenously, or by the routes defined in claim 19.

10

27. The method according to claim 24 or 25, wherein the nucleic acid(s) is/are contained in a VLN device and/or are formulated as defined in claim 22.

15 28. The method according to any one of claims 25-27, which includes at least one administration of the nucleic acids per year, such as at least 2, at least 3, at least 4, at least 6, and at least 12 administrations per year

20 29. A method for increasing the muscle mass of an animal, the method comprising down-regulating GDF-8 activity according to the method of any one of claims 1-28 to such an extent such that the muscle mass is increased at least 5% when compared to animals which exhibit normal GDF-8 activity, such as at least
25 10, 15, 20, 25, 30, 35, 40, and 45%.

30. A GDF-8 analogue which is derived from an animal GDF-8 polypeptide wherein is introduced a modification which has as a result that immunization of the animal with the analogue induces production of antibodies against the GDF-8 polypeptide,
30 such as a modification as defined in any one of claims 1-18.

31. An immunogenic composition comprising an immunogenically effective amount of a GDF-8 polypeptide autologous in an ani-

mal, said GDF-8 polypeptide being formulated together with an immunologically acceptable adjuvant so as to break the animal's autotolerance towards the GDF-8 polypeptide, the composition further comprising a pharmaceutically and immunologically acceptable carrier and/or vehicle.

32. An immunogenic composition comprising an immunogenically effective amount of an GDF-8 analogue according to claim 29, the composition further comprising a pharmaceutically and immunologically acceptable carrier and/or vehicle and optionally an adjuvant.

33. An immunogenic composition according to claim 31 or 32, wherein the adjuvant is selected from the group consisting of the adjuvants of claim 22.

34. A nucleic acid fragment which encodes an GDF-8 analogue according to claim 29.

35. A vector carrying the nucleic acid fragment according to claim 34, such as a vector capable of autonomous replication.

36. The vector according to claim 35 which is selected from the group consisting of a plasmid, a phage, a cosmid, a minichromosome, and a virus.

37. The vector according to claim 35 or 36, comprising, in the 5'→3' direction and in operable linkage, a promoter for driving expression of the nucleic acid fragment according to claim 34, optionally a nucleic acid sequence encoding a leader peptide enabling secretion of or integration into the membrane of the polypeptide fragment, the nucleic acid fragment according to claim 34, and optionally a terminator.

38. The vector according to any one of claims 41-44 which, when introduced into a host cell, is either capable of being integrated in the host cell genome or which is not capable of being integrated in the host cell genome.

5

39. The vector according to claim 37 or 38, wherein the promoter drives expression in a eukaryotic cell or drives expression in a prokaryotic cell.

10 40. A transformed cell carrying the vector of any one of claims 35-39, such as a transformed cell which is capable of replicating the nucleic acid fragment according to claim 34.

41. The transformed cell according to claim 40, which is a micro-organism selected from a bacterium, such as a bacterium of the genus *Escherichia* (preferably *E. coli*), *Bacillus*, *Salmonella*, or *Mycobacterium* (preferably a non-pathogenic *Mycobacterium* cell such as *M. bovis* BCG), a yeast, a protozoan, or a cell derived from a multicellular organism selected from a fungus, an insect cell such as an S₂ or an SF cell, a plant cell, and a mammalian cell.

42. The transformed cell according to claim 40 or 41, which expresses the nucleic acid fragment according to claim 34, such as a transformed cell which secretes or carries on its surface, the GDF-8 analogue according to claim 30.

43. The method according to any one of claims 1-18, wherein presentation to the immune system is effected by administering a non-pathogenic micro-organism or virus which is carrying a nucleic acid fragment which encodes and expresses the GDF-8 polypeptide or analogue.

44. The method according to claim 43, wherein the virus is a non-virulent pox virus such as a vaccinia virus or wherein the micro-organism is a bacterium such as the bacterium defined in claim 41.

5

45. The method according to any claim 43 or 44, wherein the non-pathogenic micro-organism or virus is administered one single time to the animal.

10 46. A composition for inducing production of antibodies against GDF-8, the composition comprising

- a nucleic acid fragment according to claim 34 or a vector according to any one of claims 35-39, and
 - a pharmaceutically and immunologically acceptable carrier
- 15 and/or vehicle and/or adjuvant.

47. The composition according to claim 46, wherein the nucleic acid fragment is formulated according to claim 25 or 27.

20 48. A stable cell line which carries the vector according to any one of claims 35-39 and which expresses the nucleic acid fragment according to claim 34, and which optionally secretes or carries the GDF-8 analogue according to claim 30 on its surface.

25

49. A method for the preparation of the cell according to any one of claims 40-42, the method comprising transforming a host cell with the nucleic acid fragment according to claim 34 or with the vector according to any one of claims 35-39.

30

50. A method for the identification of a modified GDF-8 polypeptide which is capable of inducing antibodies against unmodified GDF-8 in an animal species where the unmodified GDF-8 polypeptide is a self-protein, the method comprising

- preparing, by means of peptide synthesis or genetic engineering techniques, a set of mutually distinct modified GDF-8 polypeptides wherein amino acids have been added to, inserted in, deleted from, or substituted into the amino acid sequence of an GDF-8 polypeptide of the animal species thereby giving rise to amino acid sequences in the set which comprise T-cell epitopes which are foreign to the animal species,
- testing members of the set for their ability to induce production of antibodies by the animal species against the unmodified GDF-8, and
- isolating the member(s) of the set which significantly induces antibody production against unmodified GDF-8 in the animal species.

15

51. A method for the preparation of an immunogenic composition comprising at least one modified GDF-8 polypeptide which is capable of inducing antibodies against unmodified GDF-8 in an animal species where the unmodified GDF-8 polypeptide is a self-protein, the method comprising

20

- preparing, by means of peptide synthesis or genetic engineering techniques, a set of mutually distinct modified GDF-8 polypeptides wherein amino acids have been added to, inserted in, deleted from, or substituted into the amino acid sequence of an GDF-8 polypeptide of the animal species thereby giving rise to amino acid sequences in the set comprising T-cell epitopes which are foreign to the animal,
- testing members of the set for their ability to induce production of antibodies by the animal species against the unmodified GDF-8, and
- admixing the member(s) of the set which significantly induces production of antibodies in the animal species which are reactive with GDF-8 with a pharmaceutically and

25

30

immunologically acceptable carrier and/or vehicle, optionally in combination with at least one pharmaceutically and immunologically acceptable adjuvant.

- 5 52. The method according to claim 50 or 51, wherein preparation of the members of the set comprises preparation of mutually distinct nucleic acid sequences, each sequence being a nucleic acid sequence according to claim 34, insertion of the nucleic acid sequences into appropriate expression vectors,
10 transformation of suitable host cells with the vectors, and expression of the nucleic acid sequences, optionally followed by isolation of the expression products.

1/5




Fig. 1A

2/5




Fig. 1B

3/5




Fig. 1C

4/5




Fig. 1D

5/5




Fig. 2

SEQUENCE LISTING

<110> M&E Biotech A/S

<120> Method for down-regulating GDF-8 activity

<130> AutoVacGDF-8 DK 1

<160> 23

<170> PatentIn Ver. 2.1

<210> 1

<211> 375

<212> PRT

<213> Homo sapiens

<400> 1

Met Gln Lys Leu Gln Leu Cys Val Tyr Ile Tyr Leu Phe Met Leu Ile
1 5 10 15

Val Ala Gly Pro Val Asp Leu Asn Glu Asn Ser Glu Gln Lys Glu Asn
20 25 30

Val Glu Lys Glu Gly Leu Cys Asn Ala Cys Thr Trp Arg Gln Asn Thr
35 40 45

Lys Ser Ser Arg Ile Glu Ala Ile Lys Ile Gln Ile Leu Ser Lys Leu
50 55 60

Arg Leu Glu Thr Ala Pro Asn Ile Ser Lys Asp Val Ile Arg Gln Leu
65 70 75 80

Leu Pro Lys Ala Pro Pro Leu Arg Glu Leu Ile Asp Gln Tyr Asp Val
85 90 95

Gln Arg Asp Asp Ser Ser Asp Gly Ser Leu Glu Asp Asp Asp Tyr His
100 105 110

| | | |
|---|-----|---------|
| Ala Thr Thr Glu Thr Ile Ile Thr Met Pro Thr Glu Ser Asp Phe Leu | | |
| 115 | 120 | 125 |
| Met Gln Val Asp Gly Lys Pro Lys Cys Cys Phe Phe Lys Phe Ser Ser | | |
| 130 | 135 | 140 |
| Lys Ile Gln Tyr Asn Lys Val Val Lys Ala Gln Leu Trp Ile Tyr Leu | | |
| 145 | 150 | 155 160 |
| Arg Pro Val Glu Thr Pro Thr Thr Val Phe Val Gln Ile Leu Arg Leu | | |
| | 165 | 170 175 |
| Ile Lys Pro Met Lys Asp Gly Thr Arg Tyr Thr Gly Ile Arg Ser Leu | | |
| | 180 | 185 190 |
| Lys Leu Asp Met Asn Pro Gly Thr Gly Ile Trp Gln Ser Ile Asp Val | | |
| | 195 | 200 205 |
| Lys Thr Val Leu Gln Asn Trp Leu Lys Gln Pro Glu Ser Asn Leu Gly | | |
| | 210 | 215 220 |
| Ile Glu Ile Lys Ala Leu Asp Glu Asn Gly His Asp Leu Ala Val Thr | | |
| 225 | 230 | 235 240 |
| Phe Pro Gly Pro Gly Glu Asp Gly Leu Asn Pro Phe Leu Glu Val Lys | | |
| | 245 | 250 255 |
| Val Thr Asp Thr Pro Lys Arg Ser Arg Arg Asp Phe Gly Leu Asp Cys | | |
| | 260 | 265 270 |
| Asp Glu His Ser Thr Glu Ser Arg Cys Cys Arg Tyr Pro Leu Thr Val | | |
| | 275 | 280 285 |
| Asp Phe Glu Ala Phe Gly Trp Asp Trp Ile Ile Ala Pro Lys Arg Tyr | | |
| | 290 | 295 300 |
| Lys Ala Asn Tyr Cys Ser Gly Glu Cys Glu Phe Val Phe Leu Gln Lys | | |
| 305 | 310 | 315 320 |
| Tyr Pro His Thr His Leu Val His Gln Ala Asn Pro Arg Gly Ser Ala | | |
| | 325 | 330 335 |

Gly Pro Cys Cys Thr Pro Thr Lys Met Ser Pro Ile Asn Met Leu Tyr
340 345 350

Phe Asn Gly Lys Glu Gln Ile Ile Tyr Gly Lys Ile Pro Ala Met Val
355 360 365

Val Asp Arg Cys Gly Cys Ser
370 375

<210> 2

<211> 362

<212> PRT

<213> Meleagris gallopavo

<400> 2

Met Gln Ile Leu Val His Pro Val Ala Leu Asp Gly Ser Ser Gln Pro
1 5 10 15

Thr Glu Asn Ala Glu Lys Asp Gly Leu Cys Asn Ala Cys Thr Trp Arg
20 25 30

Gln Asn Thr Lys Ser Ser Arg Ile Glu Ala Ile Lys Ile Gln Ile Leu
35 40 45

Ser Lys Leu Arg Leu Glu Gln Ala Pro Asn Ile Ser Arg Asp Val Ile
50 55 60

Lys Gln Leu Leu Pro Lys Ala Pro Pro Leu Gln Glu Leu Ile Asp Gln
65 70 75 80

Tyr Asp Val Gln Arg Asp Asp Ser Ser Asp Gly Ser Leu Glu Asp Asp
85 90 95

Asp Tyr His Ala Thr Thr Glu Thr Ile Ile Thr Met Pro Thr Glu Ser
100 105 110

Asp Phe Leu Val Gln Met Glu Gly Lys Pro Lys Cys Cys Phe Phe Lys
115 120 125

4

Phe Ser Ser Lys Ile Gln Tyr Asn Lys Val Val Lys Ala Gln Leu Trp
 130 135 140

Ile Tyr Leu Arg Gln Val Gln Lys Pro Thr Thr Val Phe Val Gln Ile
 145 150 155 160

Leu Arg Leu Ile Lys Pro Met Lys Asp Gly Thr Arg Tyr Thr Gly Ile
 165 170 175

Arg Ser Leu Lys Leu Asp Met Asn Pro Gly Thr Gly Ile Trp Gln Ser
 180 185 190

Ile Asp Val Lys Thr Val Leu Gln Asn Trp Leu Lys Gln Pro Glu Ser
 195 200 205

Asn Leu Gly Ile Glu Ile Lys Ala Phe Asp Glu Asn Gly Arg Asp Leu
 210 215 220

Ala Val Thr Phe Pro Gly Pro Gly Glu Asp Gly Leu Asn Pro Phe Leu
 225 230 235 240

Glu Val Arg Val Thr Asp Thr Pro Lys Arg Ser Arg Arg Asp Phe Gly
 245 250 255

Leu Asp Cys Asp Glu His Ser Thr Glu Ser Arg Cys Cys Arg Tyr Pro
 260 265 270

Leu Thr Val Asp Phe Glu Ala Phe Gly Trp Asp Trp Ile Ile Ala Pro
 275 280 285

Lys Arg Tyr Lys Ala Asn Tyr Cys Ser Gly Glu Cys Glu Phe Val Phe
 290 295 300

Leu Gln Lys Tyr Pro His Thr His Leu Val His Gln Ala Asn Pro Arg
 305 310 315 320

Gly Ser Ala Gly Pro Cys Cys Thr Pro Thr Lys Met Ser Pro Ile Asn
 325 330 335

Met Leu Tyr Phe Asn Gly Lys Glu Gln Ile Ile Tyr Gly Lys Ile Pro
 340 345 350

Ala Met Val Val Asp Arg Cys Gly Cys Ser
 355 360

<210> 3

<211> 375

<212> PRT

<213> Gallus sp.

<400> 3

Met Gln Lys Leu Ala Val Tyr Val Tyr Ile Tyr Leu Phe Met Gln Ile
 1 5 10 15

Ala Val Asp Pro Val Ala Leu Asp Gly Ser Ser Gln Pro Thr Glu Asn
 20 25 30

Ala Glu Lys Asp Gly Leu Cys Asn Ala Cys Thr Trp Arg Gln Asn Thr
 35 40 45

Lys Ser Ser Arg Ile Glu Ala Ile Lys Ile Gln Ile Leu Ser Lys Leu
 50 55 60

Arg Leu Glu Gln Ala Pro Asn Ile Ser Arg Asp Val Ile Lys Gln Leu
 65 70 75 80

Leu Pro Lys Ala Pro Pro Leu Gln Glu Leu Ile Asp Gln Tyr Asp Val
 85 90 95

Gln Arg Asp Asp Ser Ser Asp Gly Ser Leu Glu Asp Asp Asp Tyr His
 100 105 110

Ala Thr Thr Glu Thr Ile Ile Thr Met Pro Thr Glu Ser Asp Phe Leu
 115 120 125

Val Gln Met Glu Gly Lys Pro Lys Cys Cys Phe Phe Lys Phe Ser Ser
 130 135 140

Lys Ile Gln Tyr Asn Lys Val Val Lys Ala Gln Leu Trp Ile Tyr Leu
 145 150 155 160

<210> 4

<211> 376

<212> PRT

<213> Mus musculus

<400> 4

Met Met Gln Lys Leu Gln Met Tyr Val Tyr Ile Tyr Leu Phe Met Leu
1 5 10 15

Ile Ala Ala Gly Pro Val Asp Leu Asn Glu Gly Ser Glu Arg Glu Glu
20 25 30

Asn Val Glu Lys Glu Gly Leu Cys Asn Ala Cys Ala Trp Arg Gln Asn
35 40 45

Thr Arg Tyr Ser Arg Ile Glu Ala Ile Lys Ile Gln Ile Leu Ser Lys
50 55 60

Leu Arg Leu Glu Thr Ala Pro Asn Ile Ser Lys Asp Ala Ile Arg Gln
65 70 75 80

Leu Leu Pro Arg Ala Pro Pro Leu Arg Glu Leu Ile Asp Gln Tyr Asp
85 90 95

Val Gln Arg Asp Asp Ser Ser Asp Gly Ser Leu Glu Asp Asp Asp Tyr
100 105 110

His Ala Thr Thr Glu Thr Ile Ile Thr Met Pro Thr Glu Ser Asp Phe
115 120 125

Leu Met Gln Ala Asp Gly Lys Pro Lys Cys Cys Phe Phe Lys Phe Ser
130 135 140

Ser Lys Ile Gln Tyr Asn Lys Val Val Lys Ala Gln Leu Trp Ile Tyr
145 150 155 160

Leu Arg Pro Val Lys Thr Pro Thr Thr Val Phe Val Gln Ile Leu Arg
165 170 175

Leu Ile Lys Pro Met Lys Asp Gly Thr Arg Tyr Thr Gly Ile Arg Ser
180 185 190

Leu Lys Leu Asp Met Ser Pro Gly Thr Gly Ile Trp Gln Ser Ile Asp
195 200 205

Val Lys Thr Val Leu Gln Asn Trp Leu Lys Gln Pro Glu Ser Asn Leu
210 215 220

Gly Ile Glu Ile Lys Ala Leu Asp Glu Asn Gly His Asp Leu Ala Val
225 230 235 240

Thr Phe Pro Gly Pro Gly Glu Asp Gly Leu Asn Pro Phe Leu Glu Val
245 250 255

Lys Val Thr Asp Thr Pro Lys Arg Ser Arg Arg Asp Phe Gly Leu Asp
260 265 270

Cys Asp Glu His Ser Thr Glu Ser Arg Cys Cys Arg Tyr Pro Leu Thr
275 280 285

Val Asp Phe Glu Ala Phe Gly Trp Asp Trp Ile Ile Ala Pro Lys Arg
290 295 300

Tyr Lys Ala Asn Tyr Cys Ser Gly Glu Cys Glu Phe Val Phe Leu Gln
305 310 315 320

Lys Tyr Pro His Thr His Leu Val His Gln Ala Asn Pro Arg Gly Ser
325 330 335

Ala Gly Pro Cys Cys Thr Pro Thr Lys Met Ser Pro Ile Asn Met Leu
340 345 350

Tyr Phe Asn Gly Lys Glu Gln Ile Ile Tyr Gly Lys Ile Pro Ala Met
355 360 365

Val Val Asp Arg Cys Gly Cys Ser
370 375

<211> 375

<212> PRT

<213> Bos taurus

<400> 5

Met Gln Lys Leu Gln Ile Ser Val Tyr Ile Tyr Leu Phe Met Leu Ile
 1 5 10 15

Val Ala Gly Pro Val Asp Leu Asn Glu Asn Ser Glu Gln Lys Glu Asn
 20 25 30

Val Glu Lys Glu Gly Leu Cys Asn Ala Cys Leu Trp Arg Glu Asn Thr
 35 40 45

Thr Ser Ser Arg Leu Glu Ala Ile Lys Ile Gln Ile Leu Ser Lys Leu
 50 55 60

Arg Leu Glu Thr Ala Pro Asn Ile Ser Lys Asp Ala Ile Arg Gln Leu
 65 70 75 80

Leu Pro Lys Ala Pro Pro Leu Leu Glu Leu Ile Asp Gln Phe Asp Val
 85 90 95

Gln Arg Asp Ala Ser Ser Asp Gly Ser Leu Glu Asp Asp Asp Tyr His
 100 105 110

Ala Arg Thr Glu Thr Val Ile Thr Met Pro Thr Glu Ser Asp Leu Leu
 115 120 125

Thr Gln Val Glu Gly Lys Pro Lys Cys Cys Phe Phe Lys Phe Ser Ser
 130 135 140

Lys Ile Gln Tyr Asn Lys Leu Val Lys Ala Gln Leu Trp Ile Tyr Leu
 145 150 155 160

Arg Pro Val Lys Thr Pro Ala Thr Val Phe Val Gln Ile Leu Arg Leu
 165 170 175

Ile Lys Pro Met Lys Asp Gly Thr Arg Tyr Thr Gly Ile Arg Ser Leu
 180 185 190

10

Lys Leu Asp Met Asn Pro Gly Thr Gly Ile Trp Gln Ser Ile Asp Val
195 200 205

Lys Thr Val Leu Gln Asn Trp Leu Lys Gln Pro Glu Ser Asn Leu Gly
210 215 220

Ile Glu Ile Lys Ala Leu Asp Glu Asn Gly His Asp Leu Ala Val Thr
225 230 235 240

Phe Pro Glu Pro Gly Glu Asp Gly Leu Thr Pro Phe Leu Glu Val Lys
245 250 255

Val Thr Asp Thr Pro Lys Arg Ser Arg Arg Asp Phe Gly Leu Asp Cys
260 265 270

Asp Glu His Ser Thr Glu Ser Arg Cys Cys Arg Tyr Pro Leu Thr Val
275 280 285

Asp Phe Glu Ala Phe Gly Trp Asp Trp Ile Ile Ala Pro Lys Arg Tyr
290 295 300

Lys Ala Asn Tyr Cys Ser Gly Glu Cys Glu Phe Val Phe Leu Gln Lys
305 310 315 320

Tyr Pro His Thr His Leu Val His Gln Ala Asn Pro Arg Gly Ser Ala
325 330 335

Gly Pro Cys Cys Thr Pro Thr Lys Met Ser Pro Ile Asn Met Leu Tyr
340 345 350

Phe Asn Gly Glu Gly Gln Ile Ile Tyr Gly Lys Ile Pro Ala Met Val
355 360 365

Val Asp Arg Cys Gly Cys Ser
370 375

<210> 6

<211> 375

<212> PRT

<213> Ovis sp.

<400> 6

Met Gln Lys Leu Gln Ile Phe Val Tyr Ile Tyr Leu Phe Met Leu Leu
1 5 10 15

Val Ala Gly Pro Val Asp Leu Asn Glu Asn Ser Glu Gln Lys Glu Asn
20 25 30

Val Glu Lys Lys Gly Leu Cys Asn Ala Cys Leu Trp Arg Gln Asn Asn
35 40 45

Lys Ser Ser Arg Leu Glu Ala Ile Lys Ile Gln Ile Leu Ser Lys Leu
50 55 60

Arg Leu Glu Thr Ala Pro Asn Ile Ser Lys Asp Ala Ile Arg Gln Leu
65 70 75 80

Leu Pro Lys Ala Pro Pro Leu Arg Glu Leu Ile Asp Gln Tyr Asp Val
85 90 95

Gln Arg Asp Asp Ser Ser Asp Gly Ser Leu Glu Asp Asp Asp Tyr His
100 105 110

Val Thr Thr Glu Thr Val Ile Thr Met Pro Thr Glu Ser Asp Leu Leu
115 120 125

Ala Glu Val Gln Glu Lys Pro Lys Cys Cys Phe Phe Lys Phe Ser Ser
130 135 140

Lys Ile Gln His Asn Lys Val Val Lys Ala Gln Leu Trp Ile Tyr Leu
145 150 155 160

Arg Pro Val Lys Thr Pro Thr Thr Val Phe Val Gln Ile Leu Arg Leu
165 170 175

Ile Lys Pro Met Lys Asp Gly Thr Arg Tyr Thr Gly Ile Arg Ser Leu
180 185 190

Lys Leu Asp Met Asn Pro Gly Thr Gly Ile Trp Gln Ser Ile Asp Val
195 200 205

12

Lys Thr Val Leu Gln Asn Trp Leu Lys Gln Pro Glu Ser Asn Leu Gly
210 215 220

Ile Glu Ile Lys Ala Leu Asp Glu Asn Gly His Asp Leu Ala Val Thr
225 230 235 240

Phe Pro Glu Pro Gly Glu Glu Gly Leu Asn Pro Phe Leu Glu Val Lys
245 250 255

Val Thr Asp Thr Pro Lys Arg Ser Arg Arg Asp Phe Gly Leu Asp Cys
260 265 270

Asp Glu His Ser Thr Glu Ser Arg Cys Cys Arg Tyr Pro Leu Thr Val
275 280 285

Asp Phe Glu Ala Phe Gly Trp Asp Trp Ile Ile Ala Pro Lys Arg Tyr
290 295 300

Lys Ala Asn Tyr Cys Ser Gly Glu Cys Glu Phe Leu Phe Leu Gln Lys
305 310 315 320

Tyr Pro His Thr His Leu Val His Gln Ala Asn Pro Lys Gly Ser Ala
325 330 335

Gly Pro Cys Cys Thr Pro Thr Lys Met Ser Pro Ile Asn Met Leu Tyr
340 345 350

Phe Asn Gly Lys Glu Gln Ile Ile Tyr Gly Lys Ile Pro Gly Met Val
355 360 365

Val Asp Arg Cys Gly Cys Ser
370 375

<210> 7

<211> 376

<212> PRT

<213> Rattus norvegicus

<400> 7

13

Met Ile Gln Lys Pro Gln Met Tyr Val Tyr Ile Tyr Leu Phe Val Leu
 1 5 10 15

Ile Ala Ala Gly Pro Val Asp Leu Asn Glu Asp Ser Glu Arg Glu Ala
 20 25 30

Asn Val Glu Lys Glu Gly Leu Cys Asn Ala Cys Ala Trp Arg Gln Asn
 35 40 45

Thr Arg Tyr Ser Arg Ile Glu Ala Ile Lys Ile Gln Ile Leu Ser Lys
 50 55 60

Leu Arg Leu Glu Thr Ala Pro Asn Ile Ser Lys Asp Ala Ile Arg Gln
 65 70 75 80

Leu Leu Pro Arg Ala Pro Pro Leu Arg Glu Leu Ile Asp Gln Tyr Asp
 85 90 95

Val Gln Arg Asp Asp Ser Ser Asp Gly Ser Leu Glu Asp Asp Asp Tyr
 100 105 110

His Ala Thr Thr Glu Thr Ile Ile Thr Met Pro Thr Glu Ser Asp Phe
 115 120 125

Leu Met Gln Ala Asp Gly Lys Pro Lys Cys Cys Phe Phe Lys Phe Ser
 130 135 140

Ser Lys Ile Gln Tyr Asn Lys Val Val Lys Ala Gln Leu Trp Ile Tyr
 145 150 155 160

Leu Arg Ala Val Lys Thr Pro Thr Thr Val Phe Val Gln Ile Leu Arg
 165 170 175

Leu Ile Lys Pro Met Lys Asp Gly Thr Arg Tyr Thr Gly Ile Arg Ser
 180 185 190

Leu Lys Leu Asp Met Ser Pro Gly Thr Gly Ile Trp Gln Ser Ile Asp
 195 200 205

Val Lys Thr Val Leu Gln Asn Trp Leu Lys Gln Pro Glu Ser Asn Leu
 210 215 220

Gly Ile Glu Ile Lys Ala Leu Asp Glu Asn Gly His Asp Leu Ala Val
225 230 235 240

Thr Phe Pro Gly Pro Gly Glu Asp Gly Leu Asn Pro Phe Leu Glu Val
245 250 255

Lys Val Thr Asp Thr Pro Lys Arg Ser Arg Arg Asp Phe Gly Leu Asp
260 265 270

Cys Asp Glu His Ser Thr Glu Ser Arg Cys Cys Arg Tyr Pro Leu Thr
275 280 285

Val Asp Phe Glu Ala Phe Gly Trp Asp Trp Ile Ile Ala Pro Lys Arg
290 295 300

Tyr Lys Ala Asn Tyr Cys Ser Gly Glu Cys Glu Phe Val Phe Leu Gln
305 310 315 320

Lys Tyr Pro His Thr His Leu Val His Gln Ala Asn Pro Arg Gly Ser
325 330 335

Ala Gly Pro Cys Cys Thr Pro Thr Lys Met Ser Pro Ile Asn Met Leu
340 345 350

Tyr Phe Asn Gly Lys Glu Gln Ile Ile Tyr Gly Lys Ile Pro Ala Met
355 360 365

Val Val Asp Arg Cys Gly Cys Ser
370 375

<210> 8

<211> 375

<212> PRT

<213> Sus scrofa

<400> 8

Met Gln Lys Leu Gln Ile Tyr Val Tyr Ile Tyr Leu Phe Met Leu Ile
1 5 10 15

15

Val Ala Gly Pro Val Asp Leu Asn Glu Asn Ser Glu Gln Lys Glu Asn
 20 25 30

Val Glu Lys Glu Gly Leu Cys Asn Ala Cys Met Trp Arg Gln Asn Thr
 35 40 45

Lys Ser Ser Arg Leu Glu Ala Ile Lys Ile Gln Ile Leu Ser Lys Leu
 50 55 60

Arg Leu Glu Thr Ala Pro Asn Ile Ser Lys Asp Ala Ile Arg Gln Leu
 65 70 75 80

Leu Pro Lys Ala Pro Pro Leu Arg Glu Leu Ile Asp Gln Tyr Asp Val
 85 90 95

Gln Arg Asp Asp Ser Ser Asp Gly Ser Leu Glu Asp Asp Asp Tyr His
 100 105 110

Ala Thr Thr Glu Thr Ile Ile Thr Met Pro Thr Glu Ser Asp Leu Leu
 115 120 125

Met Gln Val Glu Gly Lys Pro Lys Cys Cys Phe Phe Lys Phe Ser Ser
 130 135 140

Lys Ile Gln Tyr Asn Lys Val Val Lys Ala Gln Leu Trp Ile Tyr Leu
 145 150 155 160

Arg Pro Val Lys Thr Pro Thr Thr Val Phe Val Gln Ile Leu Arg Leu
 165 170 175

Ile Lys Pro Met Lys Asp Gly Thr Arg Tyr Thr Gly Ile Arg Ser Leu
 180 185 190

Lys Leu Asp Met Asn Pro Gly Thr Gly Ile Trp Gln Ser Ile Asp Val
 195 200 205

Lys Thr Val Leu Gln Asn Trp Leu Lys Gln Pro Glu Ser Asn Leu Gly
 210 215 220

Ile Glu Ile Lys Ala Leu Asp Glu Asn Gly His Asp Leu Ala Val Thr
 225 230 235 240

Phe Pro Gly Pro Gly Glu Asp Gly Leu Asn Pro Phe Leu Glu Val Lys
 245 250 255

Val Thr Asp Thr Pro Lys Arg Ser Arg Arg Asp Phe Gly Leu Asp Cys
 260 265 270

Asp Glu His Ser Thr Glu Ser Arg Cys Cys Arg Tyr Pro Leu Thr Val
 275 280 285

Asp Phe Glu Ala Phe Gly Trp Asp Trp Ile Ile Ala Pro Lys Arg Tyr
 290 295 300

Lys Ala Asn Tyr Cys Ser Gly Glu Cys Glu Phe Val Phe Leu Gln Lys
 305 310 315 320

Tyr Pro His Thr His Leu Val His Gln Ala Asn Pro Arg Gly Ser Ala
 325 330 335

Gly Pro Cys Cys Thr Pro Thr Lys Met Ser Pro Ile Asn Met Leu Tyr
 340 345 350

Phe Asn Gly Lys Glu Gln Ile Ile Tyr Gly Lys Ile Pro Ala Met Val
 355 360 365

Val Asp Arg Cys Gly Cys Ser
 370 375

<210> 9

<211> 374

<212> PRT

<213> Danio rerio

<400> 9

Met His Phe Thr Gln Val Leu Ile Ser Leu Ser Val Leu Ile Ala Cys
 1 5 10 15

Gly Pro Val Gly Tyr Gly Asp Ile Thr Ala His Gln Gln Pro Ser Thr
 20 25 30

17

Ala Thr Glu Glu Ser Glu Leu Cys Ser Thr Cys Glu Phe Arg Gln His
 35 40 45

Ser Lys Leu Met Arg Leu His Ala Ile Lys Ser Gln Ile Leu Ser Lys
 50 55 60

Leu Arg Leu Lys Gln Ala Pro Asn Ile Ser Arg Asp Val Val Lys Gln
 65 70 75 80

Leu Leu Pro Lys Ala Pro Pro Leu Gln Gln Leu Leu Asp Gln Tyr Asp
 85 90 95

Val Leu Gly Asp Asp Ser Lys Asp Gly Ala Val Glu Glu Asp Asp Glu
 100 105 110

His Ala Thr Thr Glu Thr Ile Met Thr Met Ala Thr Glu Pro Asp Pro
 115 120 125

Ile Val Gln Val Asp Arg Lys Pro Lys Cys Cys Phe Phe Ser Phe Ser
 130 135 140

Pro Lys Ile Gln Ala Asn Arg Ile Val Arg Ala Gln Leu Trp Val His
 145 150 155 160

Leu Arg Pro Ala Glu Glu Ala Thr Thr Val Phe Leu Gln Ile Ser Arg
 165 170 175

Leu Met Pro Val Lys Asp Gly Gly Arg His Arg Ile Arg Ser Leu Lys
 180 185 190

Ile Asp Val Asn Ala Gly Val Thr Ser Trp Gln Ser Ile Asp Val Lys
 195 200 205

Gln Val Leu Thr Val Trp Leu Lys Gln Pro Glu Thr Asn Arg Gly Ile
 210 215 220

Glu Ile Asn Ala Tyr Asp Ala Lys Gly Asn Asp Leu Ala Val Thr Ser
 225 230 235 240

Thr Glu Thr Gly Glu Asp Gly Leu Leu Pro Phe Met Glu Val Lys Ile
 245 250 255

Ser Glu Gly Pro Lys Arg Ile Arg Arg Asp Ser Gly Leu Asp Cys Asp
 260 265 270

Glu Asn Ser Ser Glu Ser Arg Cys Cys Arg Tyr Pro Leu Thr Val Asp
 275 280 285

Phe Glu Asp Phe Gly Trp Asp Trp Ile Ile Ala Pro Lys Arg Tyr Lys
 290 295 300

Ala Asn Tyr Cys Ser Gly Glu Cys Asp Tyr Met Tyr Leu Gln Lys Tyr
 305 310 315 320

Pro His Thr His Leu Val Asn Lys Ala Ser Pro Arg Gly Thr Ala Gly
 325 330 335

Pro Cys Cys Thr Pro Thr Lys Met Ser Pro Ile Asn Met Leu Tyr Phe
 340 345 350

Asn Gly Lys Glu Gln Ile Ile Tyr Gly Lys Ile Pro Ser Met Val Val
 355 360 365

Asp Arg Cys Gly Cys Ser
 370

<210> 10

<211> 375

<212> PRT

<213> Papio hamadryas

<400> 10

Met Gln Lys Leu Gln Leu Cys Val Tyr Ile Tyr Leu Phe Met Leu Ile
 1 5 10 15

Val Ala Gly Pro Val Asp Leu Asn Glu Asn Ser Glu Gln Lys Glu Asn
 20 25 30

Val Glu Lys Glu Gly Leu Cys Asn Ala Cys Thr Trp Arg Gln Asn Thr
 35 40 45

19

Lys Ser Ser Arg Ile Glu Ala Ile Lys Ile Gln Ile Leu Ser Lys Leu
50 55 60

Arg Leu Glu Thr Ala Pro Asn Ile Ser Lys Asp Ala Ile Arg Gln Leu
65 70 75 80

Leu Pro Lys Ala Pro Pro Leu Arg Glu Leu Ile Asp Gln Tyr Asp Val
85 90 95

Gln Arg Asp Asp Ser Ser Asp Gly Ser Leu Glu Asp Asp Asp Tyr His
100 105 110

Ala Thr Thr Glu Thr Ile Ile Thr Met Pro Thr Glu Ser Asp Phe Leu
115 120 125

Met Gln Val Asp Gly Lys Pro Lys Cys Cys Phe Phe Lys Phe Ser Ser
130 135 140

Lys Ile Gln Tyr Asn Lys Val Val Lys Ala Gln Leu Trp Ile Tyr Leu
145 150 155 160

Arg Pro Val Glu Thr Pro Thr Thr Val Phe Val Gln Ile Leu Arg Leu
165 170 175

Ile Lys Pro Met Lys Asp Gly Thr Arg Tyr Thr Gly Ile Arg Ser Leu
180 185 190

Lys Leu Asp Met Asn Pro Gly Thr Gly Ile Trp Gln Ser Ile Asp Val
195 200 205

Lys Thr Val Leu Gln Asn Trp Leu Lys Gln Pro Glu Ser Asn Leu Gly
210 215 220

Ile Glu Ile Lys Ala Leu Asp Glu Asn Gly His Asp Leu Ala Val Thr
225 230 235 240

Phe Pro Gly Pro Gly Glu Asp Gly Leu Asn Pro Phe Leu Glu Val Lys
245 250 255

Val Thr Asp Thr Pro Lys Arg Ser Arg Arg Asp Phe Gly Leu Asp Cys
260 265 270

Asp Glu His Ser Thr Glu Ser Arg Cys Cys Arg Tyr Pro Leu Thr Val
275 280 285

Asp Phe Glu Ala Leu Gly Trp Asp Trp Ile Ile Ala Pro Lys Arg Tyr
290 295 300

Lys Ala Asn Tyr Cys Ser Gly Glu Cys Glu Phe Val Phe Leu Gln Lys
305 310 315 320

Tyr Pro His Thr His Leu Val His Gln Ala Asn Pro Arg Gly Ser Ala
325 330 335

Gly Pro Cys Cys Thr Pro Thr Lys Met Ser Pro Ile Asn Met Leu Tyr
340 345 350

Phe Asn Gly Lys Glu Gln Ile Ile Tyr Gly Lys Ile Pro Ala Met Val
355 360 365

Val Asp Arg Cys Gly Cys Ser
370 375

<210> 11

<211> 109

<212> PRT

<213> Homo sapiens

<220>

<221> PEPTIDE

<222> (1)..(109)

<223> Identical to residues 267-375 in SEQ ID NO: 1

<400> 11

Asp Phe Gly Leu Asp Cys Asp Glu His Ser Thr Glu Ser Arg Cys Cys
1 5 10 15

Arg Tyr Pro Leu Thr Val Asp Phe Glu Ala Phe Gly Trp Asp Trp Ile
20 25 30

21

Ile Ala Pro Lys Arg Tyr Lys Ala Asn Tyr Cys Ser Gly Glu Cys Glu

35

40

45

Phe Val Phe Leu Gln Lys Tyr Pro His Thr His Leu Val His Gln Ala

50

55

60

Asn Pro Arg Gly Ser Ala Gly Pro Cys Cys Thr Pro Thr Lys Met Ser

65

70

75

80

Pro Ile Asn Met Leu Tyr Phe Asn Gly Lys Glu Gln Ile Ile Tyr Gly

85

90

95

Lys Ile Pro Ala Met Val Val Asp Arg Cys Gly Cys Ser

100

105

<210> 12

<211> 109

<212> PRT

<213> Bos taurus

<220>

<221> PEPTIDE

<222> (1)..(109)

<223> Identical to residues 267-375 in SEQ ID NO: 5

<400> 12

Asp Phe Gly Leu Asp Cys Asp Glu His Ser Thr Glu Ser Arg Cys Cys

1

5

10

15

Arg Tyr Pro Leu Thr Val Asp Phe Glu Ala Phe Gly Trp Asp Trp Ile

20

25

30

Ile Ala Pro Lys Arg Tyr Lys Ala Asn Tyr Cys Ser Gly Glu Cys Glu

35

40

45

Phe Val Phe Leu Gln Lys Tyr Pro His Thr His Leu Val His Gln Ala

50

55

60

Asn Pro Arg Gly Ser Ala Gly Pro Cys Cys Thr Pro Thr Lys Met Ser

65

70

75

80

Pro Ile Asn Met Leu Tyr Phe Asn Gly Glu Gly Gln Ile Ile Tyr Gly
85 90 95

Lys Ile Pro Ala Met Val Val Asp Arg Cys Gly Cys Ser
100 105

<210> 13

<211> 15

<212> PRT

<213> Clostridium tetani

<400> 13

Gln Tyr Ile Lys Ala Asn Ser Lys Phe Ile Gly Ile Thr Glu Leu
1 5 10 15

<210> 14

<211> 21

<212> PRT

<213> Clostridium tetani

<400> 14

Phe Asn Asn Phe Thr Val Ser Phe Trp Leu Arg Val Pro Lys Val Ser
1 5 10 15

Ala Ser His Leu Glu
20

<210> 15

<211> 109

<212> PRT

<213> Artificial sequence

<220>

<221> MUTAGEN

<222> (18)..(32)

<223> Tetanus toxoid P2 epitope (SEQ ID NO: 13)

<220>

<221> SIMILAR

<222> (1)..(17)

<223> Identical to residues 267-283 in SEQ ID NO: 1

<220>

<221> SIMILAR

<222> (33)..(109)

<223> Identical to residues 299-375 in SEQ ID NO: 1

<220>

<221> SITE

<222> (73)

<223> Cys or Ser

<220>

<221> SITE

<222> (90)..(91)

<223> Lys Glu or Glu Gly

<400> 15

| | | | | | | | | | | | | | | | |
|-----|-----|-----|-----|-----|-----|-----|-----|-----|-----|-----|-----|-----|-----|-----|-----|
| Asp | Phe | Gly | Leu | Asp | Cys | Asp | Glu | His | Ser | Thr | Glu | Ser | Arg | Cys | Cys |
| 1 | | | | 5 | | | | | 10 | | | | | 15 | |

| | | | | | | | | | | | | | | | |
|-----|-----|-----|-----|-----|-----|-----|-----|-----|-----|-----|-----|-----|-----|-----|-----|
| Arg | Gln | Tyr | Ile | Lys | Ala | Asn | Ser | Lys | Phe | Ile | Gly | Ile | Thr | Glu | Leu |
| | | | 20 | | | | | 25 | | | | | | 30 | |

| | | | | | | | | | | | | | | | |
|-----|-----|-----|-----|-----|-----|-----|-----|-----|-----|-----|-----|-----|-----|-----|-----|
| Ile | Ala | Pro | Lys | Arg | Tyr | Lys | Ala | Asn | Tyr | Cys | Ser | Gly | Glu | Cys | Glu |
| | | | 35 | | | | | 40 | | | | | 45 | | |

| | | | | | | | | | | | | | | | |
|-----|-----|-----|-----|-----|-----|-----|-----|-----|-----|-----|-----|-----|-----|-----|-----|
| Phe | Val | Phe | Leu | Gln | Lys | Tyr | Pro | His | Thr | His | Leu | Val | His | Gln | Ala |
| | | | 50 | | | | | 55 | | | | | | 60 | |

| | | | | | | | | | | | | | | | |
|-----|-----|-----|-----|-----|-----|-----|-----|-----|-----|-----|-----|-----|-----|-----|-----|
| Asn | Pro | Arg | Gly | Ser | Ala | Gly | Pro | Cys | Cys | Thr | Pro | Thr | Lys | Met | Ser |
| | | | 65 | | | | | 70 | | | | | 75 | | 80 |

| | | | | | | | | | | | | | | | |
|-----|-----|-----|-----|-----|-----|-----|-----|-----|-----|-----|-----|-----|-----|-----|-----|
| Pro | Ile | Asn | Met | Leu | Tyr | Phe | Asn | Gly | Lys | Glu | Gln | Ile | Ile | Tyr | Gly |
| | | | | 85 | | | | | | | | | 90 | | 95 |

| | | | | | | | | | | | | |
|-----|-----|-----|-----|-----|-----|-----|-----|-----|-----|-----|-----|-----|
| Lys | Ile | Pro | Ala | Met | Val | Val | Asp | Arg | Cys | Gly | Cys | Ser |
| | | | | 100 | | | | | | | | 105 |

<210> 16

<211> 109

<212> PRT

<213> Artificial sequence

<220>

<221> MUTAGEN

<222> (52)..(66)

<223> Tetanus toxoid P2 epitope (SEQ ID NO: 13)

<220>

<221> SIMILAR

<222> (1)..(51)

<223> Identical to residues 267-317 in SEQ ID NO: 1

<220>

<221> SIMILAR

<222> (67)..(109)

<223> Identical to residues 333-375 in SEQ ID NO: 1

<220>

<221> SITE

<222> (73)

<223> Cys or Ser

<220>

<221> SITE

<222> (90)..(91)

<223> Lys Glu or Glu Gly

<400> 16

Asp Phe Gly Leu Asp Cys Asp Glu His Ser Thr Glu Ser Arg Cys Cys
1 5 10 15

Arg Tyr Pro Leu Thr Val Asp Phe Glu Ala Phe Gly Trp Asp Trp Ile
20 25 30

Ile Ala Pro Lys Arg Tyr Lys Ala Asn Tyr Cys Ser Gly Glu Cys Glu
35 40 45

25

Phe Val Phe Gln Tyr Ile Lys Ala Asn Ser Lys Phe Ile Gly Ile Thr
50 55 60

Glu Leu Arg Gly Ser Ala Gly Pro Cys Cys Thr Pro Thr Lys Met Ser
65 70 75 80

Pro Ile Asn Met Leu Tyr Phe Asn Gly Lys Glu Gln Ile Ile Tyr Gly
85 90 95

Lys Ile Pro Ala Met Val Val Asp Arg Cys Gly Cys Ser
100 105

<210> 17

<211> 109

<212> PRT

<213> Artificial sequence

<220>

<221> MUTAGEN

<222> (83)..(97)

<223> Tetanus toxoid P2 epitope (SEQ ID NO: 13)

<220>

<221> SIMILAR

<222> (1)..(82)

<223> Identical to residues 267-348 in SEQ ID NO: 1

<220>

<221> SIMILAR

<222> (98)..(109)

<223> Identical to residues 364-375 in SEQ ID NO: 1

<220>

<221> SITE

<222> (73)

<223> Cys or Ser

<220>

<221> SITE

<222> (90)..(91)

<223> Lys Glu or Glu Gly

<400> 17

Asp Phe Gly Leu Asp Cys Asp Glu His Ser Thr Glu Ser Arg Cys Cys
1 5 10 15

Arg Tyr Pro Leu Thr Val Asp Phe Glu Ala Phe Gly Trp Asp Trp Ile
20 25 30

Ile Ala Pro Lys Arg Tyr Lys Ala Asn Tyr Cys Ser Gly Glu Cys Glu
35 40 45

Phe Val Phe Leu Gln Lys Tyr Pro His Thr His Leu Val His Gln Ala
50 55 60

Asn Pro Arg Gly Ser Ala Gly Pro Cys Cys Thr Pro Thr Lys Met Ser
65 70 75 80

Pro Ile Gln Tyr Ile Lys Ala Asn Ser Lys Phe Ile Gly Ile Thr Glu
85 90 95

Leu Ile Pro Ala Met Val Val Asp Arg Cys Gly Cys Ser
100 105

<210> 18

<211> 109

<212> PRT

<213> Artificial sequence

<220>

<221> MUTAGEN

<222> (21)..(41)

<223> Tetanus toxoid P30 epitope (SEQ ID NO: 14)

<220>

<221> SIMILAR

<222> (42)..(109)

<223> Identical to residues 307-375 in SEQ ID NO: 1

<220>

<221> SIMILAR

<222> (42)..(109)

<223> Identical to residues 308-375 in SEQ ID NO: 1

<220>

<221> SITE

<222> (73)

<223> Cys or Ser

<220>

<221> SITE

<222> (90)..(91)

<223> Lys Glu or Glu Gly

<400> 18

| | | | | | | | | | | | | | | | |
|-----|-----|-----|-----|-----|-----|-----|-----|-----|-----|-----|-----|-----|-----|-----|-----|
| Asp | Phe | Gly | Leu | Asp | Cys | Asp | Glu | His | Ser | Thr | Glu | Ser | Arg | Cys | Cys |
| 1 | | | | 5 | | | | | 10 | | | | | 15 | |

| | | | | | | | | | | | | | | | |
|-----|-----|-----|-----|-----|-----|-----|-----|-----|-----|-----|-----|-----|-----|-----|-----|
| Arg | Tyr | Pro | Leu | Phe | Asn | Asn | Phe | Thr | Val | Ser | Phe | Trp | Leu | Arg | Val |
| | | | 20 | | | | | 25 | | | | | 30 | | |

| | | | | | | | | | | | | | | | |
|-----|-----|-----|-----|-----|-----|-----|-----|-----|-----|-----|-----|-----|-----|-----|-----|
| Pro | Lys | Val | Ser | Ala | Ser | His | Leu | Glu | Tyr | Cys | Ser | Gly | Glu | Cys | Glu |
| | | 35 | | | | | 40 | | | | | 45 | | | |

| | | | | | | | | | | | | | | | |
|-----|-----|-----|-----|-----|-----|-----|-----|-----|-----|-----|-----|-----|-----|-----|-----|
| Phe | Val | Phe | Leu | Gln | Lys | Tyr | Pro | His | Thr | His | Leu | Val | His | Gln | Ala |
| | 50 | | | | | 55 | | | | | 60 | | | | |

| | | | | | | | | | | | | | | | |
|-----|-----|-----|-----|-----|-----|-----|-----|-----|-----|-----|-----|-----|-----|-----|-----|
| Asn | Pro | Arg | Gly | Ser | Ala | Gly | Pro | Cys | Cys | Thr | Pro | Thr | Lys | Met | Ser |
| 65 | | | | | 70 | | | | | 75 | | | | 80 | |

| | | | | | | | | | | | | | | | |
|-----|-----|-----|-----|-----|-----|-----|-----|-----|-----|-----|-----|-----|-----|-----|-----|
| Pro | Ile | Asn | Met | Leu | Tyr | Phe | Asn | Gly | Lys | Glu | Gln | Ile | Ile | Tyr | Gly |
| | | | 85 | | | | | | 90 | | | | | 95 | |

| | | | | | | | | | | | | |
|-----|-----|-----|-----|-----|-----|-----|-----|-----|-----|-----|-----|-----|
| Lys | Ile | Pro | Ala | Met | Val | Val | Asp | Arg | Cys | Gly | Cys | Ser |
| | | 100 | | | | | | 105 | | | | |

<210> 19

<211> 109

<212> PRT

<213> Artificial sequence

<220>

<221> MUTAGEN

<222> (49)..(69)

<223> Tetanus toxoid P30 epitope (SEQ ID NO: 14)

<220>

<221> SIMILAR

<222> (1)..(48)

<223> Identical to residues 267-314 in SEQ ID NO: 1

<220>

<221> SIMILAR

<222> (70)..(109)

<223> Identical to residues 336-375 in SEQ ID NO: 1

<220>

<221> SITE

<222> (73)

<223> Cys or Ser

<220>

<221> SITE

<222> (90)..(91)

<223> Lys Glu or Glu Gly

<400> 19

| | | | | | | | | | | | | | | | |
|-----|-----|-----|-----|-----|-----|-----|-----|-----|-----|-----|-----|-----|-----|-----|-----|
| Asp | Phe | Gly | Leu | Asp | Cys | Asp | Glu | His | Ser | Thr | Glu | Ser | Arg | Cys | Cys |
| 1 | | | | 5 | | | | | 10 | | | | | 15 | |

| | | | | | | | | | | | | | | | |
|-----|-----|-----|-----|-----|-----|-----|-----|-----|-----|-----|-----|-----|-----|-----|-----|
| Arg | Tyr | Pro | Leu | Thr | Val | Asp | Phe | Glu | Ala | Phe | Gly | Trp | Asp | Trp | Ile |
| | | | 20 | | | | | 25 | | | | | | 30 | |

| | | | | | | | | | | | | | | | |
|-----|-----|-----|-----|-----|-----|-----|-----|-----|-----|-----|-----|-----|-----|-----|-----|
| Ile | Ala | Pro | Lys | Arg | Tyr | Lys | Ala | Asn | Tyr | Cys | Ser | Gly | Glu | Cys | Glu |
| | | 35 | | | | | 40 | | | | | 45 | | | |

| | | | | | | | | | | | | | | | |
|-----|-----|-----|-----|-----|-----|-----|-----|-----|-----|-----|-----|-----|-----|-----|-----|
| Phe | Asn | Asn | Phe | Thr | Val | Ser | Phe | Trp | Leu | Arg | Val | Pro | Lys | Val | Ser |
| | | 50 | | | | | 55 | | | | | 60 | | | |

| | | | | | | | | | | | | | | | |
|-----|-----|-----|-----|-----|-----|-----|-----|-----|-----|-----|-----|-----|-----|-----|-----|
| Ala | Ser | His | Leu | Glu | Ala | Gly | Pro | Cys | Cys | Thr | Pro | Thr | Lys | Met | Ser |
| | 65 | | | | | 70 | | | | | 75 | | | | 80 |

29

Pro Ile Asn Met Leu Tyr Phe Asn Gly Lys Glu Gln Ile Ile Tyr Gly
85 90 95

Lys Ile Pro Ala Met Val Val Asp Arg Cys Gly Cys Ser
100 105

<210> 20

<211> 109

<212> PRT

<213> Artificial sequence

<220>

<221> MUTAGEN

<222> (79)..(99)

<223> Tetanus toxoid P30 epitope (SEQ ID NO: 14)

<220>

<221> SIMILAR

<222> (1)..(78)

<223> Identical to residues 267-345 in SEQ ID NO: 1

<220>

<221> SIMILAR

<222> (100)..(109)

<223> Identical to residues 366-375 in SEQ ID NO: 1

<220>

<221> SITE

<222> (73)

<223> Cys or Ser

<220>

<221> SITE

<222> (90)..(91)

<223> Lys Glu or Glu Gly

<400> 20

Asp Phe Gly Leu Asp Cys Asp Glu His Ser Thr Glu Ser Arg Cys Cys
1 5 10 15

30

Arg Tyr Pro Leu Thr Val Asp Phe Glu Ala Phe Gly Trp Asp Trp Ile
20 25 30

Ile Ala Pro Lys Arg Tyr Lys Ala Asn Tyr Cys Ser Gly Glu Cys Glu
35 40 45

Phe Val Phe Leu Gln Lys Tyr Pro His Thr His Leu Val His Gln Ala
50 55 60

Asn Pro Arg Gly Ser Ala Gly Pro Cys Cys Thr Pro Thr Lys Phe Asn
65 70 75 80

Asn Phe Thr Val Ser Phe Trp Leu Arg Val Pro Lys Val Ser Ala Ser
85 90 95

His Leu Glu Ala Met Val Val Asp Arg Cys Gly Cys Ser
100 105

<210> 21

<211> 109

<212> PRT

<213> Artificial sequence

<220>

<221> MUTAGEN

<222> (84)..(104)

<223> Tetanus toxoid P30 epitope (SEQ ID NO: 14)

<220>

<221> SIMILAR

<222> (1)..(83)

<223> Identical to residues 267-349 in SEQ ID NO: 1

<220>

<221> SIMILAR

<222> (105)..(109)

<223> Identical to residues 371-375 in SEQ ID NO: 1

<220>

<221> SITE

<222> (73)

<223> Cys or Ser

<220>

<221> SITE

<222> (90)..(91)

<223> Lys Glu or Glu Gly

<400> 21

Asp Phe Gly Leu Asp Cys Asp Glu His Ser Thr Glu Ser Arg Cys Cys
1 5 10 15

Arg Tyr Pro Leu Thr Val Asp Phe Glu Ala Phe Gly Trp Asp Trp Ile
20 25 30

Ile Ala Pro Lys Arg Tyr Lys Ala Asn Tyr Cys Ser Gly Glu Cys Glu
35 40 45

Phe Val Phe Leu Gln Lys Tyr Pro His Thr His Leu Val His Gln Ala
50 55 60

Asn Pro Arg Gly Ser Ala Gly Pro Cys Cys Thr Pro Thr Lys Met Ser
65 70 75 80

Pro Ile Asn Phe Asn Asn Phe Thr Val Ser Phe Trp Leu Arg Val Pro
85 90 95

Lys Val Ser Ala Ser His Leu Glu Arg Cys Gly Cys Ser
100 105

<210> 22

<211> 254

<212> PRT

<213> Artificial sequence

<220>

<221> SIMILAR

<222> (110)..(124)

<223> Tetanus toxoid P2 epitope (SEQ ID NO: 13)

<220>

<221> SIMILAR

<222> (125)..(145)

<223> Diphtheria toxoid P30 epitope (SEQ ID NO: 14)

<220>

<221> SIMILAR

<222> (1)..(109)

<223> 109 C-terminal residues of human and bovine GDF-8
(residues 267-375 in SEQ ID NO: 1)

<220>

<221> SIMILAR

<222> (146)..(254)

<223> 109 C-terminal residues of human and bovine GDF-8
(residues 267-375 in SEQ ID NO: 1)

<220>

<221> SITE

<222> (90)..(91)

<223> Lys Glu or Glu Gly

<220>

<221> SITE

<222> (235)..(236)

<223> Identical to (90)..(91)

<400> 22

| | | | | | | | | | | | | | | | |
|-----|-----|-----|-----|-----|-----|-----|-----|-----|-----|-----|-----|-----|-----|-----|-----|
| Asp | Phe | Gly | Leu | Asp | Cys | Asp | Glu | His | Ser | Thr | Glu | Ser | Arg | Cys | Cys |
| 1 | | | | 5 | | | | | 10 | | | | | 15 | |

| | | | | | | | | | | | | | | | |
|-----|-----|-----|-----|-----|-----|-----|-----|-----|-----|-----|-----|-----|-----|-----|-----|
| Arg | Tyr | Pro | Leu | Thr | Val | Asp | Phe | Glu | Ala | Phe | Gly | Trp | Asp | Trp | Ile |
| | | | 20 | | | | | | 25 | | | | | 30 | |

| | | | | | | | | | | | | | | | |
|-----|-----|-----|-----|-----|-----|-----|-----|-----|-----|-----|-----|-----|-----|-----|-----|
| Ile | Ala | Pro | Lys | Arg | Tyr | Lys | Ala | Asn | Tyr | Cys | Ser | Gly | Glu | Cys | Glu |
| | | | 35 | | | | | 40 | | | | | 45 | | |

| | | | | | | | | | | | | | | | |
|-----|-----|-----|-----|-----|-----|-----|-----|-----|-----|-----|-----|-----|-----|-----|-----|
| Phe | Val | Phe | Leu | Gln | Lys | Tyr | Pro | His | Thr | His | Leu | Val | His | Gln | Ala |
| | | | 50 | | | | | 55 | | | | | | 60 | |

33

Asn Pro Arg Gly Ser Ala Gly Pro Cys Cys Thr Pro Thr Lys Met Ser
65 70 75 80

Pro Ile Asn Met Leu Tyr Phe Asn Gly Lys Glu Gln Ile Ile Tyr Gly
85 90 95

Lys Ile Pro Ala Met Val Val Asp Arg Cys Gly Cys Ser Gln Tyr Ile
100 105 110

Lys Ala Asn Ser Lys Phe Ile Gly Ile Thr Glu Leu Phe Asn Asn Phe
115 120 125

Thr Val Ser Phe Trp Leu Arg Val Pro Lys Val Ser Ala Ser His Leu
130 135 140

Glu Asp Phe Gly Leu Asp Cys Asp Glu His Ser Thr Glu Ser Arg Cys
145 150 155 160

Cys Arg Tyr Pro Leu Thr Val Asp Phe Glu Ala Phe Gly Trp Asp Trp
165 170 175

Ile Ile Ala Pro Lys Arg Tyr Lys Ala Asn Tyr Cys Ser Gly Glu Cys
180 185 190

Glu Phe Val Phe Leu Gln Lys Tyr Pro His Thr His Leu Val His Gln
195 200 205

Ala Asn Pro Arg Gly Ser Ala Gly Pro Cys Cys Thr Pro Thr Lys Met
210 215 220

Ser Pro Ile Asn Met Leu Tyr Phe Asn Gly Lys Glu Gln Ile Ile Tyr
225 230 235 240

Gly Lys Ile Pro Ala Met Val Val Asp Arg Cys Gly Cys Ser
245 250

<210> 23

<211> 160

<212> PRT

<213> Artificial sequence

<220>

<221> MUTAGEN

<222> (16)..(36)

<223> Tetanus toxoid P30 epitope (SEQ ID NO: 14)

<220>

<221> MUTAGEN

<222> (37)..(51)

<223> Tetanus toxoid P2 epitope (SEQ ID NO: 13)

<220>

<221> SIMILAR

<222> (1)..(15)

<223> Identical to residues 216-230 of SEQ ID NO: 1

<220>

<221> SIMILAR

<222> (52)..(160)

<223> Identical to residues 267-375 of SEQ ID NO: 1

<220>

<221> SITE

<222> (124)

<223> Cys or Ser

<220>

<221> SITE

<222> (141)..(142)

<223> Lys Glu or Glu Gly

<400> 23

Leu Lys Gln Pro Glu Ser Asn Leu Gly Ile Glu Ile Lys Ala Leu Phe
1 5 10 15

Asn Asn Phe Thr Val Ser Phe Trp Leu Arg Val Pro Lys Val Ser Ala
20 25 30

Ser His Leu Glu Gln Tyr Ile Lys Ala Asn Ser Lys Phe Ile Gly Ile
35 40 45

35

Thr Glu Leu Asp Phe Gly Leu Asp Cys Asp Glu His Ser Thr Glu Ser
50 55 60

Arg Cys Cys Arg Tyr Pro Leu Thr Val Asp Phe Glu Ala Phe Gly Trp
65 70 75 80

Asp Trp Ile Ile Ala Pro Lys Arg Tyr Lys Ala Asn Tyr Cys Ser Gly
85 90 95

Glu Cys Glu Phe Val Phe Leu Gln Lys Tyr Pro His Thr His Leu Val
100 105 110

His Gln Ala Asn Pro Arg Gly Ser Ala Gly Pro Cys Cys Thr Pro Thr
115 120 125

Lys Met Ser Pro Ile Asn Met Leu Tyr Phe Asn Gly Lys Glu Gln Ile
130 135 140

Ile Tyr Gly Lys Ile Pro Ala Met Val Val Asp Arg Cys Gly Cys Ser
145 150 155 160